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NAVIGATION OF THE THESIS 
 
The present thesis sets out to investigate the immunological response to elite surf lifesaving (SLS) 
competition, in attempt to observe how multidisciplinary SLS athletes respond to ironman format 
surf races. Following an initial investigation into a single multidisciplinary SLS event, it became 
evident that further investigation into the gender difference in immune response and 
endocrinological response to exercise was warranted; in particular the role of ovarian hormones, 
namely estrogen and progesterone. Despite the growing participation rates in SLS, it is still 
considered a low participation sport, predominantly due to the demographical and logistical 
constraints associated with the sport requiring participants to reside and undertake training at or 
in close proximity to coastal regions. Additionally, environmental temperatures do not always 
promote water participation in some parts of Australia, and indeed the world. A direct 
consequence of low participation numbers results in few SLS athletes being available to 
participate in research, and consequently, participant recruitment becomes difficult. In addition, 
due to the seasonal nature of ocean-based sports, it became clear a substantial body of work for 
the present thesis could not be undertaken within an appropriate timeframe. As a result, the focus 
of the thesis changed to recreationally active women, with the intent to understand fundamental 
changes in the immunological and endocrinological response to exercise in relation endogenous 
and exogenous estrogen and progesterone secretion. It is the hope of the researcher that the 
findings of this thesis in relation to recreationally active women may form the basis of further 
research into elite female athletes. 
 
Prior to investigating the role of endogenous and exogenous estrogen and progesterone secretion 
to the immunological and endocrinological response to exercise, it was important to investigate 
the benefits and barriers for oral contraceptive use or non-use within a physically active 
population. Following this investigation into the perceived benefits and barriers towards oral 
contraceptive use and non-use in women of varying physical activity levels, it became evident 
that we needed to explore exactly how oral contraceptive (OC) use or non-use affects exercise 
tolerance. In particular the present thesis will focus on immunological and endocrinological 
challenges of exercising in varying environmental temperatures. The aforementioned parameters 
of human physiology were identified to warrant investigation as the endocrinological and 
immunological systems are interrelated, with the manipulation of environmental temperature 
important due to the geographical location of the recreationally active women investigated 
 ix 
 
throughout the present thesis. Additionally, exogenous estrogen and progesterone secreted 
throughout OC administration, have been reported [1] to strongly bind to the endogenous estrogen 
and progesterone receptors located within the hypothalamic and pituitary regions of the brain, it 
is likely that OC may influence the hypothalamic response  [2] to exercise to a greater extent than 
the normal menstrual cycle, with core body temperature, the mucosal immune and stress response 
to exercise vulnerable to changes in the functioning of the hypothalamus. 
 
The present thesis is comprised of nine chapters. Chapter one demonstrates the problem within 
the population and identifies the gaps in the literature, highlighting the purpose of the research as 
well as the research questions. Chapter two explores the current literature surrounding this 
research problem with emphasis placed upon the exercising population and females. Chapter three 
is experimental study one which explores the validity and reliability of a point of care saliva 
analysis test which will be used in subsequent studies and poses substantial benefits for applied 
sport science endocrinological testing. Chapter four is experimental study two which is an 
exploratory study investigating the immunological response to a single surf life saving event. 
Chapter five is experimental study three and explores the benefits and barriers for oral 
contraceptive use or non-use in women of varying physical activity levels. Chapter six is 
experimental study four and explores the mucosal immune and endocrinological response to 
incremental exercise in recreationally active women taking oral contraception compared with 
normally menstruating women. This chapter also explores the core body temperature (TC) 
response in women taking oral contraception to incremental exercise in thermo-neutral (TN) 
conditions (22C; r.h. 50%) and hot and humid (HH) (35C; r.h.  50%) environments and how 
this affects the mucosal immune system and the stress response. Chapter seven provides an overall 
discussion from all experimental studies and outlines future research to further the results attained 
from the present thesis. Chapter eight explains the principles behind the testing methodology used 
throughout the present thesis. 
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ABSTRACTS 
 
Chapter 3 (Experimental Study 1 – Paper 1) 
Saliva analysis is commonly used in applied sport science research and practice due to 
convenience and ease of sample collection with traditional measures requiring immediate 
refrigeration and taking several hours to analyse. The aim of the present study was to evaluate the 
validity and reliability of measuring salivary cortisol concentration ([sCort]) in situ with the 
Individual Profiling (IPRO) oral fluid collector (OFC) method against the Salimetrics oral swab 
(SOS) and passive drool (PD). Ten (n = 10, male = 5 and female = 5) healthy, recreationally active 
university students volunteered to participate in the present study. Participants provided three 
samples in trial one (i.e. one of OFC, SOS and PD). In trial two participants repeated the sample 
procedure from trial one, with four participants providing duplicate OFC swabs for reliability 
analysis. The duplicate swabs were analysed on duplicate lateral flow devices (LFD) to test for 
reliability. No significant difference was found between OFC and SOS (p = 0.881) and PD (p = 
0.145) measures, showing good agreement with no bias. Both duplicate OFC and LFD samples 
were not significantly different from another, with an ICC of 0.890 and 0.850 respectively. The 
present study demonstrates the IPRO method to be a valid and reliable measure of [sCort] in 
recreationally active individuals, indicating a useful and convenient measure for salivary cortisol 
testing in field environments. 
 
Chapter 4 (Experimental Study 2 – Paper 2) 
The present study examined the response of salivary immunoglobulin A (s-IgA) to endurance 
SLS competition. Elite SLS men (n = 10) and women (n = 8) volunteered to participate in the 
present study. Saliva samples of 0.5 mL were collected daily commencing 54 hr pre-event to 61 
hr post-event. Saliva samples were assessed using a portable system. Saliva samples were 
collected at rest and prior to physical exertion or activity at approximately 0500 hours to 
determine the pre-and post-competition baseline values, while the post-event sample collection 
occurred within 30 min of race completion for each athlete, between approximately 1300  – 1600 
hours. 
 
A significant (p < 0.05) increase in s-IgA concentration ([s-IgA]) was observed 61 hr post-event 
(49.21 ±8.8 µl/mL) in males compared to all other time-point samples. The results of the present 
study indicate that there is a non-significant increase in [s-IgA] for both genders immediately 
 xi 
 
following an endurance SLS event, lasting approximately 90 min. The mechanism responsible 
for the non-significant increases in [s-IgA] observed post-event in both genders and significant 
increases in [s-IgA] observed 61 h post event in males remains unclear and may reflect an 
immune-compensatory effect to protect the athlete from the acquisition of infection. Surf life 
saving athletes and coaches should monitor [s-IgA] throughout major competition periods to 
observe fluctuations in mucosal immunity, which may reflect a predisposition to infection, and 
tailor exercise and recovery prescription accordingly to minimise the risk of infection and 
subsequent declines in performance.  
 
Abstract Insert 
Upon reflecting on this paper and the possible role of gender in the mucosal immune response to 
multidisciplinary surf life saving competition, it became apparent that the menstrual cycle and 
OC use may have implications for our results, which raised several research questions, ultimately 
changing the direction of the present thesis. Do ovarian hormones influence the acute mucosal 
immune and stress response to intense exercise? In particular do exogenous ovarian hormones in 
the form of oral contraceptives cause different effects than endogenous secretions throughout the 
normal menstrual cycle? In addition, do OC affect other parameters of physiology, including the 
stress response to intense exercise and the ability of the active female to regulate TC when 
exercising? In an attempt to answer these questions, several studies were designed; a qualitative 
survey-based analysis of OC use in women of varying physical activity levels to identify if 
exercise plays a role in OC use or non-use in Australian women, as well as the perceived benefits 
and barriers towards OC use within these women. Further studies were conducted to investigate 
the effect of exogenous estrogen and progesterone in the form of OC on exercise tolerance in 
recreationally active women, with a focus on TC, s-IgA and salivary cortisol (sCort). 
 
Chapter 5 (Experimental Study 3 – Paper 3) 
The present paper explores the role of physical activity levels on OC use in active, athletic 
Australian women. The benefits and barriers for OC use are also explored. A total of 125 
Australian women (29.4 ±8.1 yr) completed a survey on their menstrual cycle and OC use. 
Women were categorised based on weekly exercise levels and intensities as either untrained (n = 
26; 32.2 ±7.3 yr: UT), recreationally active (n = 44; 30.6 ±6.8 yr: REC) or trained (n = 55; 27.1 
±8.3 yr: TR). No significant differences (p > 0.05) were observed for OC use between TR (47%), 
REC (39%) and UT (31%) women. Birth control (90%), cycle control (86%) and a reduction in 
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menstrual disturbances (88%) were the major benefits of OC use reported by all women, whereas 
the major barriers for OC use showed more variation between women. Physical activity levels do 
not appear to play a role in OC use in Australian women, although may indirectly affect the 
perceived needs of a woman.  
 
Chapter 6 (Experimental Study 4 – Paper 4) 
A key component of exercise tolerance is attenuating changes in TC throughout exercise, 
particularly in HH conditions. Elevations in TC may place the cardiac output demands of the 
exercising individual under more stress to meet metabolic and thermoregulatory loads, 
subsequently increasing the stress and immune response to exercise. Endogenous progesterone 
has been associated with increases in TC throughout the luteal phase of the menstrual cycle. 
Considering exogenous progesterone in monophasic OC is secreted in higher amounts, it is 
possible that taking OC may augment rises in TC in women. The aim of the present study was to 
investigate the role of exogenous progesterone and estrogen administration on TC at rest and 
throughout exercise. Sixteen (n = 16) recreationally active women (8 = normally menstruating; 
womenNM, 8 = taking OC; womenOC) aged 22.1 ±3.2 yr completed two incremental cycling 
tests (52.5 min) during the early follicular phase for womenNM and during the active pill phase 
for womenOC. One was conducted in TN conditions (22C; r.h. 50%; TN) and one in hot and 
humid conditions (35C; r.h.  50%; HH). Salivary cortisol ([sCort]), salivary Immunoglobulin A 
([sIgA]) were collected at baseline (approximately 0500 hours), following 30 min of acclimation 
(approximately 0530 hours) and immediately following exercise (approximately 0800 hours) in 
both TN and HH trials. No significant difference in [sCort] or [sIgA] was observed between 
groups. WomenOC demonstrated significantly (p < 0.05) higher resting Tc compared with 
womenNM in both conditions, and TC remained significantly (p < 0.05) in womenOC than in 
womenNM up to 22.5 min into the exercise test.   
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CHAPTER ONE 
 
1. 1  Introduction 
Males and females exhibit fundamental differences in physiological and morphological 
parameters [3] which may restrict aspects of exercise performance. Maximal oxygen uptake (   ΟV 2
max) is considered the gold standard measurement of cardiorespiratory endurance [4]. In general, 
the average absolute   ΟV 2 max (L/min) in males is approximately 50% greater than in females 
[5], and following correction for body mass (ml.kg-1.min-1) or lean body mass (ml.kgLBM-1.min-
1) the difference between males and females is reduced to 20-30% and less than 15% respectively 
[6], indicating distinct gender differences. If, when all variables are equal, women consistently 
exhibit lower   ΟV 2 max than males, then a rationalisation of the mechanism or mechanisms 
associated with that difference is a meaningful pursuit to optimise cardiorespiratory performance 
in female athletes and active women. One possible explanation could be the influence of the 
menstrual cycle, specifically the presence of estrogen and progesterone. Endogenous and 
exogenous estrogen and progesterone appear to affect   ΟV 2  max performance with women 
exposed to exogenous hormones [7, 8], in the form of OC exhibiting lower   ΟV 2 max compared 
with women who are considered normally menstruating i.e. not taking any form of hormonal 
contraception. It remains unknown if this decrease in aerobic capacity in response to exogenous 
estrogen and progesterone secretion is due to the structure of the molecule and the subsequent 
effect on receptor binding, or due to the shear amount of synthetic hormone exposure. Even 
though the mechanism behind this relationship remains equivocal, it does substantiate claims that 
ovarian hormones contribute to the gender difference in exercise performance. Considering the 
potential relationship between ovarian hormones and exercise performance, it is likely that other 
parameters of physiology may be affected in relation to the secretion of estrogen and progesterone. 
 
Women have been reported to exhibit higher TC than males at rest [9] and in response to exercise 
[10], and even though this difference is lowered when body surface-to-mass ratios, adipose tissue 
percentage and aerobic capabilities are controlled for [11], women still appear to have an altered 
thermoregulatory response compared with males. In particular females appear to have lower sweat 
rates than males in response to exercising in hot conditions [11]. The menstrual cycle and 
subsequent fluctuations in estrogen and progesterone may contribute to the higher TC previously 
observed [9, 10] in females compared with males. Progesterone in particular has been shown [12-
15] to increase the core temperature threshold (TC THLD) for cutaneous vasodilation and 
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subsequently sweating, consequently also leading to an elevated TC. Interestingly, little is known 
about the effect of exogenous progesterone on Tc and the TC THLD for cutaneous vasodilation. 
Considering a greater amount of progesterone is secreted during OC use compared with the 
normal menstrual cycle, it is likely that the progesterone-induced changes to TC could be 
amplified in women exposed to exogenous progesterone. If women taking OC experience higher 
(progesterone-induced) TC and TC THLD for cutaneous vasodilation, it is plausible they would 
experience a greater stress response to exercise, ultimately compromising their ability to sustain 
the metabolic demands of exercise. 
 
Cortisol is a corticosteroid, commonly secreted when the body is experiencing stress i.e. intense 
exercise, and can affect the secretion of gonadotropin releasing hormone (GnRH) [16, 17], which 
is involved in regulating the menstrual cycle [18]. Throughout the normal menstrual cycle 
fluctuations in cortisol have been reported, including decreases in the follicular phase and 
increases throughout the ovulatory phase [19, 20]. It is possible that this fluctuation in cortisol 
concentrations could be related to changes in TC, as the observed increases in cortisol secretion 
occur in the ovulatory phase when progesterone is starting to rise, subsequently causing the surge 
in TC. The lower cortisol concetrations reported in the follicular phase of the menstrual cycle 
further demonstrate an association between TC and cortisol secretion, with estrogen the 
predominant hormone secreted, which is known to lower TC [14, 15]. In addition, women taking 
OC appear to experience higher resting levels of serum cortisol compared to normally 
menstruating women [21]. It is therefore likely that not only would women taking OC experience 
a higher TC due to greater progesterone secretion, it is possible that they would also experience a 
greater stress reponse to exercise, which may affect other parameters of health and performance. 
 
Chronic elevations in resting cortisol concentrations may affect mucosal immune system 
functioning [22, 23], through the down regulation of B-Lymphocyte mobilisation [24], 
specifically [s-IgA]. Salivary Immunoglobulin A is the major antibody present in mucosal fluids 
and its function is to inhibit viral and bacterial replication and attachment to the mucosal 
epithelium of the upper respiratory tract, thereby preventing pathogen entry into the body [25-28]. 
The suppression of [s-IgA] is closely associated with the anecdotal increase in respiratory tract 
infections (URTI) in athletes [29-31], particularly surrounding periods of high stress or load i.e. 
intense training. Initially the present thesis will focus on surf lifesaving (SLS) athletes, and the 
effect of competition on [s-IgA]. Surf lifesaving is a multidisciplinary ocean-based sport, 
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involving substantial physical conditioning and skill training to achieve ‘elite’ success. The 
specific group of SLS athletes investigated in the present thesis were national level athletes, 
competing in the Kellogg’s Nutri-grain Ironman and Telstra Ironwoman Series’ at the time of 
testing. The Kellogg’s Nutri-grain Ironman and Telstra Ironwoman Series’ are exclusive, elite 
competitions which involve up to six separate races, with the overall series winner named 
champion Irornman or Ironwoman. Each of the six races are a different length, format i.e. sprint 
vs. endurance, and are held at various beaches across Australia. All races encompass the 
fundamental Ironman or Ironwoman skills of soft-sand running, ocean swimming, Malibu board 
paddling and surf ski paddling. The multi-event nature of surf lifesaving competitions may result 
in many athletes failing to fully recover between events and competitions and subsequently 
experiencing declines in performance, as anecdotally reported by SLS coaches and athletes. 
Therefore initially the present thesis sets out to investigate the [s-IgA] response to elite SLS 
competition. The association between [s-IgA], stress and overall immune health are the 
predominant reasons why the s-IgA response is often monitored in applied sport science research. 
However, due to the impracticality of conducting research with a select group of elite athletes, as 
well as the expenses associated with travel to attend various surf life saving races, the focus of 
the present thesis alters to recreationally active women. Importantly, lymphocytes exhibit 
receptors for ovarian hormones [32] and can be affected by the menstrual cycle and OC 
administration. Estrogen in particular is associated with enhanced immune function [33], with [s-
IgA] reported to rise sequentially with estrogen levels throughout the menstrual cycle [34]. 
However, considering the total concentration of exogenous estrogen secreted in OC is lower than 
throughout the normal menstrual cycle, it is possible that women taking the OC may exhibit less 
s-IgA availability on the mucosal surfaces of the upper respiratory tract, potentially predisposing 
them to infection. 
 
Traditional measures of s-IgA and salivary cortisol (s-Cort) have involved expensive and often 
time-consuming laboratory tests. These laboratory tests, such as the gold-standard enzyme linked 
immune-sorbent assay (ELISA) method can be impractical for applied exercise and sport science 
research, due to strict storage and preparatory guidelines. The ELISA method can also take several 
hours to complete the sample analysis. The present thesis also investigates the reliability and 
validity of a novel point of care s-Cort method against the gold-standard ELISA method. 
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 1. 2  Significance of the Research 
Gender differences exist in relation to exercise performance which may, in part, be attributable to 
ovarian hormones estrogen and progesterone. However, evidence is emerging that indicates 
endogenous and exogenous forms of these hormones may elicit varying effects on the health and 
exercise performance of active females, and warrants individual investigation. In particular the 
interaction between progesterone secretion and increases in TC and subsequent thermoregulatory 
demands is thought-provoking and could have major implications for women exercising in hot 
climates such as northern Australia. The additional stress placed on women exercising in hot 
conditions when exposed to high levels of progesterone could induce greater cortisol secretion 
which may affect several parameters of health and performance. In particular s-IgA suppression 
is associated with rising cortisol levels, and is also known to respond to ovarian hormone secretion 
throughout the menstrual cycle. It is important to investigate how [sCort] and [s-IgA] respond at 
rest and in response to exercise in relation to endogenous and exogenous ovarian hormone 
secretion as this may have consequences for the health and performance of the exercising woman.  
 
Currently, little is known about the TC, stress and mucosal immune response to acute exercise in 
HH conditions in normally menstruating women compared to women taking OC. This 
investigation has the potential to provide a unique insight into the way OC may be affecting health 
and performance in women who often undertake exercise in warmer climates. Additionally, there 
is little qualitative understanding of the relationship between physical activity levels and OC use 
or non-use in women and the perceived benefits and the barriers for OC use in Australian women 
remains largely unexplored, despite an increasing prevalence of women taking OC in Australia 
and worldwide [35]. The lack of understanding of how taking OC may affect exercise 
performance and the increasing usage rates of OC in active women and female athletes highlights 
the need to explore the effect of exogenous estrogen and progesterone secretions on exercise 
tolerance, as well as the perceived benefits and barriers towards OC use.  
 
1. 2  Research Questions 
The present thesis will investigate several questions associated with the effect of exogenous 
estrogen and progesterone administration on several parameters of exercise tolerance in 
recreationally active women, as well as the perceived benefits and barriers towards taking OC in 
Australian women. 
1. Is the Individual Profiling (IPRO) point of care device a valid and reliable method of 
monitoring salivary cortisol concentration? 
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2. What is the Salivary Immunoglobulin A response to a single, multidisciplinary surf 
lifesaving event?  
3. Do male and female multidisciplinary, surf lifesaving athletes exhibit a different 
immune response to competition? 
4. What is the prevalence of OC use or non-use in Australian women? Is there an 
association between physical activity levels and OC use or non-use in these women? 
5. What are the perceived benefits and barriers towards oral contraceptive use (or non-
use) in Australian women? 
6. What is the effect of OC use on the mucosal immune and endocrinological response 
to incremental exercise? 
7. Does OC affect the TC response to incremental exercise in thermo-neutral and hot 
and humid environments? 
8. Does exercise in a hot and humid environment alter the mucosal immune and 
endocrinological response in women taking OC? 
 
1. 3  Research Progress Linking the Experimental Studies 
The present thesis will investigate several questions associated with the effect of exogenous 
estrogen and progesterone administration on several parameters of exercise tolerance in 
recreationally active women, as well as the perceived benefits and barriers towards taking OC in 
Australian women. To achieve this aim, four experimental research studies were undertaken and 
are presented as chapters three, four, five and six of the thesis.  
 
Each experimental study within the present thesis was designed to build upon the preceding 
chapter to enhance our understanding of the influence of exogenous estrogen and progesterone 
administration on exercise tolerance in active women. 
 
1. 3. 1 Experimental Study One 
In preparation for experimental study four of the present thesis which involved saliva 
analysis to monitor cortisol concentrations, a validity and reliability study for a new point 
of care saliva analysis test was completed. The IPRO device is a novel method of saliva 
analysis allowing sport scientists to collect and monitor salivary analytes in a field setting. 
The purpose of experimental study one was to establish the validity and reliability of the 
IPRO device for monitoring salivary cortisol concentrations against the gold standard 
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Enzyme-Linked Immunosorbent Assay (ELISA) method to ensure the accuracy of this 
method for use throughout the present thesis. 
 
1. 3. 2  Experimental Study Two 
Experimental study two examined the immunological response to a single endurance (90 
min) SLS ironman event, which involved monitoring [s-IgA] across a six day period 
surrounding the SLS event, including two measures on as many days prior to and three 
measures in as many days following the event collected at approximately 24 hr intervals, 
with two additional samples on the day of the race, collected at approximately 5 hr 
intervals. Experimental study two was conducted to gain a novel insight into the acute 
mucosal immune (s-IgA) response surrounding a single SLS ironman and ironwoman 
event. This particular group of athletes were chosen due to the intense nature of training 
and preparation which is required to compete at the elite level and because no data 
currently existed within this population regarding mucosal immune health. Due to the 
absence of information regarding OC use or menstrual cyclicity, several additional 
research questions were developed and evolved and changed the focus of the present 
thesis towards females only, and the effect of varying levels of estrogen and progesterone, 
as well as the effect of exogenous secretions in the form of OC. However, due to 
geographical constraints and athlete availability following experimental study two, it 
became clear further research into the acute mucosal response to exercise would be 
problematic within this sample population. Therefore, the decision was made to alter the 
focus of the population from elite SLS athletes to recreationally active women, as this 
would allow recruitment and the conduction of the remaining studies, which focus on 
females, to occur more efficiently.  
 
1. 3. 3  Experimental Study Three 
Following on from the previous investigation into the immunological response to elite 
SLS competition, and the subsequent questions raised in regards to OC use in women of 
varying physical activity levels, experimental study three aimed to gain a greater insight 
into the prevalence of, and motives for OC use in Australian women of varying physical 
activity levels ranging from sedentary to athletes. Participants completed a survey 
identifying their motives for OC use or their reasons for not taking OC. Information 
regarding the type, frequency and intensities of weekly physical activity was also 
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gathered in these women to identify any trends in physical activity levels and OC use (or 
non-use). The information gathered from this investigation provided insight into the 
prevalence of OC use, the role of physical activity levels in OC use or non-use, as well 
as the common benefits and barriers towards taking OC in Australian women.  
 
1. 3. 4  Experimental Study Four 
Experimental study four examined the mucosal immune and stress response to acute 
exercise in women. Both s-IgA and cortisol have been shown to be affected by the 
menstrual cycle, and it is possible that exogenous ovarian hormone exposure may 
augment these changes, placing women taking OC under more stress during exercise and 
potentially exacerbating exercise-induced decreases in [s-IgA] subsequently increasing 
the risk of URTI. Ovarian hormones, in particular progesterone have been associated with 
rises in TC. Considering fluctuations in TC have been shown to occur across the normal 
menstrual cycle in relation to progesterone secretion, it was intriguing to investigate if 
exogenous progesterone caused similar affects in women taking OC and if these effects 
varied between TN and HH environments.  
 
Independently and collectively, each of the four experimental studies presented in the 
present thesis represent a more robust investigation of effect of exogenous estrogen and 
progesterone secretion on exercise tolerance in active women than reported previously 
and contribute to the current understanding of the demands of acute exercise in TN and 
HH environments in women taking OC.  
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CHAPTER TWO 
 
Review of the Literature 
 
2. 1  THE MENSTRUAL CYCLE AND EXERCISE TOLERANCE 
2. 1. 1 The Menstrual Cycle 
On average, the menstrual cycle is 28 days in duration but reportedly [36] ranges between 20 to 
45 days in some women [37]. The menstrual cycle can be broken down into three distinct phases, 
namely the follicular phase, luteal phase and the ovulatory phase [37-39]. The follicular phase 
begins on day one with menses and culminates with ovulation, while the luteal phase is initiated 
following ovulation through to the start of the menses [37]. In healthy women aged 19-42 yr, 
ultrasound studies have reported the follicular phase to last for 14.6 days and the luteal phase to 
last for 13.6 days in duration [40], however the phases have been reported [41, 42] to last between 
10-23 and 7-19 days in the follicular and luteal phases respectively. The large variations in phase 
length can make it difficult to predict each stage and highlights the uniqueness of the menstrual 
cycle. Throughout the follicular phase, follicle stimulating hormone (FSH) initiates the 
production of 15-20 follicles each cycle [43]. Within a normal menstrual cycle one follicle will 
become dominant, with the remaining follicles undergoing atresia [43]. The dominant follicle will 
continue to develop by acquiring increasing amounts of FSH, while releasing estradiol [43]. 
Estrogen levels will continue to rise until the end of the follicular phase at which point a positive 
feedback mechanism stimulates the secretion of luteinizing hormone (LH) which initiates 
ovulation [38, 43, 44] at which point the immature ovum is released [39]. Once the ovum is 
released the granulosa and theca cells, as well as some surrounding tissues join to form the corpus 
luteum [37, 43] as a means of stabilising the endometrium for implantation of the fertilised egg, 
which is achieved through the secretion of estrogen and progestin [37]. If fertilisation does not 
occur, both estrogen and progestin will rapidly decrease, which results in the shedding of the 
uteral lining as menstrual blood flow [38], at which point the process begins again [37].   
 
2. 1. 2 Hormonal Stimulation of the Menstrual Cycle 
The regulation of the menstrual cycle is controlled by a series of hormonal secretions, with the 
pituitary gland, which stimulates the ovaries to release varying levels of hormones depending on 
the phase of the menstrual cycle. The regulation of the pituitary gland is controlled by the 
hypothalamus which responds to internal and external stressors, including exercise and 
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temperature [45]. Throughout menstruation hypothalamic GnRH and FSH are responsible for 
stimulating the gonads for regular hormone release [46]. The hypothalamus will release GnRH in 
a pulsatile manner once per 90 min during the follicular phase and once per 60-70 min in the 
luteal phase of the menstrual cycle [43] and in response to the secretion of norepinephrine (NE), 
serotonin, and corticotropin-releasing hormone (CRH) [36]. The release of GnRH stimulates the 
pituitary gland to secrete LH and FSH [18, 47]. The secretion of FSH is crucial throughout the 
first week of the follicular phase [43] due to its role in releasing the immature ovum [39]. 
Luteinizing hormone is necessary for the growth of pre-ovulatory follicles as well as luteinisation 
and ovulation of the dominant follicle [43]. The levels of  LH, FSH and estradiol fluctuate 
throughout the menstrual cycle , upon peaking in the ovulation phase, hormone levels will 
decrease into the luteal phase [46]. The release of LH and FSH initiates the secretion of estrogen 
and progestin from the ovaries [36, 39], by activating aromatase and p450 enzymes [43]. Once 
released, estrogen and progestin signal the pituitary to control the release of LH and FSH and 
subsequently the release of GnRH from the hypothalamus, which completes the negative feedback 
loop [36, 39, 43]; this entire process is under regulation of the hypothalamic-pituitary-ovarian 
axis [16]. While NE is considered a stimulant of GnRH [36], corticosteroids and CRH reportedly 
inhibit the release of GnRH [16, 17]. Any disturbance to the hypothalamus, which causes changes 
in homeostasis such as increased stress associated with high intensity exercise could therefore 
lead to alterations the hormonal regulation and release from the ovaries, ultimately leading to an 
altered or absent menstrual cycle, which may have implications for exercising women. 
 
2. 1. 3 Ovarian Hormones 
There are two major groups of ovarian hormones which are secreted throughout the menstrual 
cycle, namely the estrogens and progestins, each of which play a crucial role in menstrual cycle 
regulation. Estrogens are a group of 18-carbon steroids which promote fat deposition in females, 
generally surrounding the buttocks, breasts and thighs [48]. Both estrogen and progestin have 
several forms, the major and most potent form of estrogen is estradiol, with estrone and estriol 
being less potent , while progesterone is the predominate form of progestin [37]. Progesterone is 
produced from 19-nortestosterone, 17-OH progesterone derivatives and 19-norprogesterone and 
is expressed in many forms with different affinities and potencies [49]. Two common types of 
progesterones are levonorgestrel and norethindrone which bind to progesterone receptors, these 
progesterones are secreted in high amounts from the corpus leutem following ovulation and 
remain high until menstruation [50]. Estrogen in its endogenous form is produced from the ovaries 
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as 17β-estradiol, which binds to both estrogen receptor alpha (ER) and estrogen receptor beta 
(ERβ) with equal affinity [51, 52]. Upon estrogen activation of ER or ERβ, two known pathways 
occur, namely the genomic and non-genomic pathways [53]. In the genomic pathway estrogen 
passes through the lipid membrane and binds to receptors on the nucleus, which will activate or 
suppress gene transcription [53]; these actions are generally delayed in onset and prolonged in 
duration [54]. Whereas, the non-genomic pathway involves the activation of cell membrane 
receptors causing intracellular messengers including nitric oxide, calcium and kinase to be 
released [53], which has a rapid onset and is short in duration [54]. Estradiol and progesterone are 
secreted in varying amounts throughout each phase of the menstrual cycle; estradiol levels are  
lower during the follicular phase, peaking just before ovulation and decreasing throughout the 
luteal phase [19, 55], while progesterone levels are at their highest in the luteal phase [46, 47] 
generally peaking six days following ovulation and progressively declining to pre-ovulatory 
levels at the beginning of menses [56]. For the purposes of the present thesis, the generic terms 
estrogen and progesterone will be used to describe each group of ovarian hormones, unless a 
specific form of either hormone is stated. 
 
2. 1. 4  Ovarian Hormones and Health 
Each ovarian hormone has a different effect on immune system functioning with progesterone 
reported to inhibit the immune response [57-60], while estrogen was observed [57-59, 61] to 
stimulate immune functioning in low doses and inhibit the immune response in high doses.  It is 
possible that the association between estrogen and cortisol may contribute to the inhibition of 
immune functioning throughout periods of high estrogen secretion i.e. the follicular phase, as 
estrogen has been suggested as a modulator of cortisol [21], with reports [19, 20, 62] of spikes in 
cortisol during ovulation; immediately following a surge in estrogen secretion. In addition to 
changes in immune health and stress in relation to fluctuating estrogen and progesterone levels, 
cardiovascular health can also be affected. Estrogen receptor alpha has several known effects on 
the cardiovascular system, including initiating an acute vasodilatory response through the release 
of  nitric oxide synthase [63, 64] in the non-genomic pathway, as well as increasing endothelial 
cell growth and reducing the proliferation of smooth muscle cells in the genomic pathway [53]. 
Due to the varying secretions of estrogen throughout the normal menstrual cycle, it is possible 
that the cardiovascular changes [53, 63, 64] which occur in response to ER activation may vary 
from phase to phase, subsequently having consequences for the health of women.  
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2. 1. 5  The Menstrual Cycle and Athletic Performance 
While it is possible for estrogen to affect the cardiovascular health of a woman, it is generally 
accepted that the menstrual cycle does not adversely affect exercise performance in the athletic 
or general population [65-67]. Maximum oxygen uptake, which is the product of the extraction 
of oxygen in the tissues and the amount of blood delivered to them [48], has been shown to be 
unaffected by normal [68-71] or hot conditions [72-74] in relation to the menstrual cycle. 
Additionally, several measures of athletic performance including aerobic capacity, anaerobic 
capacity and high intensity endurance ability are not significantly affected by menstrual cycle 
phase on several physiological tests including maximum HR, maximum minute ventilation (VE), 
maximum respiratory exchange ratio (RER), and endurance time to fatigue [65]. Moreover, 
metabolic and cardiovascular responses in untrained and trained females were monitored at rest 
and during exercise throughout the luteal and follicular phase as well as during menstruation, 
finding no response was significantly affected by any phase of the menstrual cycle [75], further 
demonstrating a lack of a relationship between endogenous estrogen and progesterone and 
exercise performance.  
 
2. 1. 6  Exercise and Common Menstrual Disturbances. 
Female athletes and active women often experience changes to their menstrual cycle depending 
on their level of physical activity [76-80], which may increase the prescription of OC to regulate 
or simulate a normal menstrual cycle. Menstrual disturbances appear to be common in adolescent 
female athletes, with reports [78, 81-83] of up to 54% of highly active women experiencing 
irregularities in their cycles. The most frequently occurring disturbances in athletes include 
changes to the duration of the menstrual cycle, delayed menarche in young women, as well as 
oligomenorrhea, dysmenorrhoea and in severe cases secondary amenorrhea [84-87]. It has been 
reported that up to 90% of women experience symptoms of dysmenorrhoea, including excessive 
menstrual pain that limits normal activities or requires medication [87-90]. The pain which is 
characteristic of dysmenorrhoea has been associated with the release of prostaglandins which are 
secreted in response to increases in myometrial activity [91]. It is also common for women to 
experience premenstrual syndrome (PMS) which may include breast tenderness, bloating and 
acne slightly prior to menstruation [92], with these factors potentially limiting or affecting a 
woman’s desire to engage in exercise. 
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In severe cases, highly active women may experience secondary amenorrhea, which is 
characterised by hypothalamic dysfunction leading to complete follicular and luteal suppression, 
resulting in a lack of estrogen secretion [93, 94]. A lack of estrogen secretion may affect the health 
and wellbeing of the woman, as estrogen is known to induce positive effects on immune and 
cardiovascular health [63, 64]. Secondary amenorrhea is more common in females athletes who 
exhibit smaller physiques with low body fat [95, 96] including endurance athletes such as runners 
and SLS athletes [97]. Secondary amenorrhea reportedly affects between one and 50% of highly 
active women but only 2-5% of the general population, suggesting a link between exercise levels 
and estrogen suppression [97-102]. Lower levels of estrogen were reported in exercising women 
compared with eumenorrheic women [93, 94], further demonstrating the relationship between 
exercise and estrogen suppression. It is likely that this absence of ovarian hormones secretion is 
due to a suppression of GnRH in response to chronically elevated cortisol and CRH secretion 
following long-term, high intensity exercise. Exercise-induced estrogen suppression may have 
implications for the health of female athletes and highly active women, with estrogen shown to 
contribute to decreases in calcium absorption in the bone, affecting development [103, 104]. 
Estrogen suppression can also negatively affect vascular function, vascular tone, homeostasis, 
fibrinolysis [105, 106] and white blood cell trafficking, and contribute to a suppression of the 
mucosal immune system [107]. 
 
2. 2  ORAL CONTRACEPTION AND EXERCISE TOLERANCE 
2. 2. 1  Oral Contraception 
Modern OC contain varying combinations and dosages of synthetic hormones, namely estrogen, 
and progesterone, depending on the type and brand of OC utilised [108]. Oral contraceptives are 
used to inhibit the HPA axis from stimulating the secretion of endogenous estrogen and 
progesterone [109]. The suppression of the HPA axis precludes the production of gonadotropins 
mid-cycle, which prevents ovulation and consequently, the ability for fertilisation to take place 
resulting in pregnancy [109, 110]. There are two types of OC; namely combined OC (COC) and 
progesterone only or mini pills. Progesterone-only mini pills are often utilised when the woman 
cannot tolerate estrogen [111, 112] and are a less commonly used form of contraception due to 
statistically preventing approximately 1 in 2 pregnancies [111]. Combined OC are characterised 
by having a specific dosage of estrogen and progesterone [111]. There are three forms of COC, 
namely monophasic, biphasic and triphasic, each of which secrete constant, two-phase or three-
phase increases in dosages of exogenous ovarian hormones [111, 112] throughout the 21-day 
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active pill phase respectively. Biphasic and triphasic COC attempt to replicate the normal 
fluctuations in hormones which occur throughout each stage of the menstrual cycle, while 
monophasic OC releases the same dosage of estrogen and progesterone throughout the entire 
cycle [37, 43]. In biphasic OC the dosage of progesterone is altered between days 7-10 and 11-
14, while estrogen secretion remains constant [112, 113]. In triphasic OC the dosage of estrogen 
is increased three times throughout the cycle. The average concentration of estrogen present in 
monophasic OC pills is 0.03 mg/d, with a range of 0.02 to 0.05 mg/d depending on the brand of 
OC utilised, while in triphasic OC pills estrogen concentration is predominantly between 0.03 and 
0.04 mg/d [114]. The concentration of progesterone in both monophasic and triphasic OC also 
reportedly varies between brands [108]. The alternate types of OC may evoke different effects on 
exercise performance, particularly cardiovascular ability when exogenous estrogen is secreted in 
varying concentrations. Women taking monophasic OC are likely to exhibit consistent 
physiological adaptations due to a constant secretion of exogenous estrogen, compared with 
women taking biphasic or triphasic OC with progressive increases in exogenous estrogen 
secretion potentially affecting cardiovascular ability, and ultimately exercise performance.  
 
Modern OC have considerably reduced the amount of synthetic hormones present compared with 
earlier generations of OC [115], with four- and ten-fold decreases in estrogen and progesterone 
respectively [37]. Despite the lower concentrations of estrogen and progesterone secretion in 
current-day (third generation) COC [37] compared with first-and second-generation OC, the 
relative secretions of both exogenous estrogen and progesterone differ from endogenous 
secretions throughout the normal menstrual cycle, with more progesterone and less estrogen 
secreted in COC compared with regular endogenous secretions [108]. Considering the 
concentration of estrogen and progesterone differ in OC users, it is probable that the effects of 
these hormones on the physiology and health of the woman would differ from normally 
menstruating women compared with women taking OC. Currently there is a lack of understanding 
with respect to the influence of exogenous estrogen and progesterone secretion on exercise 
capacity in OC users and this warrants investigation. 
 
2. 2 .2 Combined Oral Contraceptives and Menstrual Disturbances 
It is possible that highly active women who have been engaged in intense training regimes for 
substantial periods of time may use OC for cycle regulation [116], in the event that they are 
experiencing conditions such as secondary amenorrhea. In addition to regulating the menstrual 
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cycle, and despite the absence of conclusive evidence to substantiate the practice, COC are often 
used to treat dysmenorrhoea [117], with a noteworthy reduction in menstrual pain observed in 
COC users compared with placebo users [118] in women suffering from grade II or grade III 
dysmenorrhea as determined by the Andersch and Milsom dysmenorrhea index [119]. Further to 
dysmenorrhoea, COC may be useful in decreasing the symptoms associated with endometriosis, 
with reports of reduced pain in three out of four women taking OC [117, 120, 121]. A reduction in pain 
and symptoms associated with dysmenorrhoea and endometriosis in relation to OC use could be 
ideal for active women who may be experiencing these negative affects throughout exercise, and 
may contribute to the increasing rates of OC use in active women [122, 123]. Active women may 
also elect to take OC to avoid menstruation which can be done when women using COC continue 
to take active pills rather than only taking them for 21 days and then consuming the inactive pills 
which trigger menstruation [124-127], however taking OC to reduce pain and discomfort or to 
avoid menstruation may be unknowingly evoking adverse effects on exercise performance. 
While the menstrual cycle does not appear to affect exercise performance [65-67] it is possible 
that the menstrual cycle could adversely affect perception of- and motivation towards exercise. 
Early studies [48, 115, 128, 129] investigating athlete attitudes towards competing at different 
stages of their menstrual cycles revealed a belief of performing ‘best’ during the inter-menstrual 
or postmenstrual phase and ‘worst’ in the premenstrual phase in Olympic athletes. Performance 
based studies in adolescent swimmers found [130, 131] the postmenstrual and menstrual phase to 
have the best performances, while the worst were observed in premenstrual phase or at the 
beginning of menses, which may also provide motivation for active woman to take OC as the 
timing of menstruation could be manipulated surrounding competition when the athlete believes 
she will perform optimally. Active women may also elect to use COC to reduce physical and 
psychological symptoms associated with PMS [132, 133]. Despite the reported benefit that OC 
may lessen the adverse symptoms associated with the menstrual cycle, women may dislike taking 
synthetic hormones particularly if they are not sexually active or if they are using other forms of 
contraception and deem the pill to be unnecessary. Conflicting findings regarding OC use and 
non-use in women who deem them unnecessary currently exist. In a survey of 461 female medical 
students 65.3% reported using OC regardless of their marital status, while 43.4% claimed they 
did not use OC because they were not necessary, suggesting the motives and deterrents for OC 
use are quite intricate and unique to the individual woman [134], and may therefore be influenced 
by other factors such as exercise level or knowledge of the effects of taking OC on exercise 
performance.  
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2. 3  PERCEIVED BENEFITS AND BARRIERS TOWARDS ORAL 
CONTRACEPTIVE USE IN WOMEN 
2. 3. 1  Benefits of Combined Oral Contraception 
Numerous non-contraceptive benefits of taking OC exist including decreasing uterine fibroids 
[135], relief of PMS [132], endometriosis [120, 121] and ovarian cysts [117] as well as decreasing 
the risk of some cancers including endometrial, colorectal and ovarian[117] . Oral contraceptive 
use may also be helpful in lessening the symptoms of dysmenorrhea [118], acne vulgaris [136], 
iron-deficiency anaemia [137] and may lead to increases in bone mineral density [111, 138]. 
Influencing the aforementioned menstrual symptoms may be of importance to highly active 
women to minimise the risk of fractures, particularly if they have been affected by menstrual 
disturbances causing changes in endogenous estrogen secretion throughout crucial periods of 
bone development. It not uncommon for females, particularly adolescent girls to be prescribed 
OC to help attenuate the symptoms associated with acne vulgaris [139]. Sex hormone binding 
globulin levels are elevated when using COC, subsequently decreasing ovarian and androgen 
hormonal secretion [117], which can help lessen hirsutism, acne lesion grade and count and 
seborrhoea [111, 136], which may be of psychological importance to female athletes, particularly 
if competition is televised and is highly publicised. In addition, COC use may help with menstrual 
disturbances as non-OC users were reportedly referred to hospitals presenting with excessive 
periods, painful periods, irregular periods or other menstrual disturbances more often than women 
taking COC [140].  
 
The influence of OC was examined by a Cochrane review that was  unable to demonstrate a 
reduction on menstrual blood loss in response to OC administration [141]. However an earlier 
study of 45 women concluded  menstrual blood loss was lessened by 43% over two cycles in 
COC users when compared with non-users and progesterone-only users [137]. Estrogen may be 
the potential mechanism for reduced blood loss, because in women with high levels it has been 
observed to cause the inner lining of the uterus to thicken [43]. If estrogen is the major factor 
contributing to menstrual blood loss, this would explain why the recent Cochrane review [141] 
was unable to substantiate the earlier findings of Fraser and McCarron [137] as the relative 
concentrations in the OC administered in the Cochrane review [141], would have contained 
substantially less exogenous estrogen than the second generation OC likely investigated 
previously. The effect of OC on menstrual blood loss may be of particular importance to women 
suffering from menorrhagia (or menstrual blood loss of >80ml cyle-1) which can pose a threat to 
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women as two-thirds of women diagnosed with the condition are also considered to have iron-
deficiency anaemia [142]. Iron deficiency anaemia can place a serious health threat on women, 
which is why OC have often been prescribed to women to attenuate substantial menstrual blood 
loss [143]. Additionally, OC users have also been shown to exhibit elevated ferritin levels [144], 
and may therefore be able to store iron levels more effectively than non-users, which may have 
positive effects on bone development and health. It is therefore possible that OC secreting high 
dosages of estrogen may play a role in decreasing menstrual blood loss, which could be of 
importance to highly active women. Particularly women already at risk of iron-deficiency 
anaemia due to iron depletion from foot strike haemolysis and iron loss via sweating throughout 
exercise [145-147] or in women experiencing menorrhagia [148, 149] and could contribute to the 
increasing prevalence of OC use in modern-day, active women. 
 
2. 3. 2  The Risks of Oral Contraceptive Use 
In contrast to the reported health and wellbeing benefits of OC use in active women [117], [132] 
there are several risks associated with OC use, namely fluctuations in body weight [150, 151], 
breast tenderness [151], nausea [150], headaches [150] and interference with a woman’s bleeding 
pattern, which is particularly  prevalent in women using progesterone-only (mini) pills [43]. More 
serious health risks associated with OC use include increased risk of , ischaemic stroke [111, 152], 
breast [117, 138, 153] and cervical cancer [117, 138, 154], cardiac problems in smokers, 
myocardial infarction as well as a susceptibility to venous thromboembolism [111, 117, 155]. The 
risk of venous thromboembolism increases in women using OC however this increase is still 
considered minor [111], with reports  of 5, 15 and 25 cases per 100 000 in non-OC users, second 
generation OC users, third generation OC users respectively [156]. Similarly, the risk of 
ischaemic stroke is slightly increased in COC users and this risk may be exacerbated in smokers 
or in women with hypertension [117]. Furthermore, the risk of cervical cancer is slightly elevated 
in COC users, with this risk rising with increased duration of use [111, 117]. However this time-
dependent increased risk may not become pronounced until several years of OC use, with reports 
of users of five or less years not exhibiting any elevated risk compared with never-users, although 
COC users of eight or more years showed a very small increase in cervical cancer risk [157]. The 
increased risk of developing some cancers, venous thromboembolism, stroke or myocardial 
infarction, combined with non-life threatening factors such as nausea, headaches, breast 
tenderness and fluid retention may be considered barriers for OC use by some women, ultimately 
preventing them from taking OC. 
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The benefits associated with OC use appear to out-weigh the risks, with OC usage increasing in 
the Australian general population from 44.1%, 45% to 47.8% between 2005, 2008 and 2011 
respectively [158], with similar usage rates reported in the Australian athletic population [159, 
160]. It is possible, that women are not disregarding the health risks of OC use, rather this trend 
of increasing OC prevalence may reflect a lack of understanding of the way OC use may affect 
health and physiology, with women reportedly poorly informed about the effects of OC on health 
and performance [161-163]. Several survey-based studies have concluded [163-165] up to 75% 
of women are unaware of the health benefits of OC use not associated with preventing unwanted 
pregnancies. One study [166] found 54% of women believed there were substantial health risks 
associated with using OC, including cancer, heart attacks, blood clots and hypertension, with 40% 
of women unaware of any health benefits associate with OC use. However the respondents who 
were aware of the benefits of taking OC, reported cycle regulation to be the most important non-
contraceptive benefit of the pill, followed by balancing hormone levels and a reduction in 
dysmenorrhoea. An earlier study [162] found only 42% of women did not believe there were non-
contraceptive-related benefits to using the pill, while 22% stated cycle regulation as a 
supplementary benefit. A similar study to that of Bryden and Fletcher [162] of 1201 women from 
the UK, German and France aged between 16-45 years found cycle regularity, a reduction in 
dysmenorrhea and acne relief to be the most known, non-contraceptive benefits of the pill in 60%, 
42%, and 37% of women respectively [163]. Correspondingly, in a study of 2248 ninth grade 
secondary school girls, menstrual cycle irregularity and treating dysmenorrhea were reported as 
the reasons for OC use, more often than preventing unwanted pregnancies, however the age of 
participants in this study should be considered as secondary school girls may not be sexually 
active and subsequently not using OC to prevent pregnancy [139]. It is possible a greater 
awareness of the relationship between OC use, health and exercise performance could affect OC 
usages rates in women and should be considered. 
 
2. 3. 3  Oral Contraceptives and Athletic Performance 
Oral contraceptives have been shown [7, 8, 167] to lead to a reduction of 5-15% in peak oxygen 
uptake (   ΟV 2  peak) and   ΟV 2  max, which could have significant implications for exercise 
performance. Females exhibit a smaller heart volume than males and consequently display 
reduced cardiac output (Q̇) and stroke volumes [3], with Q̇ considered a major contributor to   ΟV 2
max [168, 169]. Another important factor contributing to   ΟV 2 max is haemoglobin, specifically 
the concentration and number of red blood cells [5]. Generally women will exhibit a lower 
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haemoglobin level and total red blood cell count as a result of blood loss from the menstrual cycle 
[5]. It is therefore possible that this could be different between normally menstruating women and 
women taking OC, with OC shown to reduce blood loss associated with menstruation [137, 143]. 
Additionally, muscle repair and regeneration mechanisms were reportedly [170] less effective in 
COC users compared with normally menstruating women in response to controlled eccentric 
exercise-induced muscle damage. Together, these findings [7, 8, 170],[5] suggest exogenous 
ovarian hormone secretion has a different effect on exercise performance than endogenous 
secretions. 
 
Oral contraceptives are reportedly [35] used by more than 100 million women worldwide, with 
up to 76% of Australian women in 2001 reported to have used ‘the pill’ in the past  [171]. 
Considering this high prevalence rate of COC use, it is not surprising that they are often used by 
active women. In 1997, 716 basketball, volleyball and soccer athletes were surveyed on women’s 
health, finding 46% of athletes were taking some form of OC [122]. In a subsequent study of 112 
American collegiate athletes, 44% reported taking some form of OC in 2006 [123]. Taken 
together these studies [123] [122] [35] [171] suggest OC use is increasing and depending on the 
age, demographics and socioeconomic status of women, OC use can be quite prevalent. 
Considering the growing number of women taking OC it is important to explore the way 
exogenous estrogen and progesterone secretion affects exercise tolerance and the health of the 
woman. 
 
2. 4  OVARIAN HORMONES AND THE STRESS RESPONSE TO EXERCISE 
2. 4. 1  Nervous System Activation and Cortisol Secretion 
The HPA axis is crucial in the support of regular physiological functioning, in particular adapting 
to increased stress demands [172]. The hypothalamus receives and monitors information about 
the environment through various sensory means namely, visual, olfactory and hearing sensing as 
well as information regarding temperature, pain and emotion [45]. Upon receiving this 
information, appropriate responses will be coordinated by the hypothalamus through neural 
stimulation and hormone release, in an attempt to maintain homeostasis [45]. Specifically, upon 
activation of the HPA axis, CRH neurons are sent regulatory impulses from several 
neurotransmitter systems including β-endorphin-producing neurons [173-175] and pro-
inflammatory cytokines to initiate CRH secretion, stimulating the release of ACTH from the 
pituitary gland [172, 176, 177]. At this point the adrenal cortex secretes glucocorticoids [178], 
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namely adrenalin and cortisol [177, 179, 180]. Cortisol is a very potent hormone in human 
physiology and can easily target most of the body’s cells [181]. Cortisol is responsible for several 
catabolic processes including reduced protein synthesis, increased protein degradation and 
inhibition of the inflammatory process [182, 183]. Additionally cortisol plays a role in stabilising 
metabolism and energy production [172, 184] by maintaining glucose production from protein, 
facilitating adipose metabolism and supporting vascular responsiveness, as well as regulating 
several important physiological systems, including the central nervous system (CNS), the 
cardiovascular system and the immune system [172, 185, 186]. Although the menstrual cycle does 
not appear to influence the HPA axis 139, 302, 318, the variation in the concentration of exogenous 
estrogen and progesterone secreted while taking OC may evoke a different HPA axis response 
and should be investigated as it remains largely unexplored.  
 
2. 4. 2  Cortisol and the Hypothalamic-Pituitary-Adrenal Axis 
An increase in the amount of circulating cortisol which is commonly associated with HPA axis 
activation and subsequent secretion of adrenal glucocorticoids, often results in a negative 
feedback loop which leads to HPA axis suppression [187] through the increased release of anti-
inflammatory cytokines [188]. Chronic stress has been shown to cause changes in the HPA axis, 
ultimately leading to circadian changes in cortisol secretion [189, 190] and a decreased sensitivity 
of cortisol [191] which may lead to higher circulating concentrations of cortisol. Prolonged 
increases in the levels of circulating cortisol due to chronic activation of the HPA axis could lead 
to reduced sensitivity of the hypothalamus and the pituitary to glucocorticoid signalling, which 
inhibits the negative feedback loop designed to reduce HPA axis stimulation [187]. The prolonged 
release of glucocorticoids from chronic HPA axis stimulation may adversely affect the immune 
system by decreasing the number and function of several circulating immune cells including 
lymphocytes, reducing antigen presentation [177] and can lead to degenerative health potentially 
exacerbating existing health problems [45]. Intense or prolonged exercise which elicits a greater 
stress response and subsequent release of cortisol, could ultimately contribute to the suppression 
of the immune system, which may be amplified in women taking OC due to the association 
between exogenous estrogen and increases in cortisol concentrations through amplified HPA axis 
activity [192]. If women taking OC are experiencing greater cortisol concentrations as a result of 
an estrogen-induced amplification of HPA axis activity, they may experience further reductions 
in immune functioning, ultimately predisposing them to illness.  
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2. 4. 3  The Effect of Estrogen on the Hypothalamic-Pituitary-Adrenal Axis 
Proposed changes in mineralocorticoid and glucocorticoid receptor gene expression and function 
have been suggested to be responsible for HPA axis stimulation in humans and animals [193-196]. 
Additionally, estradiol-induced impairment of negative feedback regulation [194], changes in the 
electrical and chemical characteristics of hypothalamic neurons [197] and improved CRH gene 
transcription in the hypothalamus as a result of estrogen [192] have also been suggested as 
possible mechanisms of increased HPA axis activity. Changes in the suprachiasmatic nucleus 
(SCN) which is involved in the daily regulation of cortisol secretion, in response to estrogen levels 
during the menstrual cycle may also contribute to variations in HPA axis activity [198, 199]. 
However, as  the HPA axis was not shown to be affected under control or challenge conditions 
throughout the menstrual cycle [19, 200, 201] and no evidence of daily fluctuations in HPA axis 
activity were found as a result of the menstrual cycle in healthy women [202, 203], it is possible 
that only exogenous estrogen in OC may have a pronounced effect on the SCN.  
 
2. 4. 4  Exercise and Stress 
Stress is the state in which under the influence of internal or external stimuli (stressors), 
homeostasis is threatened [204]. The core stress response, which was originally described by 
Selyne in 1936 [205, 206] indicates the acute production of glucocorticoid hormones from the 
adrenal cortex stimulates the metabolism of glucose to produce energy, which is used to evade an 
immediate threat, through the fight or flight response [207, 208]. Any disturbance of the stress 
response can result in an imbalanced physiology of the body, thus leading to enhanced 
susceptibility to infection or inflammatory disease [45]. There are several stressors which can 
elicit a cortisol response from the HPA axis. Cognitive or psychological stress is reportedly 
sufficient to lead to increases in cortisol levels [209], as well as the threat of physical danger [210] 
and ambient temperature [211].  A potent stressor is exercise, such as that undertaken by 
participants in the present thesis, as it causes substantial changes to the physiology of the organism 
and threatens homeostasis [212]. Increases in the concentration of stress hormones such as cortisol 
[213-215] have been reported to occur both during [216] and prior [217] to exercise as a result of 
physical exertion and anticipation of exercise.  
 
2. 4. 5  The Effect of Estrogen and Progesterone on Cortisol 
The effect of endogenous ovarian hormonal fluctuations on circulating cortisol levels is equivocal 
[19, 200-202, 218, 219]. With no differences observed between the plasma adrenocorticotropic 
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hormone (ACTH) and cortisol concentrations in the luteal and follicular phases of the menstrual 
cycle [21, 201, 219, 220] when challenged under high intensity (90%   ΟV 2 max) and endurance 
conditioning. While others have shown [19, 20] cortisol and ACTH levels to be decreased 
throughout the follicular phase of the menstrual cycle and increased during ovulation, at rest. 
Exogenous ovarian hormones in the form of OC appear to have clearer effects on circulating 
cortisol when compared to endogenous secretions. Women using COC reportedly exhibit 
increased resting levels of serum cortisol compared with non-contraceptive users and males [21, 
221, 222]. The elevated serum levels of cortisol which were observed [221, 222] in women using 
COC, may be a result of ethinyl estradiol which is a common estrogen found in monophasic OC. 
Ethinyl estradiol reportedly increases the production of hepatic corticosteroid-binding globulin 
(CBG) [19, 21, 223], leading to increases in the binding capacity of serum cortisol as well as the 
total concentration of cortisol and can potentially prevent connection of cells to the endothelium 
by influencing neutrophil trafficking [224]. In addition to increasing the binding capacity and 
total concentration of cortisol, an increased synthesis of CBG observed in OC users [19, 21, 222, 
223], results in lower metabolic clearance rates and larger half-life times for cortisol metabolism. 
Importantly, this increase in CBG-bound cortisol levels, appears to act as a buffer within the 
plasma, ultimately delaying HPA axis stimulation [222], consequently affecting normal circadian 
fluctuations in cortisol and potentially dampening the free cortisol response [19]. Long-term 
exposure to elevated cortisol levels can have adverse effects on the body including muscle atrophy, 
impaired growth and tissue repair and immunosuppression as well as causing changes to normal 
circadian rhythms [225-227]. Furthermore, when cortisol levels are extremely high cognitive 
processing can be adversely affected [228], which could pose complications for not only 
competitive exercise, but activities of daily living. On the basis of our current understanding of 
the influence of long term elevated cortisol levels associated with OC use it is possible that 
exogenous estrogen and progesterone administration may have adverse consequences for the 
health and performance of active women and warrants further investigation. 
 
2. 4. 6 Circadian Variations and Cortisol Secretion 
Cortisol has been shown to experience a circadian rhythm throughout the day [176] which may 
affect the secretion of cortisol in response to exercise throughout a 24 hour period [229]. Cortisol 
secretion rates are reportedly elevated after morning awakening, generally peaking within 30 - 45 
min post-awakening and progressively declining throughout the day [22]. It is this response to 
consciousness which is referred to as the cortisol awakening response (CAR) [230, 231]. The 
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CAR is a component of physiology closely regulated by the circadian cycles which are necessary 
for homeostasis and healthy living; it is not an isolated response to morning awakening [181]. 
Pruessner et al (1995) found a 50-100% increase in salivary free cortisol within 30 min of 
awakening in healthy participants [232], highlighting the demand for standardisation of testing 
protocols and caution when interpreting early morning samples [233]. Circadian variations in 
salivary cortisol appeared to be affected throughout the various stages of the normal menstrual 
cycle, with minor variations in salivary cortisol occurring in response to the various phases of the 
cycle [234, 235]. However, the CAR was neglected in both of these studies [234, 235] and the 
ovulatory phase was excluded from Odber et al (1998) [234]. It has been reported [46] that the 
CAR may be affected during ovulation due to gonadal steroids stimulating HPA axis regulation, 
and any variation in results during this period (cycle days 12-16) may reflect changes in hormonal 
levels. This variation in hormone levels which may be stimulating the HPA axis may be different 
between OC users and normally menstruating women due to the variation in concentrations of 
estrogen and progesterone secreted throughout either cycle. Suggesting differences in cortisol 
section may occur between women taking OC and women who are normally menstruating.  
 
2. 4. 7  The Effect of Exercise on Cortisol Secretion 
The intensity and duration of exercise may determine the magnitude of the stress response to 
exercise, with cortisol expected to rise sequentially with the duration of physical activity [236]. 
High intensity, acute resistance exercise has been shown to result in a 97% increase in salivary 
cortisol from baseline values [237], with increases in cortisol concentrations also observed 
following wingate sprint interval training in recreationally healthy males [238], a 6 hr relay race 
in healthy males [239] and high intensity cycling lasting 1hr in duration [240]. Once exercise 
reaches 60-65%   ΟV 2  max the HPA axis becomes stimulated and increases in TC and the 
concentration of several stress hormones including cortisol, adrenalin, growth hormone and β-
endorphin increase [241, 242], with the release of several of these stress hormones including 
adrenalin leading to increases in HR and blood flow to lymphoid tissues [242]. The intensity and 
duration of exercise may influence the extent of the cortisol response with serum levels of cortisol 
reported to remain elevated for several hours following the cessation of endurance exercise [243-
245]; indicating prolonged exercise has a more pronounced effect on serum cortisol compared to 
acute exercise. Additionally, the type of exercise undertaken may contribute to the cortisol stress 
response to exercise with cortisol observed to reach extreme values in elite rowers, which may be 
due to the large muscle mass utilised throughout rowing [246, 247], suggesting the volume of 
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muscle mass used throughout exercise may influence the subsequent stress response. 
Cardiovascular capacity may also contribute to the subsequent cortisol response to exercise, with 
highly trained individuals often evoking an increased cortisol response to exercise, compared with 
less trained individuals [248, 249]. It is possible that individuals with greater cardiovascular 
capacities may be able to sustain a greater metabolic demand for a longer period of time compared 
with less trained individuals, which may ultimately lead to a greater secretion of cortisol and 
adrenalin following exercise. The increased metabolic and thermoregulatory demands placed on 
the individual when exercise intensity increases and/or a greater muscle mass is recruited, may 
contribute to the exercise-induced increase in cortisol secretion often observed following exercise 
cessation. This increase in metabolic and thermoregulatory demand could be exacerbated in 
women taking OC if they are experiencing chronically elevated TC and cortisol secretions due to 
exogenous secretions of estrogen and progesterone. If exogenous estrogen and progesterone are 
contributing to an increase in exercise-induced cortisol levels it is important to explore if exercise 
performance is negatively affected, particularly in the context of female athletes, as this may 
ultimately affect their decision to continue or discontinue OC use. 
 
2. 4. 8  Physiological Role of Cortisol 
Cortisol can have both anabolic and catabolic effects on various parameters of human physiology 
[250]. In an anabolic manner, cortisol increases hepatic gluconeogenesis [250], a metabolic 
pathway which produces energy from non-carbohydrate substances. The catabolic actions of 
cortisol include a breakdown of tissue (adipose and lean) for energy production, and can inhibit 
the growth of connective tissue [250]. Several immune cells such as lymphocytes, granulocytes 
and monocytes and macrophages exhibit glucocorticoid receptors which bind cortisol [45, 251] 
and subsequently reduce the regulation of cytokine-producing cells, through the inhibition of NF-
KB [45]. The suppression of NF-KB causes a change in gene expression and deregulates normal 
immune functioning [45], causing changes in cellular trafficking and proliferation, antibody 
production, as well as impaired effector functions of lymphocytes [252, 253]. In particular, a 
major inhibitory effect of elevated cortisol is decreasing transepithelial transport of s-IgA and in 
vivo B-lymphocyte antibody synthesis [24, 254-256], as well as being linked to decreases in B-
lymphocyte mobilisation [24] following exercise. If women taking OC are exposed to greater 
concentrations of cortisol post-exercise, they may be at risk of compromising immunity. 
Subsequently at risk of illness and infection, which may adversely affect exercise performance in 
active women and the ability to compete in female athletes. 
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2. 5  THE IMMUNE SYSTEM AND EXERCISE 
2. 5. 1  The Structure of the Immune System 
The immune system is designed to protect the organism from pathogens including viral and 
bacterial infections which may compromise homeostasis and subsequently health. The common 
mucosal immune system is a key self-defence mechanism and it exists to prevent harmful 
pathogens and antigens from entering the organism. The common mucosal immune system 
connects a number of immune structures throughout the body to protect the host from antigen 
presentation [257], namely the gut, urogenital tract, oral cavity and respiratory system [258]. The 
mucosal immune system is the first barrier to infection by microorganisms and protects the 
surfaces of both the respiratory and gastrointestinal tracts [259]. 
 
2. 5. 2  The Structure of the Common Mucosal Immune System 
Two components of the immune system unite to form the structure of the common mucosal 
immune system, namely the innate immune system and the adaptive immune system, each of 
which play a crucial role in immune system processing. The innate immune system is comprised 
of several anatomic and physiological components including mucous membranes and is 
considered the first aspect of the immune system to fight infection [260, 261]. The adaptive 
immune system is responsible for the proliferation of T- and B-cells [262], which produce plasma 
cells and eventually antibodies, such as s-IgA [263]. Once a B-cell receptor comes into contact 
with an antigen, daughter B- and T-cells are created which bind specifically to the antigen [263]. 
The daughter B- and T-cells can multiply into plasma cells and produce Immunoglobulins such 
as antibodies or form memory cells which will identify the antigen more efficiently upon 
secondary contact [263]. Common actions of immunoglobulins include binding to antigens on 
microorganisms, neutralizing bacterial toxins, inhibiting bacterial and viral movement and entry 
into host cells, as well as facilitating cytotoxicity by TC and NK cells and phagocytosis against 
toxins [264]. 
 
2. 5. 3  Salivary Immunoglobulin A 
Salivary immunoglobulin A is considered one of the most abundant proteins in the saliva [265] 
and is often monitored in applied sport science research as athletes experiencing a reduction in 
[s-IgA] below 40% of their mean values were reported to have a 50% chance of developing an 
URTI within three weeks [31]. There are several protective functions of s-IgA including 
preventing antigens and microbes including influenza from adhering to and penetrating the 
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epithelium (immune exclusion), preventing replication of intracellular pathogens during 
transcytosis through epithelial cells (intracellular neutralization), and binding to antigens in the 
sub-mucosa, facilitating their evacuation from the lamina propria via a secretory component (SC) 
through the epithelium and back to the lumen (immune excretion) [25, 258, 266-268]. Even 
though the initiation of up to 95% of all infections occurs at the mucosal surfaces in which s-IgA 
is the most abundant immunoglobulin [269, 270], decreases in [s-IgA] do not solely equate to 
infection , rather the [s-IgA] on mucosal surfaces is an indicator of the potential risk of infection 
[271]. However it does provide a convenient method of monitoring the health of an individual, 
particularly in response to exercise when venepuncture is not always accessible or sanitary.  
 
2. 5. 4  The Structure of Salivary Immunoglobulin A 
The base structure of immunoglobulins consists of four polypeptide chains comprised of two 
identical light chains (MW 25 kDa) and two identical heavy chains (MW 50-77 kDa) [177, 264, 
272, 273]. The light and heavy chains are bound together by both covalent disulphide bridges and 
non-covalent interactions [177]. The light chains are generic among immunoglobulins; however 
variations in the heavy chains occur depending on their specific immunoglobulin class [264, 273, 
274]. Heavy and light chains exhibit both variable and constant regions, which consist of the 
region containing the antigen-binding site and the region determining the fate of the antigen, 
respectively [177, 273-275]. Immunoglobulins are bi-functional in nature, with different 
functions at opposing ends of the molecule [264]. The fragment crystallized (Fc) (55 kDa) [275] 
portion stimulates several aspects of the immune response by binding to complement and Fc 
receptors on the antigen-antibody complex [177, 264]. The opposing end of the immunoglobulin 
is responsible for antibody binding and is made up of two fragment antibody binding (Fab) 
segments (MW 45 kDa) [177, 264], [275]. The molecular mass of the two IgA monomers, the 
joining (J)-chain and the SC which join to form a single polymeric molecule [177, 272, 276, 277], 
is 300 000, 15 600 and 70 000 Da respectively. 
 
The assembly of an s-IgA molecule includes the fundamental immunoglobulin structure [278] as 
well as a J-chain and a SC which acts to construct a polymer from multiple monomers [279], as 
well as stabilising and protecting the IgA polymer from breakdown. The J-chain is synthesised in 
plasma cells, while the SC is produced by mucosal epithelial cells and both are disulphide-linked 
to the Fc region of the IgA molecule [276, 279]. The SC acts as a s-IgA receptor, while stabilising 
the structure of polymeric IgA protecting IgA from protein breakdown when secreted into saliva 
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[177, 279, 280]. When the SC is membrane-bound it is referred to as a poly-immunoglobulin 
receptor (pIgR) and acts as receptor for transepithelial transport of polymeric IgA (pIgA) [278, 
281]. The expression of the pIgR has been reportedly altered in response to intense exercise [282] 
and the secretion of estrogen [283], which could contribute to exercise-induced suppression of [s-
IgA] in active women and may explain why female athletes exhibit lower concentrations of s-IgA 
[284-286].  
 
2. 5. 5  The Production of Salivary Immunoglobulin A 
Salivary immunoglobulin A is produced by plasma cells situated nearby the ducts and acini of the 
salivary glands, with each salivary gland secreting a unique concentration of cells depending on 
its nature [287]. Acinar cells can be divided into two forms, namely serous and mucous cells [288]. 
Serous acinar cells are located in the parotid gland and secrete a thin, watery and amylase-rich 
form of saliva through a excretory duct into the oral mucosa [288], whereas both serous and 
mucous acinar cells are present in the submandibular gland, producing a viscous and mucin-rich 
saliva, which is secreted into the sublingual mucosa [288]. Each salivary gland contributes 
varying amounts of saliva into the oral cavity which highlights the demand for standardisation 
when collecting saliva; if samples are collected from different parts of the oral cavity the 
respective concentrations of proteins as well as secretion rates can vary and lead to a 
misinterpretation of mucosal immune status.  
 
The process of s-IgA production involves the contribution of the pIgR, the J-Chain, specific 
endosomes and the SC, to transport pIgA to mucosal surfaces, including the upper respiratory 
tract [259, 289, 290]. Polymeric IgA is transported to mucosal epithelial cells through the 
transmembrane glycoprotein pIgR [279, 291]. The pIgR is synthesised in the rough endoplasmic 
reticulum and then transported to the Golgi apparatus [291] where it is divided into vesicles before 
travelling to the basolateral surface of epithelial cells [291]. At the basolateral surface of epithelial 
cells [275], the pIgR recognises and binds to J-containing pIgA [276] to form the pIgR-pIgA 
complex [259, 292]. The pIgR-pIgA complex undergoes endocytosis and is transported to 
basolateral early endosomes [272, 279, 291], where it is secreted through a common endosomal 
compartment to reach the apical membrane [275]. At the apical membrane the pIgR-pIgA 
complex is broken down through proteolysis into apical recycling endosomes (ARE) [291, 293]. 
Once broken down, pIgR binds extracellular, leading to the secretion of s-IgA [294] and the SC 
as either part of the s-IgA complex or in free form [291]. Once the SC has been released, portion 
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of the pIgR can be re-utilised as an apical early endosome (AEE), and recycled back to the apical 
surface by ARE [291]. Polymeric-immunoglobulin receptors are continuously transported 
independent of pIgA binding, when this occurs, any unoccupied receptors undergo proteolysis, 
and the SC is released [266]. The SC is synthesised in epithelial cells, which line the mucous 
membranes and exocrine glands [276, 290], not plasma cells. The SC was observed to be a 
proteolytic fragment of the pIgR [295] and only pIgA which exhibits a J chain can bind to the 
surface of pIgR containing epithelial cells [296]. In s-IgA, there is a 1:1 stoichiometry between 
the SC and dimeric IgA, with epithelial cells synthesising one pIgR particle for every one 
transported. 
 
2. 5. 6  Initiating the Production of Salivary Immunoglobulin A 
Two possible mechanisms have been suggested to initiate the production of s-IgA; the local 
response theory and the common mucosal immune system theory [292]. The local response theory 
suggests that the proliferation and differentiation of the lymphoid cells in the duct-associated 
lymphoid tissue (DALT) near the salivary glands are stimulated by the presence of oral antigens 
[292]. The common mucosal immune system theory is based on the influx of antigen-susceptible 
IgA precursor B-cells from mucosa-associated lymphoid tissue (MALT) to the salivary glands 
[292]. When the MALT comes into contact with an antigen, IgA B-and T-cells exit into the 
circulation, where they target the lamina propria of the intestine, lungs and exocrine glands i.e. 
salivary glands [277, 292]. Once the IgA B-and T-cells reach the mucosal and glandular tissues, 
they grow and mature into IgA plasma cells [278] and are secreted. A number of other factors 
have been shown to initiate the production and release of s-IgA. Importantly, the nervous system 
has also been shown to increase the secretion of s-IgA into saliva through the stimulation of the 
sympathetic and parasympathetic nervous systems [297, 298]. The autonomic nervous system 
supplies nerves to the immune cells in lymphoid organs and has been shown to induce changes in 
local immune processing [299]. In particular, the autonomic nervous system has been shown to 
enhance the transfer of s-IgA [300], however in vivo studies have not conclusively proven it to 
enhance the release of IgA [300]. It is possible that there are several mechanism for which s-IgA 
is produced, each of which could be affected by external factors such as circulating hormone 
levels as well as exercise-induced stress. 
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2. 5. 7  Exercise and the Immune System 
The number and function of several cells of innate and adaptive immunity are affected in response 
to exercise [301]. Several changes in the functioning of the adaptive immune system have been 
observed in response to exercise lasting 90 min or greater including decreases in [s-IgA] as well 
as decreases in B- and T-cell numbers, proliferation and function [30, 302-305]; these changes 
lead to impaired cell-mediated immunity [30]. The extent of which the mucosal immune system 
is affected by exercise appears to be directly related to the volume and intensity of exercise [301, 
306-308]. Moderate intensity exercise of between 40-60%   ΟV 2  max appears to stimulate 
immune functioning, through increases in [s-IgA] and secretion rates [264, 309-311], whereas 
decreases in nasal and salivary IgA concentrations [312] and the proliferative responses of 
lymphocytes to mitogens [261] have been observed following intense exercise between 55-80% 
  ΟV 2 max, further underlining the relationship between exercise intensity and immune system 
function.  
 
Several studies have investigated the s-IgA response to exercise over various training intensities, 
concluding the greatest immune response was observed throughout endurance training in 
moderately active runners and elite swimmers [313, 314], with shorter, intense periods of training 
showing less substantial changes in mucosal immunity [315, 316]. Prolonged, heavy exertion has 
been shown to decrease [s-IgA] by 9.3 and 5.5% in runners [317] and swimmers [310] 
respectively. To further demonstrate the association between exercise intensity and the s-IgA 
response [318, 319], up to a 65% decrease in [s-IgA] was observed following intense cycling 
[320], while little or no change in [s-IgA] or output was observed in response to low or moderate 
intensity swim training [321], tennis drills [322], acute and prolonged weight training [323].  
Further decreases in [s-IgA] have also been reported following kayaking [306], rowing [307, 324], 
hockey [325], interval exercise on a cycle ergometer [326], repeat sprint cycling (Wingate tests) 
[238, 327], basketball [328] and running [302, 316, 321, 329]. Similarly, moderate exercise 
(greater or equal to 3.0 metabolic equivalent (METS)) in non-athletic, healthy adults was reported 
to decrease the annual risk of URTI by 20-30% [330], which is indicative of the ‘J-curve’ theory 
suggested by Nieman [331]. The J-curve theory suggests that infection risk is directly 
proportionate to the amount of exercise undertaken as well as the intensity and duration of the 
exercise, regardless of the population. The J-curve theory suggests that both low and high levels 
of physical activity are associated with an increased susceptibility to illness, while a moderate 
level of physical activity is associated with a reduced risk of URTI [331-333]. The J-curve theory 
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is of particular importance when considering recreationally active women rather than sedentary 
women or female athletes, as the exercise-induced stress and mucosal immune response should 
be relatively unaffected and up-regulated respectively. However if the recreationally active 
woman is taking OC, it is possible that a greater exercise-induced stress response may occur, even 
following moderate intensity activity, which may have consequences for the mucosal immune 
system, including decreases in [s-IgA], which may have otherwise led to a surge following the 
same exercise session.  
 
2. 5. 8  Exercise and the Production of Salivary Immunoglobulin A 
Intense exercise has been reported to adversely affect the pIgR by decreasing messenger 
ribonucleic acid (mRNA) expression in the submandibular gland [282].  Interestingly, moderate 
exercise has been suggested as an up-regulator of pIgR production [334], as a result of nervous 
system stimulation and subsequent changes in hormone secretion [256]. If pIgR expression is 
increased, the ability of mucosal epithelial cells to transport dimeric IgA will be enhanced [291]. 
Additionally, several pro-inflammatory cytokines which are synthesised upon viral and bacterial 
invasion, contribute to the up-regulation of pIgR expression [291]. If the transcytosis of pIgA to 
pIgR is enhanced as a result of pIgR up-regulation throughout moderate exercise, pathogen and 
antigen neutralization may occur more readily [291].  
 
2. 5. 9  The Effect of Cortisol on Salivary Immunoglobulin A 
Cortisol has been reported to adversely affect the immune system by impeding the synthesis of 
B-lymphocytes [254-256, 335], and in particular by down-regulating the production and transport 
of s-IgA [24, 336]. Several authors [310, 337] have reported increases in cortisol as a result of 
acute, prolonged or intensive training did not cause changes in post-exercise [s-IgA] in swimmers 
or runners. The effect of the physical stress associated with exercise on s-IgA remains equivocal, 
despite a known association between psychological stress and the suppression of s-IgA [338, 339]. 
Given the established influence of psychological stress on sCort levels, it is possible that the type 
of stress leading to the secretion of cortisol, may contribute to the subsequent effect on mucosal 
immunity.  
 
2. 5. 10  The Effect of Carbohydrate intake of Salivary Immunoglobulin and Cortisol 
Dietary patterns may influence the immune response to exercise as several components of the 
immune system require nutrients and vitamins for normal functioning [340]. Glutamine is well 
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established as an energy source for the cells of the immune system, however it has now been 
identified as an important fuel for lymphocytes [340]. During physical exercise, muscles and 
organs require increasing levels of glutamine to function, which may lead to glutamine debt, 
ultimately compromising the availability of glutamine for energy demands [340]. Even though a 
recent study was unable to conclude an association between post-exercise decline in immune 
function and decreased plasma glutamine concentrations [29], a reduced incidence of URTI 
following marathons in trained runners occurred following the ingestion of beverages containing 
glutamine [341]. In addition to reducing the incidence of URTI, carbohydrate (CHO) ingestion 
has been suggested to assist in maintaining plasma glucose concentrations, consequently reducing 
the stress hormone response to exercise [29]. Several studies have investigated the use of CHO 
beverage consumption before, during and after 2.5 hr of exercise concluding higher plasma 
glucose levels resulted in a reduced cortisol response, lower granulocyte and monocyte 
phagocytosis and oxidative burst activity, and a diminished pro-and-anti-inflammatory cytokine 
response [342-344]. It is therefore possible that fuel availability may also contribute to the stress 
and mucosal immune response to exercise. 
 
2. 5. 11  Circadian Variations in Salivary Immunoglobulin A 
Circadian rhythms have been reported to affect saliva flow rate, with the highest flow being 
reported at 0400 hours and the lowest observed at 2000 hours. It is vital that sample collection 
procedures are standardised to account for circadian rhythms and do not induce subsequent stress 
on the participant, as this can lead to distorted results [233]. The effects of circadian variations on 
[s-IgA] have been investigated [24, 345], with varying results. Dwyer, et al (2010) reported no 
evidence that [s-IgA] was higher in the morning or evening [345], whereas Hucklebridge, et al 
(1998) and Gleeson et al (2001) reported [24, 346] [s-IgA] was higher in the morning but slowly 
decreased until a plateau was achieved approximately six hours after awakening. It is possible 
that saliva flow rate may have contributed to the discrepancies between findings, with dehydration 
following overnight fasting reducing the flow rate of saliva into the oral cavity; subsequently [s-
IgA] appears to be higher. In addition to dehydration from overnight fasting, oral drying as a 
result of high environmental temperatures may cause variations in saliva flow rate, and should be 
considered when interpreting results in hot and humid (HH) conditions. 
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2. 6  OVARIAN HORMONES AND THE IMMUNE RESPONSE TO EXERCISE 
2. 6. 1  The Effect of Estrogen and Progesterone on the Immune System 
Lymphocytes exhibit specific receptors to which estrogen and progesterone connect, namely the 
ER and ERβ, as well as the progesterone receptor (PR) [32, 38, 347]. These ovarian hormones 
influence cell responses by connecting to nuclear and non-nuclear receptors [348], with estrogen 
largely shown to enhance immune response and progesterone reported to reduce immune function 
[57-60, 349]. Specifically estrogen has been shown to affect B-cell development leading to 
increased concentrations of immunoglobulins [9, 350] as well as regulating the T-helper 1 (TH1) 
and T-helper 2 (TH2) response, with low levels of estrogen invoking TH1-mediated immune 
response and high levels of estrogen leading to TH2-mediated immune response [351]. Estrogen 
is a key contributor to maintaining normal immune function in women [33, 107]. A significant 
positive linear correlation was observed between estrogen and [s-IgA] in healthy pre-menopausal 
women [352], with the pattern of [s-IgA] mimicking serum estradiol through the various phases 
of the menstrual cycle [34, 57, 58]. Additionally the decreasing [s-IgA] observed throughout the 
postovulatory phase coincided with decreases in estradiol in parotid saliva [34], reinforcing 
previous research concluding elevated estrogen levels were associated with enhanced immune 
function [353]. The phase of the menstrual cycle, combined with exercise-induced changes, may 
further augment the risk of URTI in women i.e. during the follicular phase of the menstrual cycle 
when estrogen secretion is lower, and consequently the production of s-IgA appears reduced. The 
effect of exercise on [s-IgA] throughout the follicular phase of the menstrual cycle should be 
investigated to establish if women experiencing low secretions of estrogen are amplifying 
exercise-induced decreases in mucosal immunity.  
 
2. 6. 2  The Effect of Estrogen and Progesterone on Salivary Immunoglobulin A 
The normal menstrual cycle has been observed to influence the release of the SC which is an 
imperative part of s-IgA production [283], when estradiol levels are elevated [34]. Specifically, 
estradiol is reportedly [34] the predominant sex-steroid hormone which controls the synthesis and 
release of the SC, which could explain its profound effect on [s-IgA]. Additionally, salivary 
estradiol, is reportedly [352] significantly correlated with salivary IgA in healthy women, and the 
pattern of serum estradiol mimics [s-IgA] through the various phases of the menstrual cycle [34], 
further demonstrating the relationship between estrogen and s-IgA. While the mechanism remains 
equivocal, estrogen and progesterone have been shown to affect the expression of the pIgR 
throughout the oestrous cycle in humans [283] and rats [354]. Saliva composition and secretion 
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into the oral cavity are also thought to be affected by estrogen receptors, which are located in the 
oral epithelium and salivary glands [355]. Estrogen may therefore play a role in s-IgA regulation, 
by modulating the expression of the SC and pIgR as well as saliva secretion. Despite the 
association between s-IgA and endogenous estrogen throughout the menstrual cycle [33, 107], 
less is known about the relationship between exogenous ovarian hormones and s-IgA production. 
It is however possible that women taking monophasic OC may experience increases in [s-IgA] 
more consistently than women who are normally menstruating due to the constant supply of 
exogenous estrogen throughout the active pill phase. Despite the constant secretion of estrogen in 
COC particularly monophasic preparations, the total amount of estrogen secreted remains lower 
then throughout the normal menstrual cycle, which may explain why women taking OC 
experienced an 82 and 38% decrease in lymphocytes following cycling for 90 min at 65%   ΟV 2
peak when compared to male controls [221, 356], whereas no significant changes in leukocytes, 
neutrophils, and monocytes were observed in normally menstruating women in response to 
running [357, 358] and cycling [359, 360] when compared to male controls. Together, these 
studies [352, 357, 358] suggest that endogenous and exogenous estrogen secretion may have 
different effects on [s-IgA] in  healthy pre-menopausal women and investigation into the effect 
of OC on [s-IgA] in response to exercise should be conducted to identify if exogenous and 
endogenous secretions of estrogen evoke different responses from the mucosal immune system. 
 
2. 7  OVARIAN HORMONES AND THE CORE BODY TEMPERATURE RESPONSE 
TO EXERCISE 
2. 7. 1  Core Body Temperature in Humans 
Core body temperature is regulated at a ‘set-point’ of approximately 37C in humans [361] and 
maintains stability due to nerve cells located within the hypothalamus [361] while the body is at 
rest. Throughout exercise TC will rise proportionately alongside exercise intensity, with this 
increase in TC augmented in HH conditions [361, 362]. Environments with high humidity cause 
further issues specifically for thermoregulation, as the ability for sweat to evaporate is drastically 
reduced [362]. When heat dissipation is occurring at the same rate as heat generation a plateau in 
TC occurs [361, 362], which enables the individual to sustain the metabolic and thermoregulatory 
demands of exercise without risking premature fatigue. Interestingly, throughout steady state 
exercise, the rise in TC has been suggested to occur proportionally to metabolic rate, rather than 
as a result of ambient temperature [363]; consequently, if women taking OC are experiencing a 
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higher metabolic demand than normally menstruating women in response to exercise it is possible 
they may experience a greater increase in TC. 
 
2. 7. 2  The Effect of Exercise on Core Body Temperature 
Increased muscular contractions which occur throughout exercise produce heat from excess 
energy production to meet the metabolic demands of exercise [362]. Throughout the initial stages 
of exercise heat generation often exceeds heat dissipation [361]. When this occurs, a small amount 
of the heat generated from exercise is lost through the skin [361], however the majority of the 
heat returns to the core of the body via a convective gradient of venous blood returning to the 
heart [362], ultimately causing an increase in TC. As TC continues to increase, central thermo-
detectors located within the hypothalamus and spinal cord recognise the increasing heat needs to 
be reduced, and subsequently initiate thermoregulatory mechanisms, including increasing 
cutaneous vasodilation and sweating [361]. Exercise-induced rises in TC may be influenced by 
environmental conditions, with higher environmental temperature likely causing more rapid 
increases in internal temperature [362]. Investigations into the TC response to exercise must 
include both TN and thermally-stressful i.e. hot conditions to examine the role of the external 
environmental on internal temperature regulation. 
 
2. 7. 3  Core Body Temperature and Exercise Performance 
Heat stress has been shown to result in reduced stroke volume and increased HR in response to 
moderate-intensity exercise [364, 365], which compromises Q̇, ultimately affecting exercise 
performance [365]. A compromised Q̇ may explain why exercise time to exhaustion is reportedly 
influenced by the degree of change in TC from pre-exercise levels [366-369]. Monitoring TC 
throughout exercise, particularly in HH conditions is crucial as elevations in TC above an optimal 
level can negatively affected exercise performance [361]. When TC increases, blood flow 
distribution is placed under substantial demand to maintain the metabolic, cardiovascular and 
thermoregulatory requirements of exercise [361]. If any of the aforementioned parameters are 
compromised, it may substantially affect the ability to perform exercise, and may lead to 
premature fatigue [361]. Rising TC has been reported to contribute to premature fatigue 
throughout exercise [361, 364], by increasing the ratio of  / β waves, which contribute to a 
reduced alertness and arousal throughout exercise [361]. This reduction in alertness and arousal 
negatively affects the motivation to continue exercising [361] and is considered a defence 
mechanism which is triggered when TC exceeds an optimal and safe level [370]. In addition to 
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changes in the ratio of  / β waves, a reduction in cerebral blood flow may occur when TC is high, 
also causing further changes to alertness and arousal and potentially contributing to fatigue[370]. 
Further to changes in the ratio of  / β waves, cardiovascular drift has been shown [371-373] to 
have a plausible causal link with a decreased   ΟV 2 max during heat stress. With dehydration 
considered another contributor to premature fatigue while exercising in hot conditions through 
reduced locomotor muscle blood flow, oxidative metabolism and Q̇ [374]. Several authors [375, 
376] have proposed the TC in which exercise performance is affected and fatigue is experienced 
approaches 40C, however in untrained individuals, a TC approaching 38C is sufficient to cause 
exhaustion [377-379]. Establishing at what point TC initiates these anticipatory defence 
mechanisms, which may be contributing to premature fatigue throughout tolerance exercise, 
could prove beneficial for the management of active women and female athletes and reduce the 
risk of premature fatigue throughout exercise. 
 
2. 7. 4  The Effect of Estrogen and Progesterone on Core Body Temperature 
The role of endogenous estrogen and progesterone on resting TC is well established [9, 10, 12-
15], with progesterone shown to increase basal body temperature by 0.3C - 0.5C [380-382] 
during periods of high secretion, while estrogen reportedly attenuates this effect subsequently 
lowering TC [14, 15, 383, 384]. Estrogen and progesterone interact in an antagonistic manner, and 
when both hormones are secreted simultaneously, the effect of progesterone appears to surpass 
estrogen [380, 385-387], thereby resulting in increases in TC. Endogenous secretions of estrogen 
and progesterone are known to influence TC and the TC THLD for cutaneous vasodilation [12-14] 
by modifying warm and cool sensitive neuron activity [14, 383, 386, 388]. It is therefore not 
surprising that fluctuations in TC occur throughout the various phases of the menstrual cycle. 
Some forms of hormonal contraception, including the injectable progesterone method, have been 
shown to cause increases in TC throughout the 24-36 hr period following administration [389]. 
Additionally, women taking OC were reported to experience an increase of 0.3C in TC, with HR 
observed to increase by 8 bpm-1 in response to exercising in a HH environment (30C; r.h. 50%) 
[2]. Which could be indicative of a higher demand on Q̇ to distribute blood to the skin for cooling 
in response to the elevated TC, while maintain adequate blood flow to working muscles to meet 
the metabolic demands of exercise. Considering the association between high TC and an increased 
risk of premature fatigue [361, 364], the role of OC on TC should be investigated, to identify if 
exogenous progesterone and estrogen administration is causing further increases in TC, ultimately 
increasing a woman’s risk of premature fatigue. 
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2. 7. 5  Progesterone and the Cardiovascular System 
Progesterone in its endogenous form has been shown [76] to increase minute ventilation 
throughout the luteal phase of the menstrual cycle and could be indicative of elevated cutaneous 
vasodilation to meet thermo-regulatory demands due to the elevated TC associated with high 
levels of progesterone [390]. Similarly, several small studies [380, 385, 391-393] have identified 
higher HR at rest and throughout exercise during the luteal phase of the menstrual cycle, further 
substantiating the likelihood of a greater cardiovascular demand throughout periods of high 
progesterone secretion. Even though several studies [65, 68, 69, 394] concluded no substantial 
differences in HR at rest and in response to exercise in women throughout the menstrual cycle in 
TN and HH conditions [73, 74, 395, 396], increases in Q̇, plasma volume, stroke volume and 
systolic blood pressure have been observed in women using monophasic OC for two-to-six 
months [397-399], which suggests that exogenous progesterone may affect the cardiovascular 
system in a similar manner to endogenous progesterone. Endogenous progesterone fluctuates 
throughout the various phases of the menstrual cycle, where as in monophasic OC, a constant 
supply is secreted throughout the 21-day active pill phase. Consequently women taking OC would 
experience these cardiovascular changes on a more consistent basis than women who are normally 
menstruating, which may influence exercise performance. 
 
2. 7. 6  Thermoregulation 
Thermoregulation is comprised of two mechanisms, namely heat dissipation and heat generation, 
which act to either cool down or warm up the body depending on the internal and external stimuli 
[400]. There are several mechanisms for heat dissipation within the human thermoregulatory 
system, namely radiative heat, convective heat and evaporative cooling [401]. Radiative heat 
involves the transfer of heat into the surrounding environment, via electromagnetic waves [401]. 
Convective heat involves the transfer of heat from one place to another via a fluid moving over a 
solid surface, displacing and replacing the fluid in immediate contact with the solid [401]. Both 
radiative and convective heat are used to maintain homeostasis throughout activities of daily 
living, however throughout exercise, these two methods of heat dissipation are often insufficient 
to attenuate rises in TC at which point evaporative cooling becomes crucial. Evaporative cooling 
is a result of vaporisation of water from the skin (sweating), and the subsequent transfer of water 
vapour to the external environment [401]. Importantly, for effective evaporative cooling, the 
external environment must allow sufficient sweat evaporation, that is the environmental 
temperature should not exceed skin temperature [401], with relative humidity (r.h.) also playing 
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an integral role. The ability of active women to employ effective cooling mechanisms i.e. 
evaporative cooling, throughout exercise is crucial to avoid overheating. Endogenous 
progesterone increases TC and the TC THLD for cutaneous vasodilation, thereby potentially delaying 
the onset of evaporative cooling, and considering exogenous progesterone in OC is secreted in 
higher concentrations than throughout the menstrual cycle, investigations must be undertaken to 
examine how exogenous progesterone is affecting TC and consequently exercise performance, 
particularly in hot conditions when heat dissipation is crucial to avoid overheating.  
 
2. 7. 7  Endogenous Ovarian Hormones and Thermoregulation 
The cells of the endothelium [402] as well as smooth muscle in peripheral vasculature, [403] 
exhibit estrogen receptors which may induce vasodilation [404-406] or vasoconstriction in 
response to fluctuating hormone levels throughout the menstrual cycle, subsequently influencing 
blood flow [14, 407]. Additionally, estrogen and progesterone may influence sex-steroid binding 
neurons on the preoptic/anterior hypothalamus (PO/AH) [383, 408]. Progesterone reportedly 
reduces warm-sensitive neuron activity [47, 386, 388] subsequently, inhibiting the heat-loss 
mechanism and leading to increases in TC. While estrogen inhibits coldand stimulates warm-
sensitive neurones, which ultimately inhibits heat-retaining mechanisms, subsequently decreasing 
core body temperatures [14, 15, 383, 384]. When progestin alone was administered to women, 
elevations in TC occurred, however when estrogen was administered alongside progestin, these 
changes in thermoregulation were not observed [14], suggesting that estrogen’s effect on 
progesterone could attenuate changes in TC. Further research demonstrated that while estrogen 
may attenuate some of the effects of progesterone, when both hormones are consistently elevated 
i.e. in the luteal phase of the menstrual cycle, TC remains increased, suggesting progesterone has 
more pronounced effect on thermoregulation than estrogen [380, 385-387]. Progesterone has 
therefore been closely associated [12-15] with TC. If endogenous progesterone is playing a role 
in determining the TC response at rest and in response to exercise, it is possible that women taking 
OC, who are consistently exposed to progesterone in higher amounts, may experience further 
increases in TC which may affect the initiation of thermoregulatory mechanisms throughout 
exercise. 
 
Increases in TC have been associated with elevations in the threshold for cutaneous vasodilation 
throughout exercise [380, 385, 392, 409, 410] during the luteal phase of the menstrual cycle. In 
normally menstruating women, differences in the TC THLD have been observed [380, 385, 410, 411] 
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between the follicular and luteal phases of the menstrual cycle, further demonstrating the link 
between elevated progesterone levels and a higher TC THLD [412, 413]. A higher threshold 
throughout the mid-luteal phase has been observed [413, 414] compared to the mid-follicular 
phase of the menstrual cycle, when progesterone levels were elevated and decreased respectively. 
Similar findings have been reported in exercising women, with increases in oesophageal 
temperature and the threshold for phalangeal cutaneous vasodilation observed [380, 385, 409-411] 
to be higher throughout the mid-luteal phase of the menstrual cycle in response to passive changes 
in ambient temperature. Additionally, exercising women with an oesophageal temperature higher 
than 37.5C were observed [392] to have a 40-50% increase in forearm skin blood flow 
throughout the luteal phase when compared to the follicular phase of the menstrual cycle, after 
the TC THLD was reached. This may be an over-compensatory mechanism as the TC may have been 
required to reach a higher point before cooling mechanisms were initiated, potentially placing the 
exercising woman under more stress than if cooling was initiated earlier, which may increase Q̇ 
demands to maintain the metabolic loads associated with exercise and could have substantial 
implications for metabolic capacity while exercising [392]. The increase in Q̇ could explain the 
elevated HR response observed [76] in women exercising throughout the luteal phase of the 
menstrual cycle, and could place the exercising woman in a greater state of stress throughout the 
luteal phase of the menstrual cycle, when TC is elevated and thermoregulation is less efficiently 
achieved, which may have implications for the health and exercise performance of the woman.  
 
2. 7. 8 Exogenous Ovarian Hormones and Thermoregulation 
While little is known about the role of exogenous ovarian hormones in thermoregulation, 
considering the effect of the menstrual cycle on central regulatory mechanisms [390, 415-417], it 
is possible that exogenous estrogen and progesterone would cause similar changes to TC and the 
TC THLD for cutaneous vasodilation. The increase in TC observed [390, 400] throughout the luteal 
phase of the menstrual cycle may also occur during high-dose progesterone phases of some COC 
or while using progesterone-only pills. Increases to the TC THLD in monophasic OC users have 
been reported [390, 415], which may be due to the higher level of exogenous progesterone 
secreted in COC when compared with endogenous secretions throughout the normal menstrual 
cycle [108]. However, the change in basal body temperature from 0.3C to 0.5C observed 
throughout the luteal phase of the menstrual cycle [76, 382] is reportedly less pronounced in OC 
users [43]. This may reflect a consistent secretion of exogenous estrogen throughout the OC cycle 
compared with endogenous decreases following the rupture of the corpus lutem in the early stages 
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of the luteal phase. The constant secretion of estrogen may attenuate the effect of progesterone 
on TC, and consequently women using COC with high estrogen doses may be less affected by 
progesterone-related increases in TC and the TC THLD for cutaneous vasodilation. Nevertheless, the 
ability to minimise increases in TC in active women may have substantial consequences for 
performance and the subsequent stress responses to exercise, and it is important to investigate the 
effect of exogenous estrogen and progesterone on TC. 
 
2. 8  SALIVA ANALYSIS IN RESEARCH 
2. 8. 1  Saliva Composition 
Saliva is a hypotonic fluid which plays a crucial role in health. Saliva has a pH of approximately 
6.64 and a density between 1002 and 1012g/L [418, 419] and is comprised of numerous inorganic 
and organic compounds including electrolytes, water and proteins [420-422]. The predominant 
proteins in saliva include mucins, proline-rich proteins, lysosomes, peroxidases, lacoferrin, 
histatins, agglutinins, amylase, albumin and immunoglobulins [423]. Saliva provides a crucial 
antiviral and antibacterial role in the oral cavity [321] through its functions against pathogens 
[424], including defence proteins which act in either specific or non-specific manner, inhibiting 
the growth and replication of microorganisms [425, 426]. Approximately 20% of total plasma 
volume, which equates to around 750ml is translocated daily via the salivary glands [256, 427].  
A secretion of between 750 to 1500 ml per day is considered healthy in humans [256, 419, 428], 
with an unstimulated saliva secretion rate of approximately 0.03-0.65 ml/min, and stimulated 
saliva as a result of mastication, secreted at a rate of 1.5-6.0 ml/min [428-430].  
 
2. 8. 2  Saliva Analysis in Applied Sport Science Research 
Saliva analysis is a valid, reliable and convenient way to measure several biomarkers of stress 
and health and is commonly used in applied sport science research [424, 431-433]. Saliva 
collection can be performed frequently, more rapidly and requires less medical training then blood 
collection [256, 418, 419, 434, 435] and can be readily used for diagnostic and health surveillance 
purposes [319, 320, 436, 437] in applied sport science research [435]. In addition, very low levels 
of a specific biomarker and low abundant proteins can be detected in saliva samples [436, 438, 
439], potentially decreasing the risk of non-specific interference and hydrostatic interactions 
[440]. A sample volume of between 0.5ml-2.0ml is generally sufficient to elicit an accurate saliva 
analysis, depending on the sensitivity and reliability of the analysis system being utilised [441]. 
Saliva analysis is the preferred method of evaluation in younger individuals as it can be difficult, 
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undesirable or unethical to rely on blood and urine collection [332]. Additionally, saliva has been 
described as a filtration of blood, in that it reflects the physiological condition of the body [440, 
442]. Saliva is not as complex and varying as serum, which has been shown to exhibit substantial 
variations in protein concentrations, with protein half-lives ranging from a few seconds to several 
months [440]. Despite reports of the total concentrations of the various compounds found in saliva 
being less than their respective serum and plasma concentrations; they have been reported to 
provide a reliable reference for analysis [443, 444], and could be a useful marker of monitoring 
mucosal immunity in athletes [445]. The systemic circulation and the salivary ducts are separated 
by a thin layer of epithelial cells, thus circulation facilitates the transfer of substances to the saliva 
through either active carriage, diffusion through the cell membrane or via a concentration gradient 
[440]. The lenience of this exchange is a major reason why saliva may be ideal for diagnostic 
purposes in an applied sport science environment. The serum components of saliva are derived 
from the vasculature which originates from the ceratoid arteries [446] and contains the same 
molecules found in systematic circulation [420]. Oral fluid analysis has been suggested to be more 
advantageous over serum samples due to better performance and efficiency than plasma analysis 
[424]. Additionally, some salivary measures, namely steroids, have been suggested to provide a 
more sensitive marker of changes in hormones than blood [447-449]. Literature indicates [448] 
that salivary measures of IgA and cortisol are both valid and reliable in identifying 
immunosuppression, with saliva collection often used in applied sport science research due to its  
simplicity and non-invasive nature [256, 418, 419, 434, 435] in contrast to blood samples. 
 
Saliva flow rate, concentration and volume have been shown to directly relate to the method of 
saliva collection [450, 451]. The methods include draining, spitting, suction and swabbing [451-
453], for the collection of either unstimulated saliva or stimulated saliva. Approximately 40 mg 
of unstimulated salivary IgA/kg body weight is transported to the mucosal surface every day [272]. 
Saliva can be stimulated via mechanical stimulation e.g. chewing on paraffin or acid 
stimulation[454, 455]. The usual method for saliva stimulation is mastication (chewing on 
paraffin) or gustatory stimulation (i.e. use of citric acid or sour candy drops on the participants 
tongue). However these foreign substances used to stimulate saliva tend to affect the fluid pH 
level and can stimulate the water phase of saliva secretion, subsequently causing a dilution in the 
concentration of proteins in the sample [456, 457]. To avoid such disturbances to results, 
unstimulated saliva was utilised throughout the present thesis. Whole saliva can be obtained with 
or without stimulation, however major differences in salivary proteins can be obtained if saliva is 
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stimulated [420]. Unstimulated saliva can have two components, namely spontaneous secretion 
and reflex secretion [288]. Spontaneous secretion refers to low amounts of saliva being 
continuously produced without an extraneous stimuli [288]. Reflex secretion involves minor 
stimulation through drying of the oral mucosa or mild mechanical stimulation e.g., minor jaw and 
tongue movements or mastication [288]. Stimulated saliva consists mainly of water and is derived 
from the parotid  and submandibular salivary glands [288, 458]. Whereas a large portion of 
unstimulated saliva is derived from the submandibular salivary gland, with significant 
contributions from the sublingual and minor salivary glands [288] and contains proline rich 
proteins [439] and approximately three times more IgA than stimulated parotoid secretion [459, 
460]. This has been replicated in whole saliva with similar results [461]. Even though it is possible 
to attain isolated samples from specific salivary glands, whole saliva is the only practical 
collection method for field-based research[233]. 
 
2. 8. 3  The Secretion of Saliva into the Oral Cavity 
Whole saliva is comprised of a variety of oral fluids secreted in different volumes from three 
major and 600 minor salivary glands [288, 420, 430]. The major salivary glands include the 
submandibular, parotid and sublingual which contribute 65%, 23% and 4% of saliva into the oral 
cavity respectively [420], with minor salivary glands contributing 8% of saliva into the oral cavity 
[420]. Each salivary gland has an abundance of blood vessels and nerves which connect to each 
gland at the hilum and gradually separate into branches [435]. Arterial capillaries supply the 
parotid glands and originate from the external carotid artery, the sublingual and submental arteries 
supply the sublingual glands and the facial and lingual arteries supply the submandibular glands 
[256]. The salivary glands are comprised of several excretory units (acini) and a distinctive duct 
system [292]. Primary glandular (i.e. acinar) cells assemble to form a sac-like lumen, which forms 
the acini [292]. The acinar cells are categorised as either mucous or serous cells, depending on 
which type of cell they secrete [292], with each duct secreting a distinctive set of proteins [292] 
and each saliva gland producing a combination of secretions of several groups of cells which 
combine to constitute whole saliva [292]. The frequency at which s-IgA is secreted into the oral 
cavity is determined by plasma cells producing IgA in the submucosa and/or the rate of IgA 
transcytosis across epithelial cells, which relies on the availability of the pIgR [269]. It is possible 
that only intense exercise is sufficient to induce increased mobilisation of the pIgR [462], which 
could be the reason why moderate intensity exercise does not elicit substantial changes in s-IgA 
secretion rate and concentration [463]. The fluids secreted into the oral cavity from the major and 
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minor salivary glands contain epithelial immune cells, microbes and serum transudate from the 
mucosa and sites of inflammation [464, 465]. A number of factors can affect saliva composition, 
including the source of saliva (whole saliva or individual glands), flow rate, nature of the stimulus 
or physical exertion, diurnal and hormonal variations and the degree of hydration of the subject 
[256, 321, 430, 466, 467].  
 
2. 8. 4  Saliva Gland Innervation and Saliva Secretion 
Salivary glands are innervated by both parasympathetic and sympathetic nerves [435], which can 
influence saliva secretion and flow rate through the vasoconstriction or vasodilation of the blood 
vessels supplying the salivary glands [256, 468, 469]. While standard whole saliva secretion and 
composition is predominantly regulated by the autonomic nervous system [256, 470], increases 
in saliva secretion are reportedly due to parasympathetic nervous system stimulation leading to 
the vasodilation of the capillaries which supply the saliva glands, resulting increased blood flow 
[471]. Whereas decreases in saliva flow rate have been identified as a result of vasoconstriction 
of the blood vessels surrounding the oral mucosa [256, 472] due to sympathetic nervous system 
activation in response to intense and prolonged exercise [473].  
 
2. 9  SUMMARY 
The ability for a woman to tolerate and recover from exercise is crucial for maintaining health as 
well as improving performance. Several components of physiology including the mucosal 
immune system and the cortisol-driven stress response are known to be influenced by the 
frequency, duration and intensity of exercise [308, 474-477]. It is important that women are aware 
of how these parameters of physiology are affected by taking OC. The normal menstrual cycle 
can affect resting concentrations of s-IgA and sCort, which may also pose implications during 
and following exercise, with external factors such as ambient temperature providing additional 
complications, particularly in relation to maintaining homeostasis by regulating TC. Considering 
the relative concentrations of endogenous and exogenous estrogen and progesterone secreted 
throughout the normal menstrual and OC cycles vary, both must be considered separately to 
provide novel insight into a woman’s ability to tolerate exercise in both TN and HH environmental 
conditions. The aim of the present thesis is to explore the effect of exogenous estrogen and 
progesterone on the [s-IgA] and [sCort] response to exercise in varying environmental conditions. 
The insight gained from this investigation may assist in exercise prescription and recovery in 
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active women to reduce the risk of mucosal immune suppression and/or rising cortisol levels, 
which may compromise health. 
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CHAPTER THREE 
 
Experimental Study One 
The Validity and Reliability for a Salivary Cortisol Point of Care Test 
 
3. 1  Introduction 
Saliva has previously been described as a filtration of blood, in that it reflects the physiological 
condition of the body [440, 442]. The systemic circulation and salivary ducts are separated by a 
thin layer of epithelial cells, thus circulation facilitates the transfer of substances in to saliva 
through either active carriage, diffusion through the cell membrane or via a concentration gradient 
[440]. The lenience of this exchange is a major reason why saliva may be ideal for diagnostic 
purposes in an applied sport science environment, in which venepuncture may be inconvenient or 
unsanitary. Cortisol is amongst the most commonly assayed biomarker in saliva and is considered 
to be a true reflection of serum and plasma levels in healthy adults [424, 431-433] newborns [478], 
children and adolescents [479] and elderly subjects [480]. Salivary cortisol remains consistent 
with serum cortisol levels at rest and throughout exercise as well as upon stimulation of 
adrenocorticotropic and corticotropin-releasing hormones [449, 481, 482].  Very low levels of a 
specific biomarker and low abundant proteins can be detected in saliva samples [436, 438, 439], 
and therefore the risk of non-specific interference and hydrostatic interactions is potentially 
decreased [440]. Additionally, a sample volume of between 0.5ml-2.0ml is generally sufficient to 
elicit an accurate saliva analysis, depending on the sensitivity and reliability of the analysis system 
being utilised [441], and can be performed frequently, more rapidly and requires less medical 
training then blood collection [256, 418, 419, 434, 435] and therefore presenting a more attractive 
and athlete-friendly option for use in applied sport science research and practice [319, 320, 435-
437, 445]. 
 
Cortisol is secreted in response to intense exercise [483, 484], via HPA axis activation [435]. 
Cortisol is primarily catabolic in nature and when secreted causes a reduction in protein synthesis 
and the inflammatory process, while increasingly protein degradation and compromising several 
parameters of immune function [182, 183]. Monitoring cortisol levels may provide the coach or 
sport scientist with valuable information regarding the stress response to exercise or training [435], 
which may assist in monitoring athlete well-being as well as adaptation to-and recovery from 
exercise. Over a sustained period of time high exercise-induced salivary cortisol levels may reflect 
overtraining [485], which can lead to a reduction in peak power, as well as in isometric and 
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concentric muscle contractions [486]. When symptoms of overtraining are appearing in an athlete, 
early diagnostic measures, rest and regeneration are key to recovery [487]. The availability of 
non-invasive and convenient measures to remotely monitor the health and well-being of an athlete 
may allow coaches and sport scientists to monitor the exercise-induced stress response throughout 
training and may be used in conjunction with medical diagnosis, for the early detection of over-
training.  
 
Traditional salivary cortisol tests can take several hours to receive a result. When investigating 
the cortisol response to exercise, timely feedback is crucial for the appropriate management of 
the athlete or active individual. An innovative point of care system for salivary diagnostics has 
been developed for cortisol monitoring and can provide feedback within 15 min of sample 
collection. This point of care saliva analysis system is known as IPRO and has the potential to 
drastically change the way coaches and athletes can monitor the stress response to training and 
competition. The IPRO point of care salivary cortisol test has undergone preliminary validity and 
reliability investigations in English Football League Championship Academy soccer players 
[488]. Twenty-nine saliva samples was measured by the IPRO and was also analysed by ELISA 
within 4 hr of sample collection. All samples were reported [488] to be within the measurement 
range for both IPRO and ELISA analysis ranging between 1.09 -9.45 ng/ml and 0.50 – 6.26 ng/ml 
respectively. In addition, 16 IPRO samples were measured on two separate LFD on two occasions, 
each 30 min apart, reporting [488] good agreement with mean within coefficient of variation (CV) 
between repeats of 6.88%. Similar results have been produced for a point of care test on s-IgA for 
the IPRO system [488-490]. The day-to-day reliability of the IPRO device has not been 
investigated which would establish the suitability of the device for ongoing monitoring of salivary 
cortisol.  
 
The aim of the present study is to investigate the validity and reliability of the IPRO point of care 
sCort test against gold-standard ELISA methods in healthy, active individuals. 
 
3. 2  Methods 
3. 2. 1 Participants: Ten (n = 10, male = 5 and female = 5) healthy, active university students 
volunteered to participate in the present study. Participants were Exercise and Sport Science 
students from the same cohort, who participated in weekly recreational exercise such as running, 
cycling, swimming and team sports. Participants were instructed to refrain from strenuous 
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exercise 12 hr prior to saliva collection on both testing occasions. Participants were also instructed 
to avoid consuming food or brushing their teeth in the two hr prior to sample collection and had 
not consumed alcohol for at least 24 hr. Participants were asked to keep their morning routines as 
similar as possible on each day of sample collection, with testing occurring at the same time and 
location on both testing occasions. All participants signed informed consent prior to participating 
in this study. This study was approved by the Bond University Human Research Ethics Committee 
(BUHREC). 
 
3. 2. 2 Sample Collection: Unstimulated whole saliva was collected by IPRO OFC (IPRO 
Interactive, Wallingford, UK), Salimetrics SOS (Salimetrics LLC, State College, PA, USA) and 
Salimetrics PD (Salimetrics LLC, State College, PA, USA) and assessed for salivary cortisol 
concentration ([sCort]). Participants were seated in a quiet, safe environment for saliva collection 
and asked to rinse their mouth out with water 10 min prior to sample collection. Saliva collection 
occurred on the same day and time, on two occasions separated by four weeks. Participants were 
considered to be under the same physiological and psychological stress surrounding both testing 
occasions. However, it is important to note that perceived physical and psychological stress was 
not measured through perceived stress scales which take into consideration recent life events, 
chronic difficulties, trait anger and depression [491]; all factors which may influence cortisol 
secretion at rest, and poses a limitation of the present study. During trial one (T1), a total of three 
saliva samples were collected (i.e. one of each OFC, SOS and PD, in that order) (Figure 7). During 
the second trial (T2) the same measures were collected, in order from T1, however two OFC’s 
were placed in the oral cavity simultaneously (OFC1 and OFC2) in four randomly selected 
participants (Figure 7). The additional OFC samples collected in T2 were analysed on two 
separate lateral flow devices (LFD1 and LFD2) (Figure 7) and compared to investigate the 
reliability of both the OFC swab as well as the LFD using the IPRO method.  
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Figure 1. Schematic of sample collection procedures in trial one (T1) and trial two (T2). 
 
3.2.3 Salivary collection and analysis procedures: Oral fluid collector (OFC): Participants 
placed one OFC swab on top of their tongue and closed their mouth in T1 with two OFC swabs 
placed on the tongue in T2 (in four randomly selected participants only). The device consists of 
a synthetic polymer-based swab material attached to a volume adequacy indicator stem and a 
dropper bottle with extraction buffer (Figure 9A). When 0.5mL of saliva has been absorbed by 
the OFC, an indicator line of the swab stem turns bright blue at which point the OFC is removed 
from the participant’s mouth and placed (swab down) into a dropper bottle (Figure 9B). The 
dropper bottle contains 3mL of buffer which consists of sodium phosphate, salts, detergents and 
preservatives to attenuate the growth of microorganisms, as well as extraction agents to target 
analytes from the cotton based swab. Saliva samples are stable at room temperature and were 
stored according to manufacturer’s recommendations (IPRO Interactive, Wallingford, UK). 
 
For analysis, the dropper bottle containing 3mL of buffer and the OFC saliva sample was 
repeatedly inverted with care lightly shaken for 2 min. Two drops of the buffer solution and saliva 
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sample mixture was placed onto the sample pad of the LFD (Figure 10C) and incubated at room 
temperature for 10 min, as per manufacturer’s instructions (IPRO Interactive, Wallingford, UK). 
The liquid uses a capillary action to travel through the conjugate pad hydrating the dried conjugate. 
The liquid continues to flow through the nitrocellulose membrane towards the wicking pad at the 
end of the strip. Once the liquid flows across the membrane, the gold-labelled anti-cortisol will 
be captured by the cortisol test line resulting in the appearance of a red line. Cortisol binds to the 
gold-labelled anti-cortisol molecule; and if cortisol is present, it will result in fewer gold particles 
being captured by the cortisol test line. The test line intensity is inversely proportional to the 
cortisol concentration present in the sample. After 10 min of incubation, the LFD was placed into 
the Lateral Flow Reader and analysed which then converted the line intensity into the 
corresponding [sCort]. 
 
Salimetrics oral swab (SOS): To standardise saliva collection procedures between point of care 
and ELISA testing methods, the SOS was used as it is similar to the OFC. The SOS is a polymer 
cylindrical swab (10mm × 30mm) (Figure 11A). Participants were instructed to place the SOS on 
top of their tongue and close their mouth, mimicking the OFC placement and procedure. After 2 
min of saliva collection the swab was placed into storage tube (Figure 11B) and centrifuged at 
1500 × g (3000 rpm) for 15 min as per manufacturers guidelines (Salimetrics LLC, State College, 
PA, USA). The saliva samples were weighed and then immediately stored in a freezer at -20C 
until ELISA analysis.  
 
Salimetrics passive drool (PD): PD was collected in 2ml cryovials (Figure 12A) (Salimetrics 
LLC, State College, PA, USA) and then sealed tightly. Saliva was passed through the SalivaBio 
collection aid into the polypropylene vial (Figure 13). Participants were encouraged to tilt their 
head forward throughout sample collection to promote saliva pooling in the oral cavity. Following 
collection all samples were centrifuged at 1500 × g (3000 rpm) for 15 min. The saliva samples 
were weighed and then immediately stored in a freezer at -20C until ELISA analysis.  
 
For analysis of SOS and PD, samples were thawed completely, placed on the vortex and 
centrifuged at 1500 × g (3000 rpm) for 15 min as per manufacturer’s guidelines (Salimetrics LLC, 
State College, PA, USA). All saliva samples, reagents and the assay plate were at room 
temperature, prior to analysis. Wash buffer concentrate of 100mL was added to 900mL of 
deionised water at room temperature for dilution. Reagents were prepared and the assay plate 
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layout was determined, testing all samples in duplicate. Subsequently, 24 mL of diluted assay was 
then pipetted into the disposable tube, followed by 25 µL of assay diluent into two wells each to 
serve as the zero and non-specific binding (NSB) wells. A further 25 µL of standards and saliva 
samples were added into the appropriate wells. The enzyme conjugate was diluted 1:1600 by 
combining 15 µL of conjugate to the 24 mL tube of diluted assay, which was placed on the vortex 
prior to adding 200 µL to each well using a multichannel pipette. The assay plate was mixed on 
a plate rotator (SpectraMax 190, Molecular Devices, Fullerton CA, USA) for 5 min at 500 rpm 
and incubated at room temperature for 1 hr. Following incubation, the plate was washed four 
times with 1X buffer, with the plate thoroughly blotted on paper towels after each wash, prior to 
being turned upright. Following washing, 200 µL of tetramethylbenzidine (TMB) substrate 
solution was added to each well with a multichannel pipette. The assay plate was the mixed on a 
plate rotator or 5 min at 500 rpm and incubated in the dark at room temperature for 25 min. 
Following incubation, 50 µL of a 3M stop solution was added to each well with a multichannel 
pipette. The assay plate was mixed on a plate rotator for a further 3 min at 500 rpm, or until all 
wells turned yellow. The assay plate was then read in a plate reader at 450 nm, within 10 min of 
adding the 3M stop solution.  
 
3. 2. 4 Statistical Analysis: Data was analysed for assumptions of normality using a Shapirio-
Wilk test, and in the event data was violated non-parametric Friedman two-way ANOVA or 
Wilcoxon Signed Rank tests were conducted. A Paired t-test was completed to compare IPROT1 
and IPROT2, as well as IPRO1 and IPRO2 and LFD1 and LFD2 samples for intra-tester and OFC 
and LFD reliability, with ICC ±SEM presented. Pearson’s correlation coefficient and One-way 
Random model for intra-rater reliability were completed to confirm reliability. A Bland-Altman 
graph was used to assess the level of agreement between IPRO compared with SOS and PD with 
at 95% CI reported. Alpha intervals were set at p < 0.05 for all correlation and hypothesis tests 
with results presented as mean ±SD. Statistical analysis was conducted using the Statistical 
Package for the Social Sciences (SPSS version 20, Chicago, IL, USA). 
 
3. 3  Results 
3. 3. 1  Validity 
A Friedman two-way ANOVA did not identify any significant (p = 0.819) difference between 
OFC and SOS or PD. A follow up analysis of pair wise comparisons was completed in the form 
of a Wilcoxon signed rank test, revealing OFC was not significantly different from SOS (p = 
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0.881, r = -0.33) or PD (p = 0.145, r = 0.32) measures. The level of agreement between IPRO vs 
SOS (Figure 8) and IPRO vs PD (Figure 9) were assessed via a Bland-Altman graph, revealing 
unbiased agreement between OFC and both SOS and PD methods. Validity and reliability 
statistics for OFC, SOS and PD are presented in Table 1. 
 
 
Figure 2. Bland-Altman scatter plot, agreement between Individual Profiling (IPRO) oral fluid 
collector (OFC) and ELISA Salimetrics oral swab (SOS). Solid lines indicate mean difference (-
0.10 nmol/L), and ±1.96 SD (5.00 nmol/L, -5.56 nmol/L). No proportional bias was present (p = 
0.976). 
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Figure 3. Bland-Altman scatter plot, agreement between Individual Profiling (IPRO) oral fluid 
collector (OFC) and ELISA passive drool (PD). Solid lines indicate mean difference (-1.32 
nmol/L), and ±1.96 SD (5.46 nmol/L, -8.06 nmol/L). No proportional bias was present (p = 0.281). 
One outlier was identified. 
 
3. 3. 2  Reliability 
Tests of normality showed no violation and Paired t-tests were conducted to establish reliability. 
No significant differences (p = 0.223, ICC = 0.685; p = 0.02 ±0.7 SEM, d = 0.06) were observed 
between OFCT1 and OFCT2, indicating good inter-tester reliability. Additionally, no significant 
difference was found between OFC1 (6.26 ±2.84 nmol/L) and OFC2 (6.46 ±3.38 nmol/L) or LFD1 
(6.35 ±3.01 nmol/L) and LFD2 (6.37 ±3.00 nmol/L). Indicating good reliability of both the OFC 
swab (p = 0.813,  ICC = 0.890; p = 0.11 ±0.4 SEM) and LFD (p = 0.977, ICC = 0.850; p = 0.00 
±0.5 SEM, d = 0.00). Descriptive statistics for OFC, SOS and PD are shown in Table 2. 
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Table 1. Validity and reliability statistics for Individual Profiling (IPRO) oral fluid collector 
(OFC), ELISA Salimetrics oral swab (SOS) and ELISA Salimetrics passive drool (PD) for 
salivary cortisol concentration [sCort]. 
 Value 95% upper 
limit 
95% lower limit 
Validity    
IPRO OFC vs. ELISA SOS    
[sCort] Mean Difference (nmol/L) -0.10  ±2.79 1.20 -1.41 
Pearson’s Correlation Coefficient (r) 0.52   
IPRO OFC vs. ELISA PD    
[sCort] Mean Difference (nmol/L) -1.32 ±3.45 0.28 -2.94 
Pearson’s Correlation Coefficient (r) 0.45   
    
Reliability    
IPRO OFCT1 vs. OFCT2    
[sCort] Mean Difference (nmol/L) -0.93 ±2.26 0.68 -2.55 
Intra Class Correlation (ICC) 0.658 0.901 0.125 
Pearson’s Correlation Coefficient (r) 0.68   
IPRO OFC1 vs. OFC2    
[sCort] Mean Difference (nmol/L) -0.20 ±1.55 -2.67 2.27 
Intra Class Correlation (ICC) 0.904 0.993 0.331 
Pearson’s Correlation Coefficient (r) 0.89   
IPRO LFD1 vs. LFD2    
[sCort] Mean Difference (nmol/L) -0.01 ±1.64 -1.39 1.35 
Intra Class Correlation (ICC) 0.868 0.971 0.514 
Pearson’s Correlation Coefficient (r) 0.85   
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Table 2. Descriptive statistics for Individual Profiling (IPRO) oral fluid collector (OFC), 
ELISA Salimetrics oral swab (SOS) and ELISA Salimetrics passive drool (PD) for salivary 
cortisol concentration [sCort]. 
 OFC SOS PD 
[sCort] Mean ±SD (nmol/L) 6.90  ±2.88 7.00  ±2.86 8.23  ±3.63 
[sCort] Mean 95% CI - Lower 5.55 5.66 6.53 
[sCort] Mean 95% CI - Upper 8.25 8.34 9.93 
[sCort] Minimum 3.08 2.29 2.28 
[sCort] Maximum 12.72 9.50 21.90 
 
3. 4  Discussion 
The results of the present study found the IPRO point of care test for salivary cortisol 
concentration [sCort] to have good agreement with the industry gold standard ELISA method. 
Additionally, the present study identified the OFC method of salivary collection to be more 
closely correlated with the SOS method (p = 0.881; d = 0.06) compared with PD method (p = 
0.145; d = 0.00) for [sCort]. This is an important finding, and suggests future salivary cortisol 
comparisons should preferentially compare OFC results to SOS results when necessary. This 
finding is in-line with previous research [492] reporting differences in results in Salivary 
Immunoglobulin A concentrations in cotton swab collection compared with passive drool 
collection and demonstrates the importance of standardising saliva collection techniques in 
research and practice. Both OFC (p = 0.813) and LFD (p = 0.977) duplicate samples were not 
statistically different, indicating good reliability between samples. This finding suggests the IPRO 
point of care method is useful for salivary cortisol testing in recreationally active individuals and 
investigators can be satisfied that any substantial inter-subject changes to [sCort] are not due to 
tester errors if proper testing protocol is followed. The results of the present study are in agreement 
with previous investigations in English Football League Championship Academy soccer players 
[488] finding the IPRO method to be in good agreement with the ELISA method for determining 
[sCort]. Together, these findings suggest the IPRO method of measuring salivary cortisol (via 
OFC collection and LFD analysis) is useful for coaches and researchers when monitoring salivary 
cortisol in both recreationally active individuals and elite level athletes. 
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Saliva analysis is commonplace in applied sport science research due to convenience of sample 
collection with between 0.5-2.0ml generally sufficient to elicit an accurate result [319, 320, 435-
437, 445], however sample analysis can be time consuming. The IPRO method produces results 
within 15 min of sample preparation, providing timely feedback, and therefore offering an 
appealing alternative method of stress monitoring in real-time. In addition, the IPRO LFD reader 
is portable and can be used in the field for real-time analysis, bridging the gap between laboratory 
and field testing in applied sport science research and practice. The immediate availability of 
information regarding physiological demands of exercise is crucial in athlete monitoring. Coaches 
using the IPRO method for [sCort] analysis can readily monitor the stress response of their 
athletes throughout training and competition, gaining specific feedback about the demands of 
sport and exercise, providing advantage over traditional salivary cortisol measures i.e. ELISA.  
 
The results of the present study demonstrate the validity and reliability of a point of care salivary 
cortisol test for use in recreationally active individuals. Both the IPRO saliva collection (OFC) 
and analysis (LFD) aspects of the method were shown to be valid and reliable for salivary cortisol 
monitoring of [sCort] compared with the ELISA technique. Further reliability and validity testing 
should be conducted for the IPRO salivary cortisol method to confirm the findings of the present 
paper in a larger and more applied sample population including elite athletes.  
 
3. 5  Practical Applications 
The IPRO method showed a good agreement with the ELISA method for salivary cortisol analysis. 
In addition, the IPRO OFC and LFD show good reliability between samples and may prove to be 
a useful method for coaches and sport scientists to monitor changes in [sCort] in response to 
training and competition. 
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CHAPTER FOUR 
 
Experimental Study Two 
The Response of Salivary Immunoglobulin A to Elite Surf Lifesaving Competition 
 
 
4. 1  Introduction  
The influence of exercise on immune system function has been investigated in elite sports 
including swimming [313, 493] kayaking [306, 307] and running [305, 494]. In particular, URTI 
have been identified [495] as the most common infection experienced by highly trained athletes 
and are frequently responsible for athlete absence from training and competition [331]. Pyne 
(1999) [496] concluded that acquiring an URTI during training or competition may lead to 
detrimental effects on the health and performance of elite athletes.  
 
Tomasi and colleagues [497] reported that a predisposition to URTI often observed in athletes 
may be a result of a depressed immune response following intense exercise. In particular, 
decreases in s-IgA, the most abundant immunoglobulin at the mucosal surfaces of the upper 
respiratory tract, have been shown [270] to initiate up to 95% of all infections. Salivary 
immunoglobulin A represents the first line of defence against pathogens by preventing 
colonization and replication of viruses and bacteria on the mucosal surface of the upper 
respiratory tract [28]. It has been demonstrated [270, 313] that decreasing concentrations of s-IgA 
are associated with a predisposition to respiratory illness and can be a useful marker for 
respiratory infection risk [31]. Saliva analysis has become a widely accepted and utilised measure 
in applied research and team sport monitoring strategies [306, 451, 493] due to the non-invasive 
nature of sample collection and improved analysis methodologies for determining the s-IgA 
concentration [319]. The s-IgA concentration has been shown [477] to correlate more highly with 
URTI than serum antibodies or other immune parameters and as such provides a worthwhile 
measure for integrated athlete monitoring protocols in individual and team sports.  
 
Multiple studies [306, 315, 319] have investigated the effects of endurance exercise similar to that 
undertaken by elite SLS athletes, reporting decreases in s-IgA concentration in response to intense 
kayaking [306, 307] (>60%   ΟV 2  max), a seven month swim training program [313] and 
marathon running [305]. However, other studies [493, 498, 499] have reported no change in s-
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IgA concentration following intermittent and continuous exercise, including soccer and rugby 
competition and prolonged (>1.5 hr in duration) swimming. Increased s-IgA concentration 
following cycling [500] and basketball competition and training [501] have been reported to 
further demonstrate the acute impact of exercise on the immune system. Mackinnon  [264] 
identified  that the degree of s-IgA suppression is dependent on the intensity of the exercise. 
Currently, a discrepancy exists with respect to the acute s-IgA response to exercise and may be 
associated with methodological differences related to sample size and method of collection. 
 
Despite current research [307, 331, 496] examining the immune response to intense training for 
specific sports, few studies [499, 501] have investigated the changes in s-IgA concentrations 
during competitive exercise performance and the acute response of s-IgA to elite SLS competition 
is unknown. Elite SLS competition is a physically demanding sport that requires substantial 
physical conditioning, with athletes regularly participating in multiple daily training sessions - six 
days a week. In SLS, the ‘ironman’ race has emerged as the most demanding multi-disciplinary 
event through the consecutive performance of the four major skills of SLS namely soft sand beach 
running, surf swimming, surf board paddling and surf ski paddling [502] in a single event. Multi-
disciplinary surf athletes complete each skill over varying course formats and distances and are 
associated with performance durations from fifteen min to four and half hours [503] for any one 
event. It is also common for athletes to compete in heats, semi-finals and finals on a single day of 
competition [502]. Despite the professional status of the sport, currently few studies [502] have 
investigated the effects of training and competition on the elite SLS athlete and there is a lack of 
understanding regarding the endocrine and immunological response of elite SLS athletes to 
training and competition. The aim of the present study was to investigate the s-IgA response of 
elite men and women to a single, endurance SLS competitive event. The endurance SLS event 
under investigation involved continuous loops of a competitive course, which integrated surf 
swimming, surf board paddling and surf ski paddling in the open ocean. Male competitors raced 
for approximately 90 min and female athletes competed for approximately 60 min. No previous 
studies have examined the relationship between the exercise-related response of s-IgA and the 
predisposition of athletes to develop URTI in SLS athletes following competition. 
 
4. 2  Methods 
Approach to the Problem: Athletes provided daily unstimulated saliva samples in a non-fasted 
state over a period of six days at approximately from 54 hr pre-event to 61 hr post-event. All 
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saliva samples collected at training sessions occurred at approximately 0500 hours. Saliva 
samples collected on the day of event varied in response to the schedules time of competition; 
pre-event samples were collected prior to warm up between 0900 and 1100 hours, while post-
event samples were collected between 1300 and 1500 hours, after cool down. The daily training 
and saliva collection schedule is outlined in Table 1. Data were examined for each subject at each 
saliva sample collection time point. Throughout the pre and post-event sample collection period, 
subjects participated in all scheduled training and recovery sessions (Table 3).  
 
Table 3. The daily training and saliva collection schedule of SLS athletes throughout the six-day 
testing period (n = 25). 
Test 
48hr 
Pre-
Event 
24hr 
Pre-
Event 
Pre-
Event 
30min 
Post-
Event 
24hr Post-
Event 
48hr 
Post-
Event 
72hr 
Post-
Event 
Training 
Schedule 
0500 
Swim 
0500 
Swim 
0900 – 
11:00 
Pre 
Event 
1300-
16:00 
Post-
Event 
0900 
Recovery 
0500 
Swim 
0500 
Swim 
Saliva 
Test 
15min 
Prior to 
Training 
15min 
Prior to 
Training 
15min 
Prior to 
Warm 
Up 
After 
cool 
down / 
recovery. 
15min 
Post-
Awakening 
15min 
Prior to 
Training 
15min 
Prior to 
Training 
 
4. 2. 1  Participants: A total of 25 athletes competing in the 2012/2013 Kellogg’s Nutri-Grain 
Ironman and Telstra Ironwoman series were invited to participate in this study. Eighteen (n = 18) 
participants (male n = 10, female n = 8) volunteered to participate in this study (age: 24.4 y ± 7.5 
yr). All athletes that volunteered to participate in the study provided written informed consent and 
completed medical history and physical activity readiness questionnaires (PARQ). The protocol 
associated with the investigation was approved by the Bond University Human Research Ethics 
Committee (BUHREC). 
 
4. 2. 2  Procedures: The present study was undertaken during one of the 2012/2013 Kellogg’s 
Nutri-Grain Ironman and Telstra Ironwoman events which was approximately 90 min in duration 
and included all four skills of Ironman and Ironwoman competition; soft sand beach running, surf 
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swimming, surf board paddling and surf ski paddling that constituted separate stages of a single 
competition race.  Each lap was a total distance of 1993m with the surf board paddling, surf swim, 
surf ski and run stages set at 662m, 421m, 750m and 160m respectively. Each skill was completed 
in sequence and repeated four times.  
 
Unstimulated saliva was collected via an Oral Fluid Collector (IPRO OFC, IPRO Interactive, 
Oxfordshire, UK) consisting of a synthetic polymer based material on a polypropylene tube. The 
OFC has a volume adequacy indicator, providing a clear colour change when 0.5mL (±20%) of 
passive saliva is collected. All subjects were instructed to swallow any saliva present, before 
placing the OFC on their tongue. All subjects were requested to avoid the ingestion of food and 
fluids other than water in the 60 min before providing each saliva sample and to refrain from 
brushing their teeth two hours before each saliva sample collection session. Subjects were 
instructed to wait for a period of 10 min after their last consumption of water before commencing 
the saliva sample collection process. Saliva samples were collected from each athlete at their 
training and race venue as determined by the sample collection protocol to minimise disruption 
to the participants’ pre-event routine and preparation. 
  
Saliva Immunoglobulin A (µg/mL) was analysed in duplicate via a commercially available lateral 
flow immunoassay test kits (LFD; IPRO Interactive Ltd., Oxfordshire, England) and are reported 
as absolute measures for within individual variation.  The lateral flow principle of saliva analysis, 
or immunochromatographic strip (ICS) test was conducted in accordance with manufacturer 
instructions. For the LFD, two drops of saliva/buffer mix are added to the sample window of the 
LFD cassette. The liquid runs the length of the test strip via capillary action creating a control and 
test line visible in the test window.  Five min after the sample is added the test line intensity is 
measured in an IPRO plate reader (IPRO Interactive Ltd., Oxfordshire, England). The test line 
intensity is inversely proportional to the s-IgA concentration in the sample. The s-IgA intra-assay 
coefficient of variation as a percentage was 8.0%.   
 
4. 2. 3  Statistical Analysis: All data are expressed as mean ±SEM. A one-way repeated measures 
analysis of variance (ANOVA) was used to compare differences in salivary IgA concentration for 
each saliva sample collection time point. When the ANOVA showed significant main effects, a 
Tukey’s post-hoc test was used to identify the source of the differences. The statistical software 
package SPSS version 21.0 was used for all data analysis. 
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4. 3  Results 
The mean baseline measures collected at 54 hr, 30 hr prior to and the morning of the event were 
33.5 ±5.6  µg/mL, 38.6 ±8.8 µg/mL and 37.4 ±8.7 µg/mL respectively for males, and 31.0 ±6.2 
µg/mL, 39.7 ±8.4 µg/mL and  34.0 ±7.2 µg/mL respectively, for females. A non-significant 
increase in s-IgA concentration was observed for both genders, post-event compared to pre-event 
with a measure of 44.3 ±8.4 µg/mL for males and 38.9 ±9.3 µg/mL for females. Samples collected 
17 hr and 37 hr post-event were measured at 39.7 ±8.9 µg/mL and 39.8 ±7.9 µg/mL respectively 
for males and 32.4 ±6.7 µg/mL and 39.88 ±8.6 µg/mL respectively for females. No significant 
change was observed for females 61 hr post-event with a mean measure of 35.6 ±7.5 µg/mL, 
however a significant increase (p < 0.05; d = 1.66) in s-IgA concentration was observed at 61 hr 
post-event in males, compared to all other time-points, with a mean measure of 49.2 ±8.8 µg/mL. 
The mean values ±SEM for both genders are shown in Figure 4. 
 
 
Figure 4. Changes in salivary IgA concentration before and after a single SLS event. Values are 
means ±SEM. * Significantly (p < 0.05) higher than all other male time-points. 
 
4. 4  Discussion 
The results of the present study provide new insight into the s-IgA response to elite SLS 
competition and demonstrate the unique characteristics of SLS in comparison to research [494] 
0
10
20
30
40
50
60
70
2 days pre
event
1 day pre
event
Pre event Post event 1 day post
event
2 days post
event
3 days post
event
S
a
li
v
a
ry
 I
m
m
u
n
o
g
lo
b
u
li
n
 A
 (
u
g
/m
L
)
Male
Female * 
 63 
 
that has reported a decrease in [s-IgA] in response to high intensity swimming [313] kayaking 
[306] and marathon running [305]. The results of the present study demonstrate that elite male 
and females SLS athletes experience a non-significant increase in [s-IgA] within 30 min post SLS 
endurance competition. Additionally, male athletes experience significant (p < 0.05; d = 1.66) 
increases in [s-IgA] 61 hr post-competition of approximately 90 min duration, when compared 
with all other time-points in males.  
 
The mechanism responsible for the changes in [s-IgA] during the present study is unclear, 
however multiple studies [264, 504] have suggested a link between physical stress from intense 
exercise, life style factors and annual training mileage and fluctuations in [s-IgA]. A possible 
mechanism associated with the results of the present study is the influence of the stimulation of 
the HPA axis in response to intense exercise, which up-regulates the production of polymeric-
IgA receptors and facilitates the active transport of the polymeric-IgA complex across epithelial 
cells [505] leading to increases in [s-IgA]. Upon stimulation, the nervous system has been shown 
to increase the secretion of s-IgA into saliva through the stimulation of the sympathetic and 
parasympathetic nervous systems [297, 298]. The autonomic nervous system supplies nerves to 
the immune cells in lymphoid organs, and has been shown to induce changes in local immune 
processing [299]. In particular, the autonomic nervous system has been shown to enhance the 
transfer of s-IgA [300]. The SLS event examined in the present study required athletes to 
physically exert themselves to exhaustion over approximately 90 min in attempt to be victorious 
and accumulate sufficient points in the series to guarantee automatic qualification for the 
subsequent competition. Combining the additional pressure of concerns over requalification for 
the following year with the challenging oceanic conditions of this particular single, endurance 
SLS event, it is therefore possible that physical exhaustion and psychological stress may have 
contributed to amplified HPA axis activation, subsequently increasing [s-IgA] as observed at 61 
hr post-event in males, as an immune-compensatory effect.  
 
Mackinnon [306] suggested  intense daily kayaking (> 70% maximal HR)  in elite athletes may 
result in adverse changes in the production and secretion of s-IgA. In particular, a malfunction of 
the mucosal plasma cells, which migrate from the gut to the minor salivary glands, which is the 
major source of IgA in whole saliva [306]. The adverse changes in the production and secretion 
of s-IgA may occur in response to variations in temperature in mucous membranes or from 
decreases in nasal fluids, ultimately leading to a reduction in IgA output [497]. Elite SLS athletes 
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undergo substantial physical conditioning to prepare for competition, with athletes commonly 
training for several years before achieving optimal strength and endurance to successfully 
compete at the elite level. It is possible that a cumulative effect of training history may have 
contributed to the changes observed in the present study.  
 
Salivary IgA concentrations were not altered in male and female elite swimmers in response to a 
five month period of training leading into the 1998 Commonwealth games [493]. Conversely, 
intense training in a cohort of 26 elite swimmers over a five month period was directly linked to 
a suppression of mucosal immunity [315]. Similar results were observed over a three week 
training period in elite kayakers, showing decreases in [s-IgA] [306]. The distinction between the 
results of the present study and studies that examined swimming [315, 493] and kayaking [306] 
are likely to be associated with variation in training volumes, competitive distances, sample 
collection times and the unique nature of multi-event endurance sports such as SLS. The athletes 
in the present sudy were competing until exhaustion in a crucial event, it is therefore difficult to 
compare to other studies [315, 493] which investigated training sessions. It is possible that the 
same exercise intensity as experienced in a competition setting, was not obtained in these studies. 
Allgrove et al [506] investigated cycling to exhaustion, reporting very-high intensity exercise was 
sufficient to induce increased transportation of s-IgA into the saliva, immediately following 
exercise, as a result of sympathetic stimulation. Allgrove [506] suggested it is possible for 
exercise to exhaustion to activate the sympathetic nervous system (SNS) and cause an increase in 
[s-IgA]. Previous studies [507, 508] have concluded exercise induced changes in [s-IgA] return 
to resting levels within 24 hours of exercise cessation. It is possible that increased neural 
activation throughout the competition and upon the resumption of regular training at 
approximately 37-61 hr post-event, may have provoked SNS activation and subsequent increases 
in [s-IgA]. The increases in [s-IgA] observed post-event in both genders and 61 hr post-event in 
males may have been exacerbated by below normal baseline measures. It is possible that baseline 
measures were lower than average as particpants were in a taper period of reduced training volume 
in preparation for the event, and therefore the reductions in training volume may not have been 
sufficient to elicit a charcacteristic change in [s-IgA] in the days prior to the event.  
 
The effect of gender on s-IgA has been investigated in the athletic population concluding females 
often exhibit slower whole saliva secretion rates than males [509] and consequently higher [s-
IgA] than males [510]. The slower whole saliva secretion rate commonly observed in females 
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may be due to hormonal differences associated with gender or the use of OC [510]. The menstrual 
cycle and OC have been shown to influence the free cortisol response, with lower levels observed 
in the follicular phase of the menstrual cycle or while using OC compared with males [510]. 
Changes in the free cortisol response could lead to alterations in [s-IgA] as cortisol plays a role 
in the movement and functional capabilities of several immune cells including B-cells [511]. It 
has been reported [510] that gender-related secretion rates may be attenuated when male and 
females of the same age group are compared. The results of the present study exhibit similar 
results for males and females, with both genders showing non-significant increases in post-event 
means compared with pre-event means. Additionally both genders exhibit non-significant 
increases in [s-IgA] 17 hr post-event however only males were observed to have a signifanct 
increase in [s-IgA] 61 hr post-event. It is possible that male athletes returned to regular training 
following the event prior to female athletes and therefore the elevated [s-IgA] observed at 61 hr 
post-event for males could be attributed to increased neural activation associated with the 
resumption of high intensity training. Additionally, it is possible that differences in hormonal 
release from varying phases of the menstrual cycle or the use of OC could have reduced the [s-
IgA] in females, however as no information was gathered regarding which phase of the menstrual 
cycle each female particpant was in at the time of sample collection, this remains anecdotal.  
 
The present study observed absolute [s-IgA] in elite SLS athletes pre- and post-event, which is 
consistent with applied research methodologies that have investigated the impact of training on 
[s-IgA] and the relationship between [s-IgA] and competitive performance in swimmers leading 
into National Championships and the 1998 Commonwealth Games [315, 493]. Salivary IgA has 
been identified to be subjected to more short-term variations compared with other salivary 
proteins [456, 512] in addition to greater within- and between-subject variations in athletes such 
as elite rowers and swimmers [324]. Variation in the number of subjects, the demands of exercise, 
saliva collection and analysis methods reduces the ability for direct comparison between the 
results of the present study and others [307, 315, 493]. As a result of the high variability of s-IgA, 
studies with small sample sizes, such as the present study, may be less likely to detect real changes 
in salivary proteins and therefore any results should be interpreted with caution [513]. 
 
The present study found a significant increase (p < 0.05; d = 1.66) in [s-IgA] 61 hr post-event in 
males, compared with all other time-points. In addition, non-significant increases in [s-IgA] were 
observed post-event when compared to pre-event in both genders, which suggests increased SNS 
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activation associated with high intensity and prolonged exercise could have led to an increased 
secretion of s-IgA into the oral cavity. However, due to the applied population and resultant 
limited sample size available for participation in the present study as well as the high within- and 
between-subject variations in s-IgA it is difficult to draw unequivocal conclusions from the results 
of the present study. It is possible that a cumulative effect of substantial physical conditioning 
over several years has had an adverse effect on the mucosal immune system, resulting in abnormal 
variations in [s-IgA]. Further longitudinal research with a greater sample size using the IPRO 
device should be conducted to determine the immunological response to elite SLS Ironmen and 
Ironwomen competition and the validity and reliability of the device for use in an applied sport 
setting.  
 
4. 5  Practical Applications 
This study demonstrated the atypical response of elite surf lifesaving athletes to that previously 
reported for athletes of similar disciplines such as swimming and kayaking, highlighting the 
variability of immunosuppressive responses. The use of a point of care, field-based saliva analysis 
system may provide coaches and athletes with the ability to individually assess the immediate 
effects of training and competition on the immune system. Swift feedback on immune functioning 
following physical exertion could allow coaches and athletes to monitor immunosuppression, 
predict the risk of infection and adjust training periodization and recovery sessions accordingly. 
Elite SLS athletes and coaches may need to implement stringent precautions while tapering prior 
to major competitions, to reduce the risk of upper respiratory tract infection as a result of lowered 
[s-IgA] in response to reduced training load. The results of the present study indicate the s-IgA 
response in the days following SLS competition may vary between genders and therefore 
individualised recovery protocols should be implemented to minimise the risk of acquiring 
respiratory infections post-exercise and reduce the risk of resuming regular training prematurely. 
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CHAPTER FIVE 
 
Experimental Study Three 
Prevalence and the associated Benefits and Barriers for Oral Contraceptive use in 
Australian women grouped for physical activity level. 
 
5. 1  Introduction 
Oral contraceptives are one form of hormonal contraception that includes the administration of 
pills that vary in their type, amount and/or preparation of synthetic sex-hormones estradiol and 
progestin. An accurate account of the prevalence of OC use is difficult given the variability in 
research findings. For instance, 25-76% of Australian women reported using OC between 2001 
and 2007 [160, 514, 515]. The wide range in the prevalence rate of OC use might be due to the 
variance in participant demographics particularly age, income, and education [160, 515, 516]. Of 
particular interest, the OC practices of female athletes were initially identified to be less prevalent 
when compared to the general population [514], although the prevalence of OC use specifically 
in Australian female athletes was reported to be similar to the general population in 2007 [160, 
515]. Beals and Hill (2006) [123] demonstrated that the prevalence of OC use may be different 
among lean-build sports (e.g., cross-country) when compared to non-lean build sports (e.g., 
softball). Thus, in order to quantify and understand the rate and motive for OC use in active 
women, a range of sports and exercise levels should be included.    
  
Despite the ambiguity surrounding the prevalence rates of OC among sample groups, it is clear 
that there has been increasing over the last three decades [134, 517, 518]. An increasing rate of 
prevalence could be attributable to the third-generation (3G) pills that contain lower dosages of 
estrogen and progestin resulting in fewer/reduced side effects such as weight gain, and nausea 
[519]. Despite the positive effect of 3G pills on side-effects, other benefits and barriers specific 
to sample groups in the population are an interesting consideration. It is reasonable to suggest that 
if the prevalence of OC differs among sports, then the perceived benefits and barriers to OC use 
might differ among sports. 
 
The benefits and barriers for OC use in women have been explored in several survey-based studies 
[163-165] suggesting that cycle regularity, a reduction in dysmenorrhea, and acne relief were the 
most common known reasons for OC use, aside from birth control. Potential weight gain, nausea, 
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and mood changes such as depression, as well as an increased risk of some cancers and 
cardiovascular disease were reported as the predominant barriers associated specifically with OC 
use in American women [520]. Despite some information about the use of OC in the general 
population, less in known about the benefits and barriers to OC use specifically in active 
populations.  
 
Recent research has identified an association between synthetic hormone administration and 
decrements in peak aerobic power [7, 8, 167] as well as a reduced ability to recover from eccentric 
exercise [521, 522]. These factors may constitute credible barriers for active women to avoid OC 
whereas they may be regarded as less important in less active women.  
 
The purpose of this paper is to explore the ‘benefits and barriers’ for OC and specifically the role 
physical activity levels play on OC use in Australian women. It is hypothesized that the 
prevalence of OC use will be high in active compared to sedentary women, to allow for cycle 
regulation or manipulation. Furthermore, we expect that the non-contraceptive motives for OC 
use within less active women may be tailored towards attenuating symptoms associated with 
dysmenorrhea, treating acne, and cycle regulation. 
 
5. 2  Methods 
5. 2. 1  Participants: Participants (n = 125) were recruited via email and social media with the 
criteria for inclusion into their respective group based upon Exercise and Sport Science Australia 
(ESSA) physical-activity intensity guidelines [523] regarding recommended frequency, duration 
and intensity of physical activity.  
 
Categorisation resulted in untrained women (UT; n = 26; 32.2 yr ±7.3 yr; i.e. < 2 sessions/wk of 
low intensity exercise or < 2 METS/session), recreationally active (REC; n = 44; 30.6 yr ±6.8 yr; 
i.e. 3-4 sessions/wk of moderate intensity exercise or 3-6 METS/session) and trained (TR; n = 55; 
27.0 yr, ±8.3 yr; i.e. 5+ sessions/week of vigorous intensity or >6 METS). Demographical 
information about participants is shown in Table 4. 
 
5. 2. 2  Procedures: A survey was created using an online, web-based survey creator 
(SurveyMonkey Inc., USA) and distributed to the athletic and general population cohorts via 
email and social media for 3 mo; of the individuals who engaged in the survey by answering at 
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least one question, 84% of surveys were completed in their entirety and accepted in the present 
study. The survey comprised twenty-five questions and aimed to identify why participants use, or 
do not use, OC. Initial physical activity background was established for both populations via 
participants being asked to provide details of the type of physical activity they undertake in an 
open-ended response, as well as the frequency, and intensity of these sessions.  
 
For women using OC (womenOC), the survey inquired about the duration of use and form of OC 
currently being used. Participants were also asked to rank the reasons for OC use from a list of 
seven responses; including birth control, cycle control and reducing menstrual disturbances. They 
were instructed to only rank the reasons relevant to them. If participants indicated there were other 
reasons not included in the list, they were asked to clarify their reason in an open-ended response. 
If participants indicated they were not currently using OC (i.e., considered “normally-
menstruating” but not necessarily regular; womenNM), they were asked to rank their reasons for 
avoiding OC. Participants were provided with nine potential deterrents including side effects, 
medical concerns or conditions, reduced exercise performance and the desire to become pregnant. 
If participants indicated there were other reasons not included in the list, they were asked to clarify 
their reason in an open-ended response.  
 
Informed consent was attained from all participants prior to participating in the survey as 
approved by the Bond University Human Research Ethics Committee. All participants remained 
anonymous unless they wished to participate in follow-up research, in which case they were asked 
to provide their name and contact details.  
 
5. 2. 3  Statistical Analysis: Chi-Square (2) Test for relatedness was conducted to identify 
common benefits and barriers for OC use or non-use within the three physical activity groups 
(UT, REC, TR). Variables showing a Pearson’s chi-square (2-sided) of p < 0.05 significance were 
re-tested with adjusted standardised residuals (z-scores). In the instance of a z-score of >1.96, a 
p-value was calculated using the standardised residual method post-hoc technique, as described 
by Beasley 1995 21 and Garcia-Perez 2003[524, 525]. An adjusted Bonferroni was used to 
maintain an accurate family-wise alpha rate by dividing the alpha level ( = .05) by the number 
of comparisons made. Our determined adj was p < 0.00. Results are presented as frequencies 
(percentages), 2 and p-values.  Data analysis was conducted using statistical software package 
(IBM SPSS Statistics Version 21). 
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5. 3  Results 
The prevalence rates of OC use were 31%, 39%, and 47% for the UT, REC, and TR groups, 
respectively. Despite an apparent mean increase in prevalence with physical activity level (Figure 
5), there were no significant differences among the three groups (p > 0.05) (see Table 4).  
 
 
Figure 5. Comparison of women taking OC between exercise groups; UT = Untrained, REC = 
Recreationally Active, TR = Trained, OC = Oral Contraception. 
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Table 4. Subject characteristics including the prevalence of oral contraceptive use in untrained 
(UT group), recreationally active (REC group) and trained (TR group) women. 
Subject characteristics / Group UT (n = 26) REC (n = 44) TR  (n = 55) 
Age (yr) 32.2 ±7.3 30.6 ±6.8 27.1 ±8.3 
Employment statusa    
Full time 15  28 21 
Part time / Casual 3 9 21 
Student 4 7 20 
Mother / Homemaker 3 3 0 
Not stated 1 0 3 
Currently using oral contraception    
Yes  8 (31%) 17 (39%) 26 (47%) 
No 18 (69%) 27 (61%) 29 (52%) 
Duration of use    
< 1 year 0 2 (12%) 1 (4%) 
1 – 3  yr 1 (13%) 4 (23%) 7 (27%) 
4 - 8 yr  3 (37%) 2 (12%) 5 (19%) 
8 – 15 yr 3 (37%) 5 (30%) 10 (38%) 
> 15 yr 1 (13%) 4 (23%) 3 (12%) 
Type of oral contraceptive    
Monophasic 2 (25%) 7 (41%) 9 (35%) 
Biphasic 0 3 (18%) 5 (19%) 
Triphasic 4 (50%) 5 (29%) 6 (23%) 
Progesterone only (i.e., mini pill) 2 (25%) 2 (12%) 6 (23%) 
Type of activity a    
Walking 17 (65%) 15 (34%) 6 (11%) 
Jogging / running 1 (2%) 18 (41%) 24 (44%) 
Cycling  2 (7%) 4 (9%) 3 (5%) 
Swimming / Surf-Based Sports / Rowing 4 (15%) 14 (32%) 28 (33%) 
Organised sport (tennis, soccer, hockey 
& netball) 
2 (7%) 5 (11%) 9 (16%) 
Group classes / Resistance training 3 (12%) 24 (55%) 33 (60%) 
Playing with children / walking pets 1 (2%) 2 (5%) 0  
Housework / Gardening 1 (2%) 0 0 
None 1 (2%) 0 0 
. a More than one response allowed per person. 
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Universally, preventing unwanted pregnancies (90%), cycle control (86%) and reducing 
menstrual symptoms (88%) were the major reasons for using OC (n = 51). Additionally, a 
decreased risk of anaemia or bone mineral density were reported as a benefit of using OC in the 
UT group (50%) and a reduction in acne in the REC group (52%) and TR group (54%) (Table 5).  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 74 
 
Table 5. Perceived benefits of using oral contraception in untrained (UT group), recreationally active (REC group) and trained (TR group) Australian 
women (n = 51). 
Note: More than 1 response allowed per person. PCOS = Polycystic Ovarian Syndrome; BMD = Bone Mineral Density. 
Benefit UT  REC  TR  
 Frequency 
Chi-
square 
(2) 
p-value 
Effect 
Size 
(w) 
Frequency 
Chi-
square 
(2) 
p-value 
Effect 
Size 
(w) 
Frequency 
Chi-
square 
(2) 
p-value 
Effect 
Size 
(w) 
Birth 
Control 
7 (87%) 1.37 0.242 0.16 15 (82%) 0.21 0.646 0.06 24 (92%) 1.96 0.162 0.20 
Cycle 
Control 
8 (100%) 0.28 0.596 0.07 12 (70%) 1.88 0.171 0.19 24 (92%) 3.06 0.080 0.24 
Reduce 
Menstrual 
Symptoms 
5(62%) 1.25 0.260 0.16 10 (58%) 0.94 0.330 0.14 20 (77%) 3.42 0.060 0.26 
Relief 
from 
PCOS 
3(37%) 0.34 0.562 0.08 7 (41%) 0.03 0.973 0.02 9 (35%) 0.10 0.749 0.04 
Reduce 
Acne 
3 (37%) 1.72 0.190 0.18 9 (52%) 0.00 0.940 0.00 14 (54%) 1.30 0.250 0.16 
Reduce 
Anaemia / 
BMD 
Loss 
4 (50%) 0.03 0.870 0.02 6 (35%) 0.03 0.860 0.02 8 (31%) 0.00 0.970 0.00 
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Daily commitment to taking the OC pill each day (57%), use of other forms of birth control (55%) 
and side effects (54%) were the major reasons for not taking OC for womenNM (n = 74) (Table 
6). In the womenNM UT group, the predominant reasons for not using OC were using other forms 
of birth control (55%) and the commitment to take the pill each day (61%). Trained women also 
reported using other forms of contraception (51%) and the presence of synthetic hormones (51%) 
as reasons for avoiding OC. Side effects associated with OC use (66%) and a desire to fall 
pregnant (66%) were the predominant reasons contributing to the avoidance of OC in the 
womenOC REC group. 
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Table 6. Perceived barriers towards oral contraceptive use in untrained, recreationally active and trained Australian participants (n = 74). 
Note: More than 1 response allowed per person. CVD = Cardiovascular Disease; DVT = Deep Vein Thrombosis. 
Barrier UT 
 
REC 
 
TR 
 
 Frequency 
Chi-
square 
(2) 
p-
value 
Effect 
Size 
(w) 
Frequency 
Chi-
square 
(2) 
p-
value 
Effect 
Size 
(w) 
Frequency 
Chi-
square 
(2) 
p-
value 
Effect 
Size 
(w) 
Using other 
Contraception 
10 (55%) 0.48 0.490 0.08 16 (59%) 0.40 0.529 0.07 15 (51%) 1.37 0.242 0.14 
Side Effects 9 (50%) 0.10 0.749 0.04 18 (66%) 2.46 0.116 0.18 13 (44%) 3.17 0.075 0.21 
Medical Condition 6 (33%) 0.11 0.741 0.04 15 (55%) 2.56 0.110 0.19 11 (37%) 1.61 0.204 0.15 
DVT / Blood Clot 1 (16%) 0.09 0.764 0.03 3 (20%) 0.64 0.423 0.09 2 (18%) 0.25 0.617 0.06 
Hypertension 2 (33%) 1.21 0.027 0.13 1 (6%) 0.49 0.482 0.08 2 (18%) 0.04 0.841 0.02 
CVD 0 0 0 0.00 1 (6%) 1.96 0.161 0.16 0 0.81 0.376 0.10 
Medical Concerns 7 (38%) 0.03 0.865 0.02 16 (59%) 4.12 0.042 0.24 9 (31%) 4.41 0.036 0.24 
Desire to Conceive 6 (27%) 0.40 0.529 0.07 18 (66%) 5.62 0.018 0.28 11 (37%) 3.13 0.077 0.21 
Commitment to 
take 
11 (61%) 1.12 0.290 0.12 17 (62%) 0.77 0.380 0.10 14 (48%) 2.92 0.090 0.20 
Synthetic 
Hormones 
8 (44%) 0.00 0.960 0.00 15 (55%) 0.44 0.510 0.08 15 (51%) 0.45 0.500 0.08 
Reduced Exercise 
Performance 
4 (22%) 0.58 0.450 0.09 13 (44%) 3.17 0.080 0.21 9 (31%) 1.17 0.280 0.13 
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A reduction in menstrual symptoms was consistently reported across all womenOC (n = 51) as a benefit of taking the pill. Common menstrual disturbances 
reported by the women as a result of OC use are shown in Table 7. 
 
Table 7. Commonly experienced menstrual symptoms as identified in women leading to OC use (n = 35). 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Note: More than 1 response allowed per person. 
Menstrual 
Symptom 
UT 
 
REC 
 
TR 
 
 Frequency 
Chi-
square 
(2) 
p-
value 
Effect 
Size 
(w) 
Frequency 
Chi-
square 
(2) 
p-
value 
Effect 
Size 
(w) 
Frequency 
Chi-
square 
(2) 
p-
value 
Effect 
Size 
(w) 
Heavy 
Period 
3 (60%) 0.14 0.704 0.06 6 (60%) 1.12 0.258 0.18 3 (15%) 1.93 0.165 0.23 
Painful 
Period 
3 (60%) 0.83 0.360 0.15 7 (70%) 0.14 0.710 0.06 12 (60%) 1.21 0.270 0.19 
Bloating 1 (20%) 0.77 0.379 0.15 5 (50%) 1.04 0.308 0.17 4 (20%) 0.07 0.787 0.04 
Breast 
Tenderness 
2 (40%) 0.09 0.764 0.05 2 (20%) 0.38 0.535 0.10 4 (20%) 0.12 0.726 0.06 
Mood 
Disturbance 
2 (40%) 0.05 0.830 0.04 3 (30%) 5.76 0.020 0.41 6 (30%) 0.55 0.460 0.13 
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The side effects and medical conditions associated with OC contributed to womenNM avoiding the use of OC (n = 40). The predominant side effects and 
medical conditions are shown in Table 8. 
Table 8. Common side effects and medical conditions of oral contraception in women (n = 40) contributing to non-OC use. 
 
Note: More than 1 response allowed per person. 
 
Side 
Effect 
 UT  
 
 REC  
 
 TR  
 
 Frequency 
Chi-
square 
(2) 
p-value 
Effect 
Size 
(w) 
Frequency 
Chi-
square 
(2) 
p-value 
Effect 
Size 
(w) 
Frequency 
Chi-
square 
(2) 
p-value 
Effect 
Size 
(w) 
Weight 
gain 
9 (100%) 2.4 0.121 0.24 12 (66%) 0.64 0.424 0.13 8 (61%) 4.12 0.042 0.32 
Increased 
appetite 
1 (11%) 0.36 0.549 0.09 3 (16%) 0.02 0.889 0.02 4 (30%) 0.12 0.726 0.05 
Increased 
acne 
2 (22%) 3.92 0.048 0.31 1 (5%) 0.00 0.944 0.00 0 0 0 0.00 
Nausea 2 (22%) 1.17 0.280 0.17 2 (11%) 0.05 0.818 0.04 1 (7%) 1.21 0.271 0.17 
Headache 3 (33%) 0.92 0.337 0.15 5 (27%) 1.77 0.184 0.21 1 (7%) 4.24 0.039 0.33 
Mood 
Changes 
6 (66%) 0.67 0.412 0.13 7 (38%) 0.14 0.711 0.06 9 (69%) 0.10 0.749 0.05 
Reduced 
Libido 
2 (22%) 0.64 0.424 0.13 9 (50%) 4.58 0.032 0.34 4 (30%) 2.07 0.150 0.23 
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5. 4  Discussion 
The results of the present study suggest physical activity levels do not play a role in the motives 
for OC use in Australian women. The predominant reasons for OC use were similar between all 
women, with birth control, cycle control and a reduction in menstrual symptoms all considered 
benefits of OC use. In both REC and TR women, a reduction in acne vulgaris was a reason 
reported to contribute to OC use, which may reflect a greater emphasis on physical appearance in 
active women compared with untrained women. Untrained women considered a reduced risk of 
anaemia and bone mineral density (BMD) a more important benefit of OC use, likely because 
they are not gaining these benefits from engaging in weight bearing exercise. Similarly to the 
current study, a previous investigation [163] identified cycle regularity (60%), a reduction in 
dysmenorrhea (42%) and acne relief (37%) to be the most known non-contraceptive benefits of 
OC in general population women. These findings are likely attributable to the ability to 
manipulate the timing of menstruation or reduce adverse symptoms associated with menstruation 
that may impede exercise when using OC which may be beneficial to active women.  
 
Heavy periods (menorrhagia) were reported in 60% of UT and REC women but merely 15% of 
TR women, suggesting an association between elevated physical activity levels and lower 
menstrual blood loss. Menorrhagia refers to a menstrual blood loss of  >80mL per cycle [526] 
and is the most frequent cause of iron-deficiency anaemia in women of reproductive age [527]. 
Menstrual blood loss may have contributed to the higher amount of UT women reporting a 
decreased risk of anaemia or reduced BMD (50%) as an important benefit of OC use, particularly 
if they are experiencing menorrhagia frequently and are not engaged in adequate weight-bearing 
exercise regimes to maintain bone health. The prevalence rate of menorrhagia reportedly ranges 
from 5-37% within the normal population in women of reproductive age [528-530], with 
approximately 12% of gynaecological referrals addressing menorrhagia [531]. Conversely, 
secondary amenorrhea is a condition characterised by the absence of menstruation for at least 
three months [93, 532] and is more commonly experienced in athletes (1-50%) compared with 
general population women (2-5%) [97-102], further substantiating an association between 
physical activity levels and menstrual functioning [97-102]. The results of the present study 
further suggest a potential association between exercise and menstrual blood loss, with less active 
women more likely to take OC to attenuate menorrhagia and anaemia and subsequently potential 
decreases in BMD.  
 
Painful periods were also reportedly a major side effect of the menstrual cycle and contributed to 
OC use in 60% of TR women. It is possible the presence of dysmenorrhea (or severe menstrual 
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pain) may interfere with physical activity and active women may wish to minimise this 
impediment. Additionally, other side effects of the menstrual cycle including bloating, breast 
tenderness and mood disturbances were also reported contributors to OC use in all women. 
Interestingly, the commitment to take OC each day was considered a common barrier in UT 
women (61%) and REC women (62%) compared with TR women (48%; p > 0.05; w = 0.20), 
which may reflect a greater amount of discipline in TR women due to strict physical activity 
habits, which may explain why more UT and REC women reported difficulties with committing 
to following the OC pill protocol.  
 
Contrasting the perceived benefits of OC usage, the major reasons for not taking OC in TR women 
were the presence of synthetic hormones (51%) as well as utilising other methods of birth control 
(51%), with similar rates observed in UT and REC women. It is possible that women may wish 
to avoid ingesting unnatural substances or may have concerns about how these exogenous 
hormones will affect health and exercise performance. However only 31% of TR women reported 
a reduction in exercise performance as a barrier for OC use, which may reflect an unawareness of 
the association between OC and reduced peak aerobic power  [7, 8, 167] and ability to recover 
from eccentric exercise [521, 522]. Medical conditions and concerns were considered a barrier of 
OC use in over half of REC women, but appear less concerning in UT and TR women, despite 
hypertension and deep vein thrombosis/blood clotting (DVT) reportedly experienced across all 
three sample groups and cardiovascular disease experienced in REC women. It is possible that 
the REC women in the present study reflect a wider range of women than TR or UT women, and 
subsequently REC women may have a higher prevalence of medical conditions or concerns in 
relation to taking OC as a result of larger sample representation. Recreationally active women 
also reported a greater desire to fall pregnant (66%; p = 0.01; w =0.28) more than UT (27%; p > 
0.05; w = 0.07) or TR (37%; p > 0.05; w= 0.21) women, which may be a further reflection of a 
wider range of women within the REC sample, compared with the UT and TR women. It is also 
possible that TR women may be preparing for upcoming competitions or events and may be less 
inclined to start a family until after they have achieved any potential athletic goals. 
 
Side effects of OC were commonly reported barriers for use in REC (66%; p > 0.05; w = 0.04), 
UT (50%; p > 0.05; w = 0.18) and TR (44%; p > 0.05; w =0.21) participants. As found in previous 
investigations [520][533], weight gain and mood changes associated with OC were considered 
major barriers for OC use which parallel those findings from the present study where weight gain 
was reported as predominant side effect in UT (100%) and REC (66%) women, while mood 
change was the most commonly reported side effect in TR (69%) women. These findings are in 
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line with a previous investigation in medical students, who found weight gain to occur in 17% of 
OC users and could provide reason for pill discontinuation [134]. It is possible however, that REC 
and TR women may be less concerned with changes in weight due to more strict dietary and 
exercise regimes, whereas UT women may be less inclined to adhere to a restricted dietary intake 
and exercise programs, and consequently this higher prevalence of weight gain. It is possible that 
TR women consider mood changes associated with OC to be a more important barrier for use 
than weight gain, as any changes to cognitive thinking and arousal may negatively affect exercise 
performance or the desire to be physically active on a daily basis. Taken together, these findings 
suggest that physical activity levels may indirectly contribute to a woman’s decision to take OC. 
 
Nausea and headaches were reported by all women as potential side effects of OC use, with 
increases in acne reportedly occurring in UT and REC women only, which is in line with previous 
research [134, 520, 533] in university students and American women reporting nausea and 
headaches as commonly experienced side effects of OC use. It is possible that TR women may 
be concerned with headaches while taking OC due to the amount of weekly exercise undertaken. 
Regular aerobic exercise has been reported [534] to lessen the pain, frequency and severity of 
headaches and migraines, and consequently TR women in the present study may experience less 
headaches than other women due to their physical activity levels, subsequently not considering 
headaches as such a barrier for OC use; further substantiating weekly physical activity levels as 
an indirect contributor to the decision to take OC. 
 
The present study identified physical activity levels do not appear to play role in OC use in 
Australian women; however the benefits of engaging in frequent exercise may indirectly affect 
the perceived needs of a woman while taking OC. All women, regardless of physical activity level 
reported birth control, cycle control and a reduction in menstrual symptoms as major benefits of 
taking OC. Less active women appear to consider a reduction in anaemia a key benefit for OC 
use as well. The reasons for not taking OC were more diverse between the sample populations, 
with the predominant reasons for not taking OC in trained women being the presence of unnatural 
hormones or utilising other methods of birth control. Untrained women also reported using other 
forms of contraception and the commitment to take the pill each day as barriers for OC use. 
Whereas, the side effects of OC use and a desire to become pregnant commonly prevented REC 
women from using OC, with all sub-groups of women reporting weight gain as a potential barrier 
for OC use, particularly women engaged in less weekly exercise. It is possible a lack of education 
and awareness about the influence of OC on health and performance has contributed to the 
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findings of the present study, and Australian women may benefit from a greater understanding of 
the effect of exogenous estrogen and progesterone on physiology.   
 
5. 5  Practical Applications 
Physical activity level does not appear to play a role in OC use in Australian women; however 
the lack of an association is interesting given the new information regarding the effect of OC on 
exercise performance. The major benefits of taking OC across all women regardless of physical 
activity levels were birth control, cycle control and reducing adverse symptoms associated with 
the menstruation. In addition, UT women commonly reported taking OC reduce the risk of 
anaemia or reductions in bone mineral density. The major barriers towards OC use irrespective 
of physical activity levels were the side effects associated with the pill, the commitment to take 
the pill every day, and the presence of unnatural hormones, as well as the use of other methods of 
birth control. In the women who reported side effects associated with taking OC as a barrier, 
weight gain, changes in mood and a reduced libido were identified as common side effects.  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
  
 83 
 
CHAPTER SIX 
 
Experimental Study Four 
Salivary cortisol and IgA response to incremental cycling in a thermally-stressful 
environment; the role of oral contraceptives and core body temperature. 
 
6. 1  Introduction 
Cortisol is considered a very potent hormone in human physiology and can easily target most of 
the body’s cells [181]. In high dosages, cortisol reportedly contributes to immune suppression 
[535]. This association between cortisol and immune function is likely attributable to the presence 
of neuroendocrine receptors located on several immune cells including lymphocytes [45]. 
Specifically, these neuroendocrine receptors can inhibit the trafficking and effector functions of  
B-lymphocytes [252], including s-IgA. Salivary immunoglobulin A is a form of B-lymphocyte 
produced in plasma cells located close to the salivary glands [424] and acts to neutralize viruses 
and toxins by inhibiting the attachment and replication of invading pathogens to the upper 
respiratory tract [427]. Salivary IgA concentration is reportedly affected by exercise with both 
increases and decreases observed [437, 536] depending on the intensity and frequency of the 
exercise undertaken. [265]. Similarly to s-IgA, it is likely that the intensity and duration of 
exercise also determines the magnitude of cortisol response to exercise [240] with high intensity 
exercise contributing to a surge in cortisol levels [237, 238, 240]. 
 
Several lymphocytes exhibit receptors for estrogen and progesterone which may affect cellular 
responses [38, 347] such as estrogen, enhancing the immune system [349], leading to increases 
in immunoglobulins [350]. In particular [s-IgA] has been shown to mimic serum estradiol 
throughout the menstrual cycle [34], demonstrating the influence of circulating ovarian hormones. 
Equivocal results have been reported regarding the effect of endogenous estrogen and 
progesterone on cortisol secretion at rest and throughout exercise [19, 21, 220], however 
exogenous secretions in the form of OC appear more apparent, leading to increases in serum 
cortisol comapred with women who are normally menstruating and men [21]. Considering the 
differences in cortisol secretion at rest between OC users and normally menstruating women, it is 
conceivable that the stress response to exercise and the subsequent effect on mucosal immunity 
would also differ and warrants investigation. 
Environmental temperature is known stressor affecting SNS and HPA axis activity and may 
provoke a large exercise-induced cortisol response [537, 538]. Passive heating can reportedly lead 
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to increases in TC of up to 1.2C consequently causing an increase in cortisol secretion [539, 540]. 
It is possible that engaging in exercise in HH conditions would evoke greater increases in cortisol 
secretion [541], which may be amplified in women taking OC if they already experience high 
secretions of cortisol. If the addition of heat stress provoked a substantial rise in [sCort] 
throughout exercise, a suppression of [s-IgA] may occur  [535], compromising the health of 
women exercising in warmer climates.  
 
Endogenous estrogen and progesterone are known to affect TC, with progesterone reported to 
negatively affect warm-sensitive neuron activity, consequently hindering heat-loss mechanisms 
[386], and likely contributes to the increase in basal body temperature of 0.3-0.5C [73, 74, 381] 
observed throughout the luteal phase of the menstrual cycle. Less is known about the effect of 
exogenous progesterone on central regulatory mechanisms particularly in hot environmental 
conditions; however it is likely that exogenous hormones would cause similar changes to TC. 
Throughout intense exercise a substantial amount of heat is produced as a result of the energy 
generated from active muscles, with this excess heat contributing to an increase in TC [47]. The 
production of excess heat and subsequent increases in TC are exacerbated if exercising in hot 
conditions, as the ability of the body to lose heat throughout conduction, convection and radiation 
is reduced [47]. It is likely that exercising in the heat would elicit a greater stress response, which 
may lead to substantial changes in mucosal immunity, and these changes may be exacerbated in 
women taking OC if they are exposed to higher cortisol secretion and TC. It is hypothesized that 
exogenous progesterone will cause an increase in core temperature in oral contraceptive users, 
which will lead to a greater secretion of cortisol and subsequently decreases in s-IgA. 
Therefore the present study aims to investigate the effect of exogenous estrogen and progesterone 
administration on the s-IgA and sCort response to cycling coupled with thermal stress.  
 
6. 2  Methods 
6. 2. 1  Participants: Sixteen (n = 16) recreationally active women volunteered to participate in 
this study, provided written informed consent to participate in this study as approved by the 
Institutional Human Research Ethics committee and were then categorised as either normally 
menstruating (n = 8, womenNM, 21.7 ±2.9yr) or taking OC (n = 8, womenOC, 22.6 ±3.5yr). 
Those participants in the womenOC cohort were required to have been taking combined 
monophasic OC for at least the prior twelve months. Those participants allocated to the 
womenNM group were void of any form of hormonal contraception in the twelve months prior 
to the commencement of the present study. All exercise trials were conducted during the early 
follicular phase for womenNM and throughout the active pill stage in womenOC in attempt to 
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achieve a stable hormonal balance between the groups and minimise menstrual disturbances such 
as pre-menstrual syndrome or dysmenorrhea influencing exercise performances. Normally 
menstruating women undertook all exercise trials within 3- 7 days of the onset of menstrual 
bleeding to ensure their menstrual phases was standardised. Participant’s plasma concentrations 
of estradiol and progesterone are shown in Table 11 to confirm cycle phase. 
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Table 9. Descriptive characteristics (mean ±SD) for participants classified as normally 
menstruating (womenNM; n = 8) and taking oral contraception (womenOC; n = 8). * Significantly 
higher (p < 0.05) than womenOC. 
 WomenNM WomenOC 
Age (yrs) 21.7 ±3.1 22.6 ±3.7 
Body Mass Pre-Exercise (kg) 64.2 ±6.2 59.7 ±6.5 
Body Mass Post-Exercise (kg) 64.1 ±5.7 59.4 ±6.4 
% Decrease 0.2 ±1.7 0.5 ±0.0 
Height (cm) 168.38 ±6.7 163.6 ±6.1 
BMD (g/cm2) 1.27 ±0.1 1.27 ±0.1 
Z-Score (SD) 2.02 ±0.8 2.21 ±1.0 
Z-Score (%) 113.67 ±5.7 115.11 ±6.2 
BMI (kg/m2) 22.40 ±1.7 22.00 ±1.8 
Total Mass (kg) 63.07 ±5.2 59.07 ±6.1 
Fat Mass (g) 16,973.33 
±2,661.3 
16,208.78 
±2,777.0 
Lean Mass (g) 43,081.33 
±6,806.0 
39,964.22 
±4,057.5  
Total body fat (%) 28.44 ±5.6 28.96 ±3.2 
Resting systolic blood pressure (mmHg) 105.8 ±9.6 108.8 ±8.0 
Resting diastolic blood pressure (mmHg) 67.5 ±8.8 65.8 ±6.7 
Max oxygen uptake (ml/kg/min-1) 44.3 ±5.1 44.59 ±4.0 
Lactate Threshold One Power Output (watts) 80 ±25 72 ±16 
Estradiol E2 (pg/ml) 91.66 ±69.29* 9.39 ±7.11 
Progesterone P4 (ng/ml) 0.31 ±0.15* 0.10 ±0.05 
 
6. 2. 2  Procedure: Each participant was required to undertake four laboratory testing sessions 
which included exercise pre-screening and DEXA scanning (Table 9), a lactate threshold testing 
to identify respective workloads and two threshold trials completed under different environmental 
conditions: TN (22C; r.h. 50%) and HH (35C, r.h. 50%); the threshold trial order was 
randomised for each participant. The initial testing session was to determine individual 
participant’s LT1 via a long-graded cycling test to exhaustion [542] utilising open circuit 
spirometry (COSMED, Chicago, Illinois, USA) and blood lactate monitoring (Lactate Pro, 
ARKRAY Inc., Japan; BLa). Each subsequent trial involved cycling (Lode, Sport Excalibur, 
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Netherlands) at 90% of LT1 for 30 min (stage 1), 135% of LT1 for 15 min (stage 2) and then 190% 
of LT1 for 7.5 min (stage 3) under either the TN or HH environmental conditions.  
 
Within one week following exercise pre-screening and the DEXA scan, each participant 
completed a long-graded exercise test to exhaustion to identify lactate threshold, to ensure the 
relative secretions of estrogen and progesterone were similar between DEXA scanning and lactate 
threshold testing. The lactate threshold test was conducted on a cycle ergometer (Lode, Sport 
Excalibur, Netherlands) with an attached programmable control unit (Lode, Sport Excalibur, 
Netherlands). Participants began cycling at 45 watts, with 15 watt increases every 4 min until BLa 
was greater than 4.0 mmol/L, as measured by a handheld automated device (Lactate Pro, 
ARKRAY Inc., Japan) from arterialised blood (earlobe). Upon reaching a BLa concentration of 
≥ 4.0mmol/L power output was increased by 15 watts every 30 sec until volitional exhaustion. 
Gas exchange was monitored via open circuit spirometry (COSMED, Chicago, Illinois, USA) to 
identify   ΟV 2 max (L/min) (Table 9). Lactate threshold one (LT1) was identified as the power 
output (watts) immediately prior to an increase in BLa of 0.4 mmol/L or greater; this point was 
used to determine relative workloads for the cycling threshold test. 
Approximately one month following the long-graded exercise test when participants were in the 
same phase of their menstrual or oral contraceptive cycle as the DEXA scan and lactate threshold 
test, they were contacted and requested to arrive at the exercise laboratory fasted (food and water) 
from 8:30pm the previous night. Upon arrival (approximately 0500 hours), participants were 
seated in a quiet, TN (21-23C) exercise laboratory where they provided one saliva sample for 
baseline [s-IgA] and [sCort] (IPRO Interactive, Wallingford, UK), and one venous blood sample 
for estrogen and progesterone (Table 9). Whole saliva was collected via an oral swab connected 
to an indicator line which turned blue once 0.5ml of saliva had been absorbed. Immediately 
following collection, the swab was placed into 3ml of buffer solution, where it remained stable 
until testing. To test each sample, two drops of the buffer/saliva solution (~100 L) are placed 
onto the sample pad of the lateral flow device (LFD) and set aside for ten min. Once the liquid 
flows across the nitrocellulose membrane, where immunoglobulin A and cortisol bind to the gold-
labelled anti-IgA or cortisol antibody. Following a ten min incubation period, the LFD is placed 
into the LFD reader, where the relative concentrations of s-IgA or cortisol are measured within 
20 sec. Participants were provided with a standardised breakfast of toast (1 slice + 0.33 per 5kg 
over 50kg body mass) and water (5mL/kg body mass).  
 
 88 
 
Following the collection of baseline saliva samples (approximately 0500 hours), Participants 
undertook a 60 min acclimation period and consumed standardised breakfast of 36.9g CHO per 
5kg over 50kg body mass and 5mL per/kg-1 body mass of room-temperature water. A second 
saliva sample for [s-IgA] and [sCort] was collected for pre-exercise values (approximately 0530 
hours), were collected following the consumption of breakfast at approximately 30 min of 
acclimation. Following 60 min of seated acclimation, participants were weighed (following 
bladder voiding) and resting measurements TC (HQ Inc., Palmetto, Florida, USA) were recorded 
while the participant was seated on the cycle ergometer. Participants commenced cycling as per 
previously described protocols [543]. Core body temperature was recorded at 20 sec intervals via 
a handheld monitoring device (CorTemp Data Recorder; HQ Inc., Palmetto, Florida, USA) for 
the duration of both threshold tests, with values averaged for the minute surrounding each of the 
time points in the threshold test. Immediately following exercise, a final saliva sample for cortisol 
and s-IgA was collected (approximately 0800 hours). Within one week, and while in the same 
menstrual or OC phase, participants returned to the exercise laboratory to undertake a second 
threshold trial under the opposing environmental condition. The second threshold trial was 
conducted identical to the first. 
 
6. 2.3  Statistical Analyses: Distribution was assessed using the Shapiro-Wilk test for normality 
and boxplots with a fully-factorial ANOVA with repeated measures used to determine 
interactions and main effects of the three independent variables: i) Group (womenNM and 
womenOC); ii) Condition (TN and HH trial); and iii) Time (Rest, Stage 1-3). Where F-values 
were significant, least squares difference (LSD) pairwise comparisons were used. Tests of 
normality for  salivary variables revealed the data was violated therefore a Mann-Whitney U and 
Friedman non-parametric equivalent test was used to determine the difference between groups 
(womenNM, womenOC) and time (baseline, pre-exercise and post-exercise) for [s-IgA] and 
[sCort], secretion rate and saliva flow rate. Data are expressed as means ±SD with alpha for 
statistical significance set at p ≤ 0.05. Statistical analysis was conducted using the Statistical 
Package for the Social Sciences (SPSS version 22, Chicago, IL, USA). 
 
6. 3  Results 
6. 3. 1  Salivary Cortisol and IgA 
No significant (p > 0.05) difference was identified for [sCort] (Figure 6) or [s-IgA] (Figure 7) or 
secretion rate (Table 12) between womenNM and womenOC at any time point under TN or HH 
conditions. 
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Table 10. Salivary Immunoglobulin A concentration ([s-IgA]) ±SD and effect size in response 
to exercising in 22C and 50% r.h. (OC22 and NM22) and 35C and 50% r.h. (OC35 and 
NM35).   
 NM22 OC22 
Effect size 
(Cohen’s d) 
NM35 OC35 
Effect size 
(Cohen’s d) 
Pre-
Acclimation 
[s-IgA] 
(µg/ml) 
507.87 
± 427.3 
644.34 
± 330.8 
0.35 
687.2 ± 
598.1 
738.77 
± 478.7 
0.09 
30 min 
Acclimation 
[s-IgA] 
(µg/ml) 
257.8 ± 
203.4 
158.6 ± 
62.5  
0.65 
215.71 
± 187.7 
166.27 
± 87.5 
0.33 
Post 
Exercise 
Test [s-IgA] 
(µg/ml) 
390.56 
± 371.0 
386.38 
±103.6 
0.01 
510.5 
±373.8 
399.5 ± 
167.6 
0.38 
 
 
Table 11. Salivary cortisol concentration ([sCort]) ±SD and effect size in response to exercising 
in 22C and 50% r.h. (OC22 and NM22) and 35C and 50% r.h. (OC35 and NM35).   
 NM22 OC22 Effect size 
(Cohen’s d) 
NM35 OC35 
 
Effect size 
(Cohen’s d) 
Pre-
Acclimation 
[sCort] 
(nmol/L) 
13.62 ± 
7.8 
16.66 ± 
9.1 
-0.35 
17.26 ± 
5.8 
20.59 ± 
8.7 
-0.45 
30 min 
Acclimation 
[sCort] 
(nmol/L) 
11.89 
±12.1 
17.49 ± 
14.6 
-0.41 
17.33 ± 
9.7 
17.88 ± 
3.7 
-0.07 
Post 
Exercise 
Test [sCort] 
(nmol/L) 
6.57 ± 
4.1 
15.4 
±10.2  
-1.13 
12.76 ± 
11.2  
15.05 ± 
5.7 
-0.25 
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Figure 6. Salivary Cortisol concentration ([sCort]) (mean ±SD) in womenOC (n = 8) 
and womenNM (n = 8) participants in response to exercising in 22C and 50% r.h. 
(OC22 and NM22) and 35C and 50% r.h. (OC35 and NM35).  
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Figure 7. Salivary Immunoglobulin A concentration ([s-IgA]) (mean ±SD) in womenOC (n = 
8) and womenNM (n = 8) participants in response to exercising in 22C and 50% r.h. (OC22 
and NM22) and 35C and 50% r.h. (OC35 and NM35).  
 
Table 12. Mean (±SD) secretion and flow rates for salivary IgA (s-IgA) and salivary cortisol 
(sCort) for female participants classified as normally menstruating (NM; n = 8) and taking oral 
contraception (OC; n = 8). 
 NM35 OC35 
 Baseline Pre-
Exercise 
Post-
Exercise 
Baseline Pre-
Exercise 
Post-
Exercise 
s-IgA Secretion Rate  
(µg/min) 
44.13 ±30.5 
24.57 
±17.5 
47.44 
±37.3 
136.03 
±163.75 
28.58 
±19.6 
84.61 
±127.9 
sCort Secretion 
Rate  
(nmol/min) 
1.27 ±0.7 2.33 ±2.3 
2.84 
±5.41 
3.26 ±3.0 3.12 ±1.85 2.58 ±2.8 
Flow Rate  
(ml/min) 
0.08 ±0.1 0.14 ±0.1 
0.14 
±0.1 
0.16 ±0.1 0.17 ±0.1 0.16 ±0.1 
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Table 10. Mean salivary IgA (s-IgA) and salivary cortisol (sCort) secretion rates for female 
participants who were classified as normally menstruating (NM; n = 8) and taking oral 
contraception (OC; n = 8). 
 NM22 OC22 
 s-IgA 
(µg/min) 
sCort 
(nmol/min) 
s-IgA 
(µg/min) 
sCort 
(nmol/min) 
Baseline 52.26  ±49.25 1.61  ±1.45 79.13  ±78.52 2.21  ±2.37 
Pre-Exercise 50.31  ±43.52 1.55  ±1.68 39.99  ±32.21 3.16  ±2.93 
Post Exercise 32.03  ±24.25 0.69  ±0.59 85.48  ±69.58 2.02  ±1.76 
Results are shown as mean (±SD). 
 
 
6. 3. 2  Core Body Temperature  
Resting TC was higher in womenOC compared to womenNM for both TN (37.35 ±0.10 vs. 37.04 
±0.21 C; p < 0.01; d = 1.88) and HH (37.46 ±0.23 vs. 37.02 ±0.25C; p < 0.01; d = 1.83; Figure 
8) trial conditions. TC remained significantly higher in womenOC compared to womenNM for 
22.5 min in HH (37.92 ±0.22 vs. 37.65 ±0.31; p = 0.05; d = 1.00) and TN conditions (37.87 ±0.19 
vs. 37.63 ±0.25; p = 0.04; d = 1.08) (Figure 8). TC increased at every time point for womenNM 
in both environmental conditions (p < 0.05; Figure 8) and was significantly higher at 45 min 
(38.14 ±0.47 vs. 37.92 ±0.26C; p = 0.04; d = 0.57) and 52.5 min (38.41 ±0.35 vs. 38.03 ±0.42°C; 
p = 0.02; d =0.98) in the HH trial compared to the TN trial (Figure 16). There was no difference 
in TC between the TN and HH trials (p > 0.05) for womenOC.  
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Figure 8. Core body temperature (mean ±SD) in womenOC (n = 8) and womenNM (n = 8) 
participants in response to exercising in 22C and 50% r.h. (OC22 and NM22) and 35C and 
50% r.h. (OC35 and NM35).  * Significant (p < 0.05) difference between womenNM and 
womenOC in both 22C and 35C. 
 
6. 4  Discussion 
The present study found no significant differences in [s-IgA] and [sCort] or secretion rates 
between womenOC and womenNM, in response to exercise in a TN or HH environment. Our 
findings are in agreement with previous research [544] finding exercising at   ΟV 2 max for 30 min 
in HH conditions (34C: r.h. 53%) was insufficient to cause a significant change in [s-IgA] 
although contradicted others reporting increases in cortisol in response to repeated bouts of 
exercise [545] or prolonged cycling [546] and decreases in s-IgA secretion rate following 2 hr of 
cycling at 62%   ΟV 2 max [547], suggesting the intensity and duration of exercise have a greater 
influence on the [s-IgA] and [sCort] response to acute cycling, regardless of environmental 
temperature or oral contraceptive status. It is possible that the duration of exercise in the present 
study was insufficient to evoke a substantial increase in [sCort], despite the HH conditions. 
Considering saliva flow rate remained relatively unchanged from pre-exercise to post-exercise in 
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the present study (Table 12), it is possible that the exercise protocol did not cause substantial 
activation of the SNS; subsequently causing vasoconstriction of the blood vessels supplying the 
saliva glands. Despite the additional stress from the high ambient temperature. Taken together, 
our findings suggest the duration and intensity of exercise in the present study was insufficient to 
evoke a substantial changes in [s-IgA] and [sCort], as well as respective secretion and saliva flow 
rates. 
 
Considering the association between elevated cortisol concentrations, decreases in the 
transepithelial transport of s-IgA and inhibition of B-lymphocyte synthesis [24, 254, 255, 335, 
336], it was hypothesised that a decrease in [s-IgA] would occur in the present study due to high-
cortisol secretions induced from exercise in the HH conditions, as demonstrated previously [547]. 
Conversely, our findings reject our hypothesis, demonstrating exercise in HH conditions did not 
evoke a substantial increase in [sCort] leading to a decrease in [s-IgA]. However, considering our 
final measure of [s-IgA] occurred immediately following exercise, it is possible that the true 
effects of cortisol on [s-IgA] were missed. Cortisol has been reported to effect B-lymphocyte 
synthesis for up to several days following exercise [255, 320, 346] and it is possible that any effect 
of cortisol on [s-IgA] in the present study had not occurred at final sample collection. However, 
considering no major changes in [sCort] were observed in the present study, it remains unlikely 
that changes in [s-IgA] would have occurred in the days following exercise.  
 
The results of experimental study four suggest that exogenous and endogenous estrogen have 
similar effects on the HPA axis and subsequent cortisol response to exercise, as neither group of 
women demonstrated a significantly different cortisol response to the cycling exercise protocol, 
regardless of the environmental temperature. Even though exogenous and endogenous secretions 
of estrogen do not appear to affect the HPA axis differently, it remains possible that estrogen was 
a mechanism contributing to the absence of an exercise-induced stress response in experimental 
study four. It is conceivable that estrogen secretion caused a dampened HPA axis response to the 
exercise stimulus, ultimately not evoking a high cortisol response. Estrogen reportedly increases 
the production of CBG, which may explain why serum cortisol levels have been reported to 
increase throughout the follicular phase of the menstrual cycle or in response to taking 
monophasic OC, when estrogen secretion is high and consistent [21, 220]. Estrogen-induced 
increases in CBG lead to reduced metabolic clearance of serum cortisol while also acting as a 
buffer, delaying activation of the HPA axis [222]. Therefore, it is possible that estrogen 
contributed to an inhibition of the neural messaging to the hypothalamus, which prevented the 
SNS from recognising and responding to the exercise stressor. If the SNS did not receive signals 
 95 
 
or these signals were delayed from the hypothalamus, it may be possible that the HPA axis was 
not sufficiently activated to evoke a substantial stress response, which may explain why [sCort] 
experienced a non-significant (p > 0.05) decrease from pre-to post-exercise in experimental study 
four. However, as no male subjects were investigated in experimental study four to act as controls, 
the influence of estradiol of HPA axis reactivity and the subsequent exercise-induced stress 
response remains anecdotal. 
 
A major finding of the present study was womenOC exhibited higher resting TC than womenNM 
under both environmental conditions, akin to previous investigations showing higher TC in 
women taking OC compared with normally menstruating women [548] or during periods of pill 
withdrawal [2, 549]. In addition womenOC also maintained higher TC than womenNM under both 
environmental conditions in response to exercise until 22.5 min. The mechanism behind the 
elevation in TC in womenOC is likely progesterone, which reportedly causes elevations in basal 
body temperature of by 0.3C - 0.5C [74, 76, 380, 382, 550] by inhibiting the heat-loss 
mechanism, leading to increases in TC by reducing warm sensitive neuron activity [47, 386, 388], 
which may have implications for thermoregulation during exercise. 
The present study is in agreement with previous studies which have reported a blunted salivary 
cortisol response to exercise in response to estrogen and progesterone, which is likely to have 
contributed to the apparent (non-significant) up-regulation of salivary IgA following acute 
exercise in the present study. In addition, the present study demonstrated womenOC exhibit 
higher TC at rest and in response to exercise in TN environments compared with women who are 
normally menstruating. 
6. 5  Practical Applications 
The results of the present study demonstrate acute exercise (< 60 min duration) in a HH 
environment does not appear to evoke a substantial change in [s-IgA] and [sCort] or secretion 
rates in recreationally active women. In addition, the presence of exogenous estrogen and 
progesterone does not appear to affect the s-IgA or sCort absolute concentrations in response to 
exercise in HH conditions. However, women taking OC appear to have an elevated TC at rest 
compared with women who are normally menstruating and it is possible that women taking OC 
may need to redirect more blood flow to the skin’s surface to dissipate accumulated heat, 
potentially compromising Q̇. 
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CHAPTER SEVEN 
 
Overall Discussion and Future Research 
 
Experimental Study One 
The Validity and Reliability for a Salivary Cortisol Point of Care Test 
 
It is important to continually bridge the gap between controlled laboratory testing and open-field 
testing to allow applied sport science to evolve. Salivary analyses are gaining significant interest 
from the modern day sport scientist due to low costs, ease of implementation, usages and relative 
non-invasiveness for application within a functioning sporting organisation. Saliva is a hypotonic 
fluid, made up of water, electrolytes and proteins [420], with an abundance of enzymes, 
immunoglobulin’s, hormones and other proteins in human saliva, many of which have been 
explored in depth using proteomic methods and identified as markers for detection of certain 
diseases, including oral cancers, as well as autoimmune and infectious disease [436, 551-554]. 
Saliva analysis has a number of applications for monitoring health and disease states as it is known 
to reflect serum levels of therapeutic, hormonal, immunologic, and toxicological molecules [436], 
as the serum components of saliva are derived from the vasculature which originates from the 
ceratoid arteries [446] and contain the same molecules found in the systemic circulation[420]. 
Oral fluid analysis may be more advantageous over serum samples due to better performance and 
efficiency than plasma analysis [424]. In addition, very low levels of a specific biomarker can be 
detected in saliva samples [436], with a total sample volume of between 0.5ml-2.0ml sufficient 
for accurate saliva analysis [441]. 
 
The gold standard laboratory tests for saliva analysis are the ELISA and EIA methods, both of 
which are a highly accurate, valid and reliable methods of determining several analytes [555] 
which may affect health and performance, but can be expensive and require controlled laboratory 
conditions. A challenge for sport scientists is to find substitute field tests, which measure the same 
physiological or performance parameters as laboratory testing, without compromising the 
integrity of the results. The two most important factors which must be considered when using a 
field test as a laboratory substitute, is the validity and reliability of the new testing method. For a 
new test or method to be considered valid, it should accurately correspond with an equivalent 
criterion or ‘gold standard’ method [556]. Demonstrating validity in new testing measures allows 
the sport scientist to be sure the new method is actually testing the specific physiology or 
performance parameter for which it is intended. In addition, the new test must also provide 
consistent and precise results, to allow for reproducibility [556]; this is known as reliability. Test 
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reliability is crucial for the sport scientist as all results should be reproducible under the same 
testing conditions, which allows the interpretation of any changes in results to be attributed to 
variables that have been manipulated i.e. training status or intensity of exercise. Experimental 
study one found the IPRO LFD method to be a valid point of care test for salivary cortisol when 
compared to Salimetrics ELISA analysis. Additionally, the OFC and LFD showed good inter-
tester and device reliability. 
 
A number of factors can affect saliva composition, including the source of saliva (whole saliva or 
individual glands), flow rate, nature of the stimulus, diurnal and hormonal variations and the 
degree of hydration of the subject [430, 466, 467]. There are several methods of collecting saliva 
in applied sport science research, namely cotton swabs [293, 557], passive drool [500, 558] and 
suction tubes [559], however it is important to consider the effect of various saliva collection 
methods on obtained results. The present study demonstrated the IPRO oral fluid collector method 
showed less variability with the Salimetrics cotton swab method (p = 0.881; r = 0.33) compared 
with the Salimetrics passive drool technique (p = 0.145; r = 0.32) suggesting the location of 
sample collection may play a role in the concentration of analytes obtained throughout testing. 
The three major salivary glands which produce saliva into the oral cavity are parotid, 
submandibular and sublingual [420] with each gland secreting different mixtures of serous-and 
mucinous-derived fluid, and therefore the levels of proteins can change depending on the location 
of saliva collection in the oral cavity [420], which may have contributed to the findings in 
experimental study one. The use of cotton swabs for sample collection may encourage consistency 
in the saliva collection process as swab placement can be standardised i.e. on top of the tongue. 
It is possible that the relative contribution of saliva (and subsequently, secretion of analytes) from 
each saliva gland could vary when passive drool techniques are utilised, which may explain why 
IPRO OFC was more closely correlated with SOS compared with PD in the present thesis.  
 
For most studies investigating the human mucosal immune system, saliva has been the mucosal 
secretion of choice, due to the non-invasive ease of collection [451]. In addition saliva analysis 
does not require experienced personnel to test and can be readily used for diagnostic and health 
surveillance purposes [436] in applied sport science research, which is why saliva has been 
utilised throughout the present thesis. Experimental study one supports an innovative point of care 
test for the accurate analysis of salivary cortisol in applied sport science research and monitoring, 
which substantially decreases sample analysis time and preparation and will help to ‘bridge the 
gap’ between laboratory and field testing, by allowing salivary cortisol to be easily monitored 
anywhere, with the accuracy of gold-standard laboratory testing. 
 98 
 
 
Experimental Study Two 
The Response of Surf Life Saving Competition on Salivary Immunoglobulin A 
 
The interaction between exercise and the immune system remains equivocal in applied sport 
science research, with conflicting reports of increases and decreases in the concentration of 
salivary immunoglobulin A following intense or prolonged exercise. Most authors agree that the 
intensity of exercise will determine the subsequent s-IgA response, with moderate intensity 
exercise eliciting a positive response and increasing [s-IgA], while intense or strenuous exercise 
reportedly decreases [s-IgA] in athletes. Upper respiratory tract infections have been identified as 
the most predominant infection experienced in highly trained athletes [560, 561], likely 
attributable to the substantial amount of time being spent in close quarters with teammates in the 
change rooms, at training and throughout travel [562]. This high prevalence of URTI in athletes 
may be exacerbated in water-based athletes, as they are consistently exposed to both airborne and 
waterborne pathogens which may cause infection. The relationship between athletic training and 
the subsequent change in [s-IgA] has been explored in several water-based sporting disciplines 
such as swimming and kayaking [306, 307, 315, 563, 564], however less is known about the [s-
IgA] response specifically to athletic competition. Experimental study two is the first 
investigation into the s-IgA response surrounding a single multidisciplinary endurance SLS event. 
The results of this study demonstrated females and males respond similarly in the 24 hr following 
competition, however males experienced a significant (p < 0.05; d = 1.66) increase in [s-IgA] 61 
hr post-event, suggesting that the immediate recovery protocols following SLS elite competition 
can be similar for males and females without increasing the risk of URTI. However ‘return to 
training’ protocols may need to be managed specifically in relation to genders. Although the 
findings did not reach statistical significance, the [s-IgA] in male athletes plateaued from 24 – 48 
hr post-event and prior to the significant increase observed at 61 hr post-event. Whereas the 
female SLS athletes maintained a similar pattern of [s-IgA] from two days pre- to 61 hr post-
event, with no significant (p > 0.05; d = 1.66) differences between any time points. These findings 
suggest that female SLS athletes experience less variation in s-IgA than male SLS athletes. 
However considering all saliva samples were collected throughout a taper and recovery period, it 
is possible that these results do not provide a true reflection of the genuine differences in [s-IgA] 
between male and female SLS athletes. Rather [s-IgA] may have remained relatively stable until 
normal training sessions were resumed at 61 hr post-event, when we observed the spike in males 
only. 
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Considering SLS athletes train for several years to achieve the physical, technical and 
psychological characteristics which are required to successfully compete at the elite level, it is 
possible the athletes may have been experiencing changes to normal mucosal immune function 
in the weeks leading up to testing, which may explain the discrepancies between the findings of 
experimental study two and previous research [306, 307, 313]. Several studies of training periods 
have reported decreases in [s-IgA], suggesting there may be a cumulative effect of exercise on 
mucosal immunity. It is possible that high intensity training over a prolonged period could cause 
a suppression of s-IgA, due to inadequate recovery between exercise sessions or insufficient 
dietary replenishment. In addition, a positive association between the intensity of the exercise and 
the degree of immune suppression has been identified [565], potentially attributable to the HPA 
axis which is stimulated in response to various stressors, including intense exercise. The SLS 
event investigated in experimental study two lasted up to 90 min in duration, with final placing’s 
crucial in determining ‘point’ allocation for subsequent races and the overall SLS champion for 
that particular season. Athletes navigated their way through unpredictable surf conditions in an 
attempt to be crowned the winner of the event, likely evoking a substantial response from the 
HPA axis. When the HPA axis is activated in response to intense exercise, the SNS is also 
stimulated [463] which can lead to an increased transportation of s-IgA into the oral cavity [506] 
particularly when the metabolic demands of exercise require an increased Q̇ [566]. Interestingly, 
SNS activation is reportedly less pronounced in trained individuals [567, 568]. Considering 
increased SNS activity is associated with an increased metabolism of the pIgR [569, 570], leading 
to an increased transportation of s-IgA into the oral cavity [463]. It is possible that trained 
individuals do not experience the same exercise-induced sympathetic nervous system activation 
as untrained individuals. Subsequently the mobilisation of the pIgR is not enhanced in the same 
manner as less trained individuals. Which may in-part explain why elite athletes have been shown 
to exhibit lower [s-IgA] than recreationally active individuals and perhaps why the increase in [s-
IgA] observed immediately post-event compared with pre-event in the present study did not reach 
statistical significance. The autonomic nervous system is predominantly responsible for the 
secretion and composition of saliva [256, 470]. Parasympathetic stimulation of saliva generally 
results in a high flow rate with low levels of organic and inorganic compounds [424], while 
sympathetic stimulation of saliva generally has a lower flow rate, with higher levels of proteins 
[454]. It is important to note that a circadian rhythm for salivary flow rate has been previously 
identified, with the highest flow being at 0400 hours and the lowest at 2000 hours [571, 572]. 
Considering the timing of sample collection leading up to the event occurred at early morning 
training sessions (approximately 0500 hours) and the event-day samples occurred later in the day, 
it is possible circadian rhythms may have contributed to the secretion of s-IgA. In addition, it is 
 100 
 
possible that the non-significant (p > 0.05; d = 1.66) increase in [s-IgA] in both males and females 
following the event is attributable to saliva stimulation from salt water as the competition was 
conducted in the ocean. 
 
An important mechanism of maintaining normal immune health is adequate recovery following 
stressful exertion such as SLS competition. Considering the well-established gender differences 
in human physiology, it is plausible that the immune system also responds and recovers differently 
to exercise in male and females. Although not significant (p > 0.05; d = 1.66), [s-IgA] from 24 – 
61 hr post-competition demonstrated different patterns between male and female SLS athletes, 
with the lack of significance potentially a reflection of sample size. A potential mechanism 
explaining why there does not appear to be a substantial difference in the pattern of [s-IgA] in the 
24-61 hr period following SLS competition may also be attributable to the menstrual status of the 
female SLS athletes. Considering the physiological and psychological demands of open-ocean 
training and competition, it is possible that female SLS athletes may have experienced menstrual 
dysfunction from chronically elevated CRH leading to a suppression of GnRH, ultimately 
preventing endogenous estrogen secretion; a condition known as secondary amenorrhea. If 
several of the female SLS athletes were experiencing secondary amenorrhea at the time of testing, 
it is possible that any estrogen-induced enhancement of [s-IgA] would not have been evident, 
which may in-part explain why the male and female SLS athletes in experimental study two did 
not exhibit significantly different [s-IgA] from 24-61 hr post competition (Figure 4). Similarly, 
no differences in [s-IgA] between males and females were reported in response to cycling, 
swimming, marathon and ultramarathon events [284, 305, 573-576], suggesting highly trained 
female athletes may not exhibit the same fundamental gender-differences in [s-IgA] as less trained 
women, who have been shown to secrete less s-IgA than males at rest [284, 577]. Even though 
long-term, intense training may reduce the endogenous estrogen-enhancing effect on [s-IgA], it 
is possible that women may elect to use OC to simulate a normal menstrual cycle, ultimately 
increasing their estrogen exposure and potentially regaining enhance mucosal immune function, 
however information on menstrual status and OC history was not collected at the time of testing, 
so this remains ancedotal until further research is conducted into the effects of OC of the mucosal 
immune system. 
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Experimental Study Three 
Prevalence and the associated Benefits and Barriers for Oral Contraceptive use in 
Australian women grouped or physical activity level. 
 
Oral contraceptives are widely used in the general population [578, 579] with reports of more 
than 60 million women worldwide taking some form of OC [162]. Additionally, OC use is 
becoming more common in the athletic population [112, 519], potentially to re-create or control 
the menstrual cycle. Considering the rising prevalence of active women taking OC [112, 519], 
and the potential effect exogenous estrogen and progesterone may have on the mucosal immune 
system and exercise tolerance, it is interesting to explore whether the decision to take OC is related 
to physical activity levels, or if there are other factors which determine motives for OC use. 
Experimental study three suggested OC prevalence progessively increases with weekly physical 
activity levels, however this finding did not reach statistical significance (p > 0.05) but does 
suggest that Australian women may be unaware of the influence taking OC may have on exercise 
tolerance and performance. The most common reasons for taking OC were similar for all women, 
regardless of physical activity levels with birth control and cycle control the predominate reasons 
for taking OC. Which is in line with previous research reporting [160, 580, 581] cycle control as 
the most commonly identified non-contraceptive benefit of taking OC. Interestingly, the 
perceived barriers for OC use appeared to differ between women, with UT women reporting the 
commitment to take the pill and using other forms of contraception as the predominant reasons 
they do not use OC. Recreationally active women commonly reported side effects of the pill and 
a desire to conceive as barriers, while TR women reported the presence of synthetic hormones 
and the use of other contraceptive methods prevented them from taking OC. Even though, the 
differences in barriers for OC use cannot be unequivocally attributed to physical activity levels, 
it remains possible that exercise and lifestyle has contributed, at least in-part, to the findings from 
experimental study three. Untrained women reported the commitment to take OC every day as 
the main barrier of OC use, and while this was also acknowledged as a barrier for use in REC and 
TR women, it was not the most prevalent response for those women, which may reflect a greater 
discipline in REC and TR women from adhering to consistent physical activity and potentially 
dietary regimes. Trained women appeared more concerned with ingesting synthetic hormones, 
which may also reflect a healthy lifestyle, which TR women are likely to exhibit. 
Even though side effects were one the most prevalent reasons for not taking OC in REC women, 
they were also commonly reported by TR and UT women as barriers for OC use. The results of 
experimental study three identified weight gain as the most common potential side effect of OC 
use in UT and REC women, and to a lesser extent, in TR women as well; however it is likely that 
the lifestyle of TR women may attenuate some of the weight gain associated with OC use, which 
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may be why weight gain appears to be less concerning to TR women. It is possible that UT and 
REC women, do not adhere to the same strict dietary regimes as TR women and due to their 
physical activity levels, weight gain may not solely be attributable to taking OC. Untrained and 
TR women both commonly reported mood disturbance as an OC-associated side effect which 
deterred them from taking the pill. It is possible that mood disturbance may affect the woman’s 
motivation and cognitive ability throughout training, which may be irritating and interfere with 
exercise, posing a substantial deterrent of taking OC in TR women. Conversely, a lack of physical 
activity, which is known to adversely affect mood [582-584], combined with the OC-associated 
changes in mood, may have contributed to the finding in UT women. Other commonly identified 
side effects of OC in experimental study three which pose a barrier to OC use included increases 
in appetite, reduced libido, increased acne vulgaris and nausea, however these symptoms don’t 
appear to be directly affected by physical activity levels and may be attributed to the OC pill or 
other external factors. 
 
In addition to the potential side effects associated with taking OC, several menstrual symptoms 
were identified in all women which may contribute to OC use. Painful periods were the 
predominant menstrual symptom reported regardless of physical activity levels. Untrained and 
REC women also reported heavy periods as a commonly experienced menstrual symptom, which 
contributed to their decision to take OC, while TR women appeared more concerned with changes 
to mood. Trained women may be less concerned about heavy periods as a decrease in menstrual 
blood flow is often associated with prolonged exercise, particularly high intensity exercise. It is 
possible that TR women were not experiencing heavy periods to the same extent as UT or REC 
women due to their training status, and therefore they did not consider reducing heavy periods a 
major benefit which contributed to taking OC, rather changes to mood was a priority as this may 
affect their desire to participate in exercise. 
 
Even though the prevalence of OC use in women is rising [162, 578, 579], women have been 
shown [161-163] to be poorly informed about the risks and benefits of OC, particularly in regards 
to health [585] and therefore may also be unaware of the effect OC can have on exercise 
performance, which may have in part contributed to the findings of experimental study three. 
Ethnic background appears to be a factor contributing towards knowledge of risks and benefits of 
taking OC, with Finnish women reportedly [586] less aware of the increased risk of thrombosis 
during OC use as well as the associated contraindication of smoking while taking OC in women 
above the age of 35 years. African-American women were found to be uninformed about the side 
effects associated with taking OC, with only 42% of women able to identify a single medical risk 
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associated with OC use [587]. In addition to ethnicity, age and education have also been suggested 
[588, 589] as factors contributing to a woman’s knowledge regarding the risks and benefits of OC 
use. The health risks of combined OC use include an increased likelihood of venous 
thromboembolism [111, 156] and ischaemic stroke [111, 152], as well as an elevated risk of 
developing  breast [117, 138, 153] and cervical cancer [117, 138, 154]. In addition, COC may 
also cause fluctuations in body weight and fluid retention, as well as breast tenderness, nausea, 
weight gain, headaches, skin problems, abdominal bleeding and ovarian cysts [111, 134, 590-
592]. The women sampled in experimental study three reported medical concerns, including deep 
vein thrombosis, cardiovascular disease, and hypertension to be barriers towards taking OC. 
Interestingly, medical concerns were more commonly identified barriers in REC (59%), 
compared with UT (38%) and TR (31%) women, which may reflect the general health status of 
the REC women compared with other women in experimental study three. However, if this is the 
case, it is thought-provoking that UT women did not express the same concerns, due to their 
increased risk of health problems associated with a lack of physical activity. 
 
There are several health risks associated with taking OC, and there are also numerous advantages 
namely, attenuating dysmenorrhea, acne vulgaris, iron-deficiency anaemia, pelvic inflammatory 
disease, as well as some cancers such as endometrial, colorectal and ovarian [111, 117, 138, 593, 
594]. A reduction in menstrual symptoms was the third most commonly reported reason for taking 
OC across all groups of women in experimental study three. Considering common menstrual 
symptoms such as dysmenorrhea reportedly occur in up to 80% of the general population [595], 
it is not surprising that women in our study identified a reduction in menstrual symptoms as a 
common benefit of taking OC. Additionally, a reduction in acne vulgaris was also commonly 
reported in REC (52%) and TR (54%) women as a benefit contributing to OC use, while only 37% 
of UT women reported taking OC to lessen the symptoms. It is possible that the age of participants 
in experimental study three contributed to this finding, as the UT women were slightly older than 
the REC and TR women, and may not suffer from symptoms associated with acne vulgaris to the 
same extent as younger women. Oral contraceptives have also been associated with decreasing 
uterine fibroids, the symptoms associated with premenstrual syndrome and endometriosis, as well 
as rheumatoid arthritis and may lead to increases in BMD [111, 117, 138]. Interestingly, UT (50%) 
women reported taking OC to reduce the risk of anaemia and BMD loss more than REC (35%) 
and TR women (31%). It is possible that REC and TR women may be less concerned with BMD 
as they are more likely to engage in frequent weight-bearing activities, and may be more inclined 
to follow stricter dietary regimes which ensure adequate iron intake to maintain bone health.  
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The results of experimental study three were unable to identify a significant association between 
physical activity levels and OC use in Australian women; however, it is interesting to consider 
that the amount of weekly exercise undertaken may unintentionally impact on the perceived needs 
of the woman. The results of experimental study three suggest TR women are less concerned with 
the BMD-enhancing effects of OC use than UT women, which may be attributed to higher 
physical activity levels in TR women. Similarly, UT and REC women reported the commitment 
to take the pill everyday as major barriers to OC use more often than TR women, which may 
reflect a greater discipline in TR women, as a result of training commitments. A further example 
of the way weekly exercise levels may unknowingly contribute to OC use is commonly reported 
side effects of OC, in particular weight gain, which was more concerning to UT women compared 
with TR. This may be a reflection of lifestyle rather than OC-induced side effects, particularly 
considering 3G OC have been shown [596, 597] to have caused far fewer changes in weight 
compared with earlier generation OC. Taken together these examples demonstrate how exercise 
may impact on the perceived needs of women and may influence what women believe to be 
benefits and barriers towards OC use, even though the major reasons why women take or do not 
take OC appear to be relatively similar regardless of physical activity levels.  
 
 
Experimental Study Four 
Salivary cortisol and IgA response to incremental cycling in a thermally-stressful 
environment; the role of oral contraceptives and core body temperature. 
 
 
Considering the findings of experimental study three and previous research [159, 160, 514] which 
suggest active and athletic women are taking OC just as frequently as women in the general 
population, it is important to investigate the way exogenous estrogen and progesterone secretion 
affects exercise tolerance, including the immune and stress response. Exercise is known to cause 
changes in normal mucosal immune function as well as stress levels depending on the intensity 
and duration of activity undertaken. Considering no significant difference in the [s-IgA] response 
to acute SLS competition was observed between males and females in experimental study two, 
which may have been attributed to their ‘elite’ training status or prolonged exercise-induced 
menstrual dysfunction, it was evident that recreationally active women may provide a more 
transparent insight into the acute mucosal immune and stress response to exercise, and were 
therefore utilised in the final two studies of the present thesis. Additionally, recreationally active 
women represent a larger population than elite athletes, which allows our findings to have greater 
practicality and applicability.  
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Experimental study four found no significant difference in [s-IgA] or [sCort] between womenNM 
and womenOC in response to acute cycling exercise, suggesting the stress and mucosal immune 
responses following short duration (< 60 min) exercise is not affected by the presence of 
exogenous estrogen and progesterone regardless of the environmental conditions. It is possible 
that 3G OC which contain substantially less amounts of estrogen and progesterone compared with 
earlier generation pills [115], may have contributed to this finding. The relative concentration of 
exogenous estrogen and progesterone in third generation OC has decreased four-and ten-fold from 
second and first generation pills respectively [37], and it is therefore possible that this reduction 
in the concentration of exogenous hormones has reduced some of the adverse effects of OC on 
health.  
 
The duration of exercise reportedly determines the subsequent cortisol response, with long 
duration (> 60 min) exercise shown  to cause increases in serum cortisol, whereas acute exercise 
is associated with minor or no changes [598] in serum cortisol levels. It is possible that the 
duration of exercise in experimental study four (52.5 min) was insufficient to cause a substantial 
rise in cortisol secretion. In addition, the intensity of exercise also appears to contribute to the 
cortisol response, with exercise intensities of < 50%   ΟV 2 max reportedly [599, 600] insufficient 
to elicit a substantial increase in cortisol secretion. It is possible that the three-tier intensity 
protocol utilised throughout the exercise trial in experimental study four was insufficient to cause 
an increase in salivary cortisol secretion. Participants were cycling at 90%, 135% and 180% of 
their individually determined lactate threshold for 30 min, 15 min and 7.5 min respectively.  
Experimental study four identified a (non-significant; p > 0.05) post-exercise increase in [s-IgA] 
regardless of OC use indicating acute exercise can up-regulate mucosal immunity in 
recreationally active women, suggesting short bouts (< 60 min) of exercise at varying intensities 
to have a beneficial effect on the mucosal immune system. Additionally, we found short duration, 
acute exercise was insufficient to cause an elevated stress response, suggesting regular physical 
activity, with adequate rest in between sessions and/or bouts may not have cortisol-induced 
adverse health consequences and is therefore unlikely to cause substantial changes to menstrual 
cycle functioning in healthy women. Importantly, the use of OC did not affect the cortisol or s-
IgA response to exercise or resting levels suggesting modern-day OC use may not elicit adverse 
effects on mucosal immunity and stress as previously associated with earlier generation pills. This 
could have implications for recreationally active women who would like to take OC but choose 
not to, due the potential exercise-induced implications on mucosal immunity and cortisol 
secretion, and the subsequent effect on exercise performance which was identified as a barrier for 
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OC use in 44% of recreationally active women sampled in experimental study three of the present 
thesis. Experimental study four demonstrated no significant difference in the mucosal immune or 
cortisol response to acute exercise in women taking OC compared with normally menstruating 
women, concluding exogenous estrogen and progesterone does not adversely affect the stress and 
mucosal health of the recreationally active woman in response to acute exercise in TN or HH 
environments and should not be considered a barrier towards taking OC in recreationally active 
women. 
 
Even though taking OC does not appear to affect the s-IgA and sCort response to exercise, it does 
appear to affect TC and the perceived demands of acute exercise. The results of experimental study 
four showed womenOC exhibit higher TC at rest and in response to incremental cycling exercise 
up to 22.5 min in both TN and HH conditions. Previous research has demonstrated women taking 
OC exhibit higher TC than women who are normally menstruating. This elevated TC is likely 
attributable to the higher secretion of exogenous progesterone in OC compared with endogenous 
secretions throughout the normal menstrual cycle, which has been reported to inhibit heat-loss 
mechanisms. Additionally, exogenous estrogen has been shown to suppress endogenous estrogen, 
reducing the antagonistic effect of estrogen on lowering TC, particularly if exogenous estrogen 
does counteract the effect of progesterone on TC in the same manner as endogenous estrogen.  
 
Following 22.5 min of exercise in both conditions, no significant difference in TC was observed 
between womenNM and womenOC suggesting even though womenOC experience higher TC in 
the initial stages of exercise, thermoregulatory mechanisms may be initiated earlier, consequently 
attenuating the progesterone-induced increases in TC and allowing womenNM and womenOC to 
approach similar peak TC towards the final stages of the exercise protocol. This finding of similar 
patterns of TC beyond 22.5 min of exercise in experimental study four, may also in-part explain 
why there was no significant difference in [sCort] and [s-IgA] post-exercise between womenNM 
and womenOC. It is possible that any exercise-induced stress from cycling in 35C in 
experimental study four was similar between groups as they experienced comparable TC from 
22.5 min of exercise.  
Limitations of Research 
 
It is important to acknowledge the limitations to research. A noteworthy limitation in 
experimental study one is an apparent overestimation of salivary cortisol concentrations below 4 
mmol and above 8 mmol and an underestimation of salivary cortisol concentrations between 4 
and 8 mmol. This apparent under-and over-estimation of salivary cortisol values, is likely 
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attributable to small sample size in experimental study one. Similarly, the outlier which is evident 
in Figure 2 would suggest the IPRO method may underestimate salivary cortisol concentration. 
However, considering this trend is only evident in one participant it may be simply due to daily 
fluctuations, and future studies with larger sample sizes should be conducted to confirm or refute 
the findings of experimental study one. In addition, daily perceived stress levels may have also 
contributed to variations in salivary cortisol concentrations from trial one to trial two. Considering 
participants did not undertake a perceived stress questionnaire or any other measures of daily 
perceived stress levels, it is possible external factors such as mood changes, work or study, 
emotional stress etc. were dissimilar in participants between the trials, contributing to variations 
in results and potential over-and under-estimations of salivary cortisol concentrations. 
 
The major limitation of experimental study two was the absence of information regarding 
menstrual cycle and oral contraceptive practices of the female surf lifesaving athletes. This 
information would have assisted in enhancing or challenging the argument of an interaction 
between ovarian hormones and salivary immunoglobulin A. In addition, a measure of perceived 
workload i.e. rating of perceived exertion was not included in experimental study two, which may 
have provided valuable insight into the perceived physical stress of training and competition. 
 
While the participants in experimental study three completed a survey in which they were able to 
provide open-ended responses for clarity if necessary, there was no forum utilised in which the 
researchers and the participants undertook interviews or open discussions to gather more in-depth 
reasoning behind each response. Furthermore, a larger sample size would have assisted in a 
greater insight into the perceived benefits and barriers of OC use in Australian women and 
allowed for a more representative study. 
 
Experimental study four collected saliva samples for [sCort] and [s-IgA] prior to-and immediately 
following acute exercise. The intensity of exercise within this acute bout was altered three times, 
however no saliva samples were collected during exercise when exercise intensity increases and 
is considered a limitation of the study. Another limitation to experimental study four, in that the 
final saliva sample for [s-IgA] and [sCort] occurred immediately following the cessation of 
exercise, and considering cortisol has been shown to influence the synthesis of B-lymphocytes 
for up to several days following intense exercise [255, 320, 346], it is possible a delayed effect of 
exercising in a HH environment may have occurred. However, considering [sCort] did not exhibit 
a substantial rise post-exercise in experimental study four as demonstrated following acute 
resistance exercise [243-245]; it is unlikely that a delayed effect of cortisol-induced suppression 
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on [s-IgA] would have occurred in the days following the exercise trial. Rather the results of 
experimental study four indicate that acute exercise (i.e. < 60 min in duration) with a three-tier 
intensity increase does not evoke substantial changes in [s-IgA] or [sCort] even with the addition 
of thermal stress, with the use of OC having no effect.  
 
Finally, the time of testing in experimental study four may have influenced our findings as 
womenOC and womenNM were exposed to varying levels of estrogen and progesterone as 
womenNM were testing throughout the early follicular phase of the menstrual cycle while 
womenOC were tested while throughout the active pill phase of their OC cycles (Table 11). While 
this presents a limitation to experimental study four, it is important to consider the practicality of 
our study in relation to recreationally active women. Women taking OC will be exposed to 
exogenous estrogen and progesterone secretion (active pill phase) for at least 21 days per month, 
with the TC response to exercise most applicable throughout the active pill phase as womenOC 
are likely to be exercising throughout this time more often than throughout menstruation or the 
inactive pill phase. While womenNM are more likely to be affected by pre-menstrual symptoms 
which may affect the desire and ability to exercise as observed in experimental study two; these 
symptoms may begin to present in the late-luteal phase of the menstrual cycle, as endogenous 
progesterone levels are beginning to decrease. It therefore appeared practical to test normally 
menstruating women following pre-menstrual symptoms or once other disturbances associated 
with menstruation had ceased or were unlikely to occur, and subsequently were tested throughout 
the early follicular phase of the menstrual cycle. 
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Future Research 
 
Further research should be conducted to identify the interaction between exogenous estrogen and 
progesterone administration on exercise tolerance in active women in response to prolonged 
exercise. Future studies should consider testing women in all phases of the menstrual cycle, to 
account for variations in the secretion of endogenous estrogen and progesterone and should 
include males as controlled participants. Similarly, women taking OC should be tested in both the 
active and inactive pill phases in monophasic OC users, as well as the periods of varying hormone 
secretion in biphasic and triphasic users. Progesterone-only (mini pill) users should also be 
considered as important participants, particularly when investigating exercise in HH conditions 
and monitoring changes in TC. Finally, research should consider both recreationally active women 
and female athletes, to explore the true effect of OC use on exercise tolerance. 
 
The long term effects of OC administration on [s-IgA] and [sCort] should also be explored. 
Previous research has suggested taking OC could lead to an increase in cortisol secretion, which 
if occurring chronically over several years of OC use, may have serious implications for the health 
of the woman. Additionally, the interaction between exercise-induced increases in [sCort] during 
OC use warrants further investigation as additional increases in [sCort] may ultimately affect 
exercise performance, if participating in exercise of a prolonged duration. Similarly [s-IgA] 
should be monitored over long-term OC use due to the known relationship between endogenous 
estrogen and immune function. If this relationship does not occur with exogenous estrogen, and 
considering exogenous estrogen is known to completely suppress endogenous secretions, it is 
possible that OC use may lead to compromised mucosal immunity, which may be exacerbated in 
active women, if engaging in frequent, high-intensity exercise. 
 
The thermoregulatory response to prolonged exercise in TN and HH conditions must also be 
explored further. The present thesis has demonstrated significant differences TC between women 
taking OC and women who are normally menstruating at rest and in response to acute exercise. 
If OC use increases TC as suggested in the present thesis, it is likely that the initiation of thermo-
regulatory mechanisms is also different, which may have significant implications for exercise 
performance, as effective thermoregulation places substantially more demand on cardiac output, 
potentially compromising exercise performance.  It is therefore imperative that future research is 
conducted into the thermo-regulatory mechanisms and demands of exercising in TN and HH 
environments in active women taking OC compared with normally menstruating women, and if 
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these factors are responsible for the increased perceived exertion throughout exercise in women 
taking OC. 
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CHAPTER EIGHT 
 
General Methodology 
 
8. 1 Individual Profiling (IPRO) Saliva Analysis 
8. 1. 1  Background 
Traditionally, saliva analysis for the purposes of laboratory testing has proven expensive and time 
consuming, however, a portable saliva analysis system has been developed which allows for point 
of care testing in real time. The demand for instant feedback is ever-growing, particularly in 
applied sport science research, where the effective relay of information could be the difference 
between winning and losing. Gleeson et al. [307] pioneered the integration of salivary analysis to 
determine athlete tolerance to the demand of training and competition and established for 
measures of [s-IgA] to be beneficial to athletes and coaches, the results must be rapidly accessible, 
as athletes may continue to train oblivious to the immunosuppression which may be occurring. 
The Individual Profiling point of care saliva analysis kit (IPRO Interactive, Oxfordshire, UK) 
represents and novel salivary analysis method for swift feedback for coaches and athletes, and 
could prove advantageous for training and recovery purposes [488]. Furthermore, the IPRO 
system is relatively inexpensive and could be a suitable method for use within sporting 
organisations [490]. The IPRO system has passed validation tests which concluded the device is 
suitable for the collection and testing of saliva using real time analysis [601]. Furthermore the 
IPRO interactive system has been shown to be in good agreement with the gold-standard ELISA 
method, for determining salivary IgA [490, 602] and cortisol (Chapter Three) levels.  
 
8. 1. 2  Equipment 
The IPRO device consists of an OFC synthetic polymer-based swab attached to a volume 
adequacy indicator stem (Figure 9A). The indicator stem is designed to turn bright blue upon the 
collection of approximately 0.5mL of saliva. Following collection, the OFC swab is placed into 
a dropper bottle containing 3mL of extraction buffer (Figure 9B). The extraction buffer is 
comprised of sodium phosphate, salts, detergents and preservatives, which act to draw the target 
analytes from the OFC swab into the buffer and to prevent the growth of microorganisms. Prior 
to sample analysis, the dropper bottle containing the saliva sample is lightly shaken for two min 
[601]. The sensitivity of the IPRO device is 10 µg/mL and the dynamic range of the device is 
18.75 µg/mL to 1200 µg/mL.  
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Figure 9. (A) IPRO OFC Swab; (B) IPRO dropper bottle containing buffer solution. 
 
8. 1. 3  Procedure 
The buffer bottle is held perpendicular to the LFD (Figure 10C) and two drops of the buffer/saliva 
solution (~100 L) are placed onto the sample pad of the LFD and set aside for ten min. The 
liquid uses a capillary action to travel through the conjugate pad hydrating the dried conjugate 
(Figure 10B) i.e. the liquid flows without the assistance of, or in opposition to external forces 
such as gravity through a narrow space. The liquid continues to flow through the nitrocellulose 
membrane towards the wicking pad at the end of the strip. Once the liquid flows across the 
membrane, the gold-labelled anti-IgA or cortisol will be captured by the respective s-IgA or 
cortisol test line resulting in the appearance of a red line (Figure 10A). Immunoglobulin A and 
cortisol bind to the gold-labelled anti-IgA or cortisol antibody. If IgA or cortisol is present, it will 
result in fewer gold particles being captured by the s-IgA or cortisol test line. Following a ten min 
incubation period, the LFD is placed into the LFD reader, where the relative concentrations of s-
IgA or cortisol are measured within 20 sec. The test line intensity is inversely proportional to the 
s-IgA or cortisol present in the sample. The IPRO LFD reader will convert the line intensity into 
the corresponding IgA or cortisol concentrations. 
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Figure 10. (A) IPRO LFD following ten minute sample incubation period; (B) IPRO LFD 
during ten minute sample incubation period, and; (C) IPRO LFD prior to sample incubation 
period. 
 
8. 2  Saliva Flow Rate 
Monitoring saliva flow rate and secretion rate is important when investigating changes in salivary 
analytes. Decreases in saliva flow rate as a result of dehydration or oral drying may appear to 
increase the concentrations of salivary analytes and several authors have proposed various 
methods of s-IgA expression, in an attempt to reduce misleading results. Commonly used methods 
of expressing s-IgA include absolute concentrations [310, 313], and ratio to total salivary protein 
[320, 437, 497], albumin [603] or osmolality [437, 547]. Considering the nature of the present 
research, in that we are manipulating the ambient temperature throughout experimental study four 
(Chapter Six) it was anticipated that dehydration may have an effect on saliva flow rate, 
potentially causing misleading results [285], as dehydration (loss of ~3% body mass) has been 
shown [604] to adversely affect saliva flow rate.  
 
8. 2. 1  Calculations of Saliva Flow and Secretion Rate 
Walsh et al (1999) [605] suggested the optimal way of expressing s-IgA to account for 
dehydration or drying effects of oral breathing throughout exercise [500, 557] is as a secretion 
rate, as this may be a more accurate representation of the total available IgA on the oral surface. 
Several authors [321, 437, 500, 605] agree the optimal equation used to express s-IgA secretion 
rate is flow rate × concentration (see below). To determine saliva flow rate, the length of time 
(min) is divided by the volume of the saliva sample (g) (see below). To determine sample volume 
the gravimetric method was adopted, whereby one gram of weighed saliva corresponds to one 
mL of saliva produced [256, 606, 607]. To express the measured concentration of the analyte, 
flow rate (as calculated above) is multiplied by the concentration of the sample [286, 607]. 
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Saliva Flow Rate (ml/min) =  
Volume (g) 
Time (min)
 
Secretion Rate (g/min) = Flow Rate (ml/min) × Concentration (μg/ml) 
 
8. 3  Enzyme Linked Immuno-Sorbent Assay 
The ELISA method is a sensitive technique [555] for measuring specific antibodies and antigens 
within a sample [608]. Antibodies are commonly manufactured in laboratory animals and purified 
from a blood or tissue sample for use in ELISA testing [608]. The purified animal antibodies are 
bound to plastic in a 96-well micro-titre plate along with a blocking agent designed to coat the 
plastic in the well which is not coated with the antigen [273, 608]. The primary antibody which 
will bind to the antigen is added to the well, followed by a secondary antibody, which will bind 
to the primary antigen [608]. The secondary antibody is conjugated which results in a coloured 
product after the substrate has been added [273, 608], which is used to identify the presence of 
the antigen in each well using a spectrophotometer (plate reader) [608]. Appearance of colour 
indicates an absence of antibodies (negative test), while the absence of colour indicates antibodies 
are present (positive test) [555], and there are several forms of ELISA procedures namely direct, 
indirect, sandwich, competitive and inhibition [555]. A competitive ELISA was used in the 
present thesis (Chapter Three). In competitive ELISA two specific antibodies are used; one is 
conjugated with enzyme and the other is present in testing sample, with both antibodies competing 
for the same antigen binding site [555].  
 
A cortisol enzyme-immunoassay (EIA) kit (Salimetrics LLC, State College, PA, USA) was used 
in a validity and reliability study (Chapter Three) to compare with the point of care saliva analysis 
system used in the experimental study four (Chapter Six) in the present thesis. The ELISA used 
was a competitive kit, in which the cortisol in the standards and samples wells compete with 
cortisol conjugated to a horseradish peroxidase for the antibody binding sites on a micro-titre 
plate. Following an incubation period (outlined below) any unbound components are washed 
away, leaving the bound cortisol enzyme conjugate to be measured by the reaction of the 
horseradish peroxidase enzyme to the substrate TMB. Following the addition of an acidic solution 
which stops the reaction, the optical density (OD) was read on a standard plate reader (iMark 
Microplate Absorbance Reader, BioRad, California, USA) at 450nm. The amount of cortisol 
enzyme conjugate identified in each well is inversely proportional to the amount of cortisol in 
each sample. 
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8. 3. 1  Sample Storage 
Following Salimetrics sample collection all saliva samples were weighed (Shimadzu Analytical 
Balance, AUW220D, Kyoto, Japan) and stored in -20C within four hr of collection an transferred 
into -80C storage after four hr for long-term storage (as per manufacturer’s instructions, 
Salimetrics LLC, State College, PA, USA) and were only thawed on the day of analysis. All IPRO 
saliva samples were stored at room temperature as per manufacture guidelines (IPRO Interactive, 
Oxfordshire, UK) until analysis. On the day of sample analysis, frozen samples were thawed and 
centrifuged at 1500 × g (3000 rpm) for 15 min (Beckman Coulter Alegra x-15R Centrifuge, Brea, 
CA, USA) to removed mucins and other particulate matter which may interfere with antibody 
binding, subsequently affecting results.  
 
8. 3. 2  Sample Collection 
8. 3. 2. 1  Salimetrics Oral Swab: To standardise saliva collection procedures between 
point of care and ELISA testing methods, the Salimetrics SOS (Figure 11A) was used as it is 
similar to the IPRO OFC. The Salimetrics SOS is a polymer cylindrical swab (10mm × 30mm) 
and participants were instructed to place the Salimetrics SOS on top of their tongue and close 
their mouth, mimicking the IPRO OFC placement and procedure. After two min of saliva 
collection the swab was placed into SOS storage tubes (Figure 11B) and centrifuged at 1500 × g 
(3000 rpm) for 15 min. The saliva samples were weighed and then immediately stored in a freezer 
at -80C until ELISA analysis. 
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Figure 11. (A) Salimetrics Oral Swab (SOS); (B) Salimetrics SOS Storage Tube. 
 
8. 3. 2. 2  Salimetrics Passive Drool: Salimetrics passive drool was collected in 2ml 
cryovials (Figure 12A) (Salimetrics LLC, State College, PA, USA) and then sealed tightly. Saliva 
was passed through the SalivaBio Collection Aid (SCA) (Figure 12B) into the polypropylene vial 
(Figure 13). Participants were encouraged to tilt their head forward throughout sample collection 
to promote saliva pooling in the oral cavity. Once the sample was completed they were 
centrifuged at 1500 × g (3000 rpm) for 15 min (Salimetrics LLC, State College, PA, USA). The 
saliva samples were weighed and then immediately stored in a freezer at -80C until ELISA 
analysis. 
  
 
 
 
 
 
 
 
 
 
Figure 12. (A) Salimetrics Passive Drool (PD) Cryovial; (B) Salimetrics PD Saliva Collection 
Aid (SCA).\ 
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Figure 13. Salimetrics PD SCA inside the Cyrovial Storage Tube. 
 
8. 3. 3  Sample Analysis Procedure 
The reagents and micro-titre plate were brought to room temperature prior to being used. The 1X 
buffer was prepared by diluting wash buffer concentrate (10X) with room temperature deionized 
water (H2O) e.g. 100mL of wash buffer concentrate (10X) and 900 mL of deionized H2O. Twenty 
five microliters (25 µL) of standards, controls and saliva samples were pipetted into the 
appropriate wells on the micro-titre plate, while 25 µL of assay diluent was pipetted into 2 wells 
to serve as the zero and two NSB wells. The enzyme conjugate was diluted by adding 15 µL to 
24 mL of assay diluent. Two hundred microliters (200 µL) of the conjugate solution was added 
to each well using a multichannel pipette. The micro-titre plate was then placed on a plate rotator 
(Thermomixer comfort, Eppendorf AG, Hamburg, Germany) for five min at 500 rpm, followed 
by one hr of incubation at room temperature. 
 
Following incubation at 22ºC, the micro-titre plate was washed using a squirt bottle containing 
1X wash buffer prepared earlier. The plate micro-titre plate was washed four times by gently 
squirting the wash buffer into each well and discarding the liquid over a sink. The plate was 
thoroughly blotted onto paper towels before turning upright. Two hundred microliters (200 µL) 
of TMB substrate solution was added to each well using a multichannel pipette and the micro-
titre plate was mixed on a plate rotator for five min at 500 rpm. The micro-titre plate was then 
incubated in the dark (covered) at room temperature for 25 min. Following incubation 50 µL of 
3M stop solution was added to the micro-titre plate with a multichannel pipette and mixed on a 
plate rotator for three min at 500 rpm. If any green colour remained following mixing, the plate 
was mixed for one additional minute at 500 rpm until the green colouring had turned to yellow. 
The bottom of the micro-titre plate was wiped with a lint-free cloth to dry and read in a plater 
reader (iMark Microplate Absorbance Reader, Bio-Rad, Hercules, CA, USA) at 450nm within 
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ten min of adding the 3M stop solution to the micro-titre plate as per manufactures guidelines 
(Salimetrics LLC, State College, PA, USA). 
 
8. 4  Core Body Temperature Monitoring 
8. 4. 1  Background 
Core body temperature is commonly used to monitor the effectiveness of thermoregulation [609-
611], particularly throughout exercise. Traditionally there are several ways of measuring TC 
namely, pulmonary artery, oesophageal, rectal and temporal measurements [612-614]. Pulmonary 
artery temperature is considered to be the best representation of TC and encompasses mixed 
venous blood from the core and periphery [615, 616]. Despite its accuracy, pulmonary artery 
measurements are invasive, involving the insertion of a catheter into the right pulmonary artery 
[617]. Oesophageal monitoring requires a temperature probe to be placed in the lower third of the 
oesophagus [618], while rectal thermometers must be inserted approximately 10cm past the anal 
sphincter [614]. A simple and non-invasive measure of TC is temporal monitoring, however as 
this involves an infrared scan of the forehead, it can be inaccurate and easily influenced by 
sweating [614, 619]. The ingestible temperature sensor is another method commonly used while 
monitoring TC in the athletic population as it does not interfere with exercise. Ingestible 
temperature sensors were utilised throughout the present thesis due to their ease of use and 
difficulties associated with recruiting young, recreationally active female participants to consent 
to rectal and/or oesophageal probes. 
 
The ingestible sensors are generally the size of a vitamin (Figure 14B), swallowed prior to 
physical activity and transmit temperature measurements to an external system for analysis or 
monitoring [614]. The ingestible sensor is a valid measure of TC throughout walking, running and 
cycling [611, 620-627] when compared with oesophageal and rectal measurements and maintains 
its correlation with the aforementioned TC measures during active and passive heating [628]. 
Additionally, the reliability of the ingestible sensor was reported with an intraclass correlation 
(ICC) of 0.99 (95% CI, 0.93-1.05) [625] following two bouts of 90 min shuttle running separated 
by seven days when compared with rectal measurements. Timing of ingestion of the sensor could 
have implications for the temperature readings throughout exercise. Additionally, food and 
beverage intake may also affect the temperature readings [614, 629] with the ingestion of cold 
water (5C to 8C) reported [629] to affect the sensor readings for up to eight hr following 
ingestion, however this may vary depending on the digestive speed on individuals [614]. A recent 
investigation [630] found it took 18.2 ±2.5 min for the ingestible sensor to leave the stomach 
following food intake, warranting the demand for a standardised time of ingestion in relation to 
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food and beverage intake surrounding acute studies [614]. If the period of sensor ingestion is too 
close to food intake it is likely that the temperature readings will be elevated due to the energy 
used to digest the food contents [614, 631].  
 
8. 4. 2  Procedure 
The CorTemp™ core body temperature monitoring system provides highly accurate temperature 
measurements (±0.1C). The temperature sensor or capsule is a small electronic device (0.88 inch 
length  0.42 inch diameter) encapsulated in an epoxy resin, and coated in silicone (Figure 14B). 
Each individual capsule was calibrated by serial number to the hand held core temperature device 
prior to the beginning of monitoring, to minimise variance in capsules. 
 
The capsule was swallowed approximately eight hr prior to monitoring in experimental study four 
(Chapter Six) of the present thesis to ensure the sensor has reached the intestinal tract prior to 
monitoring, to avoid inaccurate readings due to food and beverage intake. Participants were 
instructed to remove the attached magnet from the capsule prior to consumption, which initialises 
the silver-oxide battery inside the capsule. Upon participant arrival to the exercise laboratory the 
handheld CorTemp™ Data Recorder (Figure 14A) begins reading the signal from the ingested 
sensor, which is converted from a signal frequency into digital temperature data. Throughout 
monitoring the handheld monitor was attached to the lower back of the participant as 
recommended by the manufacturer. The digital temperature data was programed to record at 20 
sec intervals and the temperature data was downloaded via CorTrack™ II software to a PC for 
interpretation and analysis. 
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Figure 14. (A) CorTemp Data Recorder; (B) CorTemp Temperature Capsule. 
 
8. 5 Long-Graded Exercise Test to Exhaustion 
A long-graded cycling test to exhaustion was performed by each participant in preparation for 
experimental study four (Chapter Six) of the present thesis. The primary aim of the graded 
exercise test to exhaustion was to identify lactate threshold; the point at which lactate 
accumulation was greater than removal, which was used to calculate exercise intensity workloads 
or subsequent studies. The lactate threshold was identified as the point (exercise stage) prior to a 
rise in BLa concentrations of 4.0 mmol/L or greater.  
 
8. 5. 1  Test Protocol 
The long-graded exercise test to exhaustion was conducted on a cycle ergometer (Lode, Sport 
Excalibur, Netherlands) with an attached programmable control unit (Lode, Sport Excalibur, 
Netherlands). Participants began cycling at 45 watts, with 15 watt increases at four min intervals 
until BLa was greater than 4.0 mmol/L, as measured by a handheld automated device (Lactate 
Pro, ARKRAY Inc., Japan) from arterialised blood (earlobe). Upon reaching a BLa concentration 
of greater than 4.0mmol/L power output was increased by 15 watts every 30 sec until volitional 
exhaustion. Gas exchange was monitored via open circuit spirometry (COSMED, Chicago, 
Illinois, USA) to identify   ΟV 2 max (see calculations below, section 8.5.2) and minute ventilation 
(L/min). At the end of each four min stage, HR (RS800cx, Polar Electro Oy, Finland; HR), Bla 
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(Lactate Pro, ARKRAY Inc., Japan), RPE and blood pressure were collected. Throughout the 
entire test, cadence was required to be between 70-80 rpm; if cadence fell below this level the test 
was terminated.  
 
8. 5. 2   ΟV 2 MAX Calculations 
  ΟV 2 MAX = Inspired Oxygen (InspO2) – Expired Oxygen (ExspO2) 
Relative   ΟV 2 (ml/kg-1/min-1) = 
VO2 (ml/min) 
Body Mass (kg)
  
Absolute   ΟV 2 (L/min) =  
VO2 (ml/kg-1/min-1) × Body Mass (kg) 
1000 (ml)
 
 
8. 6  Threshold Trials 
Lactate threshold one (LT1) was identified from the long-graded incremental cycling test to 
exhaustion (see section 8. 5. 1), and was used a reference point for two subsequent threshold trials. 
Each threshold trial comprised of 30 min of cycling (Lode, Sport Excalibur, Netherlands) at 90% 
of LT1 (see equation below; section 8. 6. 1), 15 min at 135% and 7.5 min at 190% of LT1. The 
purpose of this protocol was to allow the participant to achieve steady state in the first stage, and 
progressively increase exercise intensity to a highly demanding final stage. Testing protocol 
remained identical for both threshold trials, the only difference being ambient temperature; with 
one trial conducted at 22C and one at 35C separated by a period of two-three days.  
 
8. 6. 1  Exercise Workloads Equations: 
The three stage workloads for threshold testing is 90%, 135% and 180% of LT1 = 
E.g. Assuming LT1 occurred at 90 watts then the equation is as follows; 
90  0.9 = 81 watts 
90  1.35 = 122 watts 
90  1.80 = 162 watts 
 
8. 6. 2  Procedure 
Participants arrived at the exercise laboratory fasted (food and water) from 8:30pm the night 
before. Upon arrival participants were seated in a quiet laboratory where they provided one saliva 
sample for IgA and cortisol (IPRO Interactive, Wallingford, UK), resting HR (RS800cx, Polar 
Electro Oy, Finland), TC (HQ Inc., Palmetto, Florida, USA), RPE and body mass (following 
bladder voiding). Additionally, a venous sample for estrogen and progesterone levels was 
collected (see section 8. 6. 2. 1 Blood Collection) while the participant was lying quietly in a 
supine position via EDTA blood sample tubes and measured on a Beckman Coulter counter. 
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Participants then entered the exercise chamber for 60 min of passive temperature acclimation. 
Participants were provided with a standardised breakfast of raisin toast with butter and jam (1 
slice + 0.33 per 5kg over 50kg body mass) and water (5mL per/kg-1 body mass). Participants were 
instructed to finish food and water prior to 30 min of acclimation. Every 15 min throughout 
acclimation, HR (bpm), RPE, TC and blood pressure were recorded and participants completed 
an athlete pre-test questionnaire (Appendix Five). Following 30 min of acclimation, another saliva 
sample was collected, followed by a subsequent venous blood sample. The participant was 
weighed (following bladder voiding) and prepared for the exercise trial. While seated at rest on 
the cycle ergometer (Lode, Sport Excalibur, Netherlands), resting HR, RPE, BLa and TC were 
collected.  
 
Following the collection of baseline measurements, the participant was instructed to begin cycling 
at their pre-determined workload. Several measures including HR, blood pressure and RPE were 
recorded every 7.5 min throughout the exercise protocol, with BLa measured at 15 min, 30 min, 
45 min and 52.5 min (exercise cessation). Core body temperature was recorded at 20 second 
intervals throughout the entire threshold test, with values averaged for the minute surrounding 
each of the time points in the threshold test. Immediately following exercise, participants were 
instructed to stop cycling and remain seated on the bike. A saliva sample for IgA and cortisol was 
immediately collected, as well as a final blood pressure measurement to ensure it was safe for the 
participant to disembark the cycle ergometer.  
8. 6. 2. 1   Blood Collection 
Participants were instructed to lie supine on a collection bed in a quite exercise laboratory. The 
phlebotomist performing the procedure gathered EDTA tube and a supplies trolley which was 
positioned alongside the collection bed for convenience. A suitable site for venepuncture was 
selected by the phlebotomist and a tourniquet was placed approximately 3-4 inches above the 
selected site. Following the application of appropriate personal protective equipment, vein 
palpation occurs. Upon selecting a vein for venepuncture, the area was cleaned and left to dry. 
The participant was instructed to squeeze their hand while the phlebotomist used their thumb to 
taut the skin over the puncture site. The needle was inserted into the vein at a 15-30º angle. Blood 
was drawn into two EDTA tubes and the tourniquet was release during sample collection. 
Following an adequate sample, the needle was removed from the participants arm and cotton wool 
was immediately placed (with pressure) on the puncture site for one-to-two minutes. Following 
compression, as band aid was placed over the incision site. All contaminated materials were 
disposed of in appropriate sharps and medical waste containers. Blood samples were immediately 
inverted and placed on ice. Samples were transported to a centrifuge where they were spun for 
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ten minutes. Following centrifugation (Beckman Coulter), samples were stored in a freezer at -
80º until sent for analysis at an external laboratory. 
 
8. 7  Duel Energy X-Ray Absorptiometry (DEXA) 
8. 7. 1  Background 
Duel Energy X-Ray Absorptiometry (DEXA) is becoming increasingly used in research and 
clinical practice to identify body composition and bone mineral density [632-634], likely due to 
its non-invasive, ease of use and low radiation exposure [635, 636]. The radiation exposure from 
a GE Lunar Prodigy whole-body scanner (DEXA; Prodigy Pro, GE Healthcare Lunar, Shanghai, 
China) produces 2 Sv, which is less radiation than normal daily exposure [637]. Duel Energy X-
Ray Absorptiometry is reportedly [637-642] accurate and precise for measuring bone mineral 
density and body composition.  
 
The supine body is scanned in a rectilinear manner, segmenting the body into a series of pixels 
[643]. Within this series of pixels the photon attenuation is measured at two different energies, 
with photon attenuation assumed to be a function of tissue composition in vivo [643-645]. In 
DEXA scanning, the body is divided into three components which are considered different by 
their X-ray attenuation properties i.e. fat, bone mineral and fat free or lean tissue [643]. Within 
any pixel, the differential absorption of two photon energies of only two components can be 
determined [643].  Soft tissues which largely consist of water and organic compounds, reduce 
photon flux substantially more than bone mineral, with the presence of bone readily identified in 
pixels compared with those with no bone present [643]. In the pixels with no bone present, a 
distinction is made between fat and lean fractions within the soft tissue present [643]. In these 
instances the composition of these soft tissue pixels is extrapolated to the soft tissue overlying 
bone to identify total body fat and lean tissue [643].  
 
8. 7. 2  Procedure 
Participants were instructed to refrain from eating and drinking in the two hours prior to the 
DEXA scan, as this may affect the water content of their stomach, potentially causing misleading 
results [646-648]. Participants were asked to bladder void immediately prior to scanning due to 
the same principle. Prior to undertaking the DEXA scan, participants were asked to complete 
medical history (Appendix One), physical activity readiness (Appendix Two) and menstrual cycle 
/ oral contraceptive history forms (Appendix Four). Additionally, following verbal and written 
explanations of the study, participants were asked to sign informed consent (Appendix Three). 
Participants removed all metal including hair clips and piercings from their body and no zips or 
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under-wires were present on clothing throughout the scan. Trained technical staff positioned the 
participant on the DEXA scanning bed, lying supine with hands and feet secured in paddles (as 
per guidelines developed by Nana et al 2012 and adopted by the Australian Institute of Sport [649, 
650]). Participants were instructed to avoid talking or moving for the duration of the total body 
composition scan, as this may cause unnecessary movements in the chest cavity and triggering 
misleading results. The x-ray arm began to move from one end of the scanning bed to the other 
while identifying the relative contribution of bone mineral and soft tissue (adipose and lean) for 
each pixel. The x-ray scanning process takes six min and twenty sec to complete.  
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Medical History Questionnaire 
Name:  _______________________________ 
Address:  _____________________________ 
_____________________________________ 
_____________________________________ 
Phone: (  )  ________________________ (W) 
Phone: (  )  ________________________ (H) 
Email:  
________________________________ 
Age:  
_________________________________ 
DOB:  
_________________________________ 
Please read the following questions very 
carefully.  If you have any difficulty please 
advise the medical practitioner. 
1.  Family History.  Indicate if any of your 
immediate family (parents, brothers, 
sisters, grandparents) have experienced 
any of the following, the age at which 
diagnosis occurred, and the person’s 
relationship to you. 
 
Relationship & Age 
High Blood Pressure  ___________________ 
High Cholesterol  ______________________ 
Heart Disease  _________________________ 
Stroke  _______________________________ 
Diabetes  _____________________________ 
Cancer  
_______________________________ 
 
2. Your Personal Medical History.  Indicate symptoms that apply to you, by placing a cross 
 in the box 
 Pain or discomfort in chest following exercise, eating or exposure to cold 
 Frequent heart palpitations or flutter 
 Pain in lower lungs when walking or climbing stairs 
 Unusual shortness of breath 
 Very poor exercise tolerance 
 Frequent dizziness 
 Chronic cough 
 Frequent colds or flu 
 Frequent headaches 
 Frequent aches or pains in joints 
 Frequent backache 
 Other current symptoms that exercise may affect 
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Are you presently experiencing, or have you ever been treated by a doctor for any of the 
following? 
Place a cross in the box 
3. Allergies: Hay fever, Eczema, Other rashes 
  Yes 
  No 
Details  
________________________________ 
 
4. Lung Problems 
(Asthma/Emphysema/Bronchitis/ 
Shortness or Breath/Other) 
  Yes 
  No 
Details  
________________________________ 
 
5. Heart Problems (Rheumatic Fever/Chest 
Pains/Palpitations/Ankle Swelling/Other) 
  Yes 
  No 
Details  
________________________________ 
6. Blood Pressure Problems 
  Yes 
  No 
Details  
________________________________ 
7. Cholesterol Problems 
  Yes 
  No 
Details  
________________________________ 
 
8. Gut Problems (Ulcer/Abdominal 
Pain/Diarrhoea/Constipation Hernia/Other) 
  Yes 
  No 
Details  
________________________________ 
9. Unexplained Weight Loss  
  Yes 
  No 
Details  
________________________________ 
10. Urinary Problems (Burning/Difficulty 
with control of urine) 
  Yes 
  No 
Details  
________________________________ 
11. Blood Loss (In vomit/Sputum/Bowel 
Action/Urine) 
  Yes 
  No 
Details  
________________________________ 
12. Easy Bruising 
  Yes 
  No 
Details  
________________________________ 
13. Endocrine Problems 
(Diabetes/Thyroid/Other) 
  Yes 
  No 
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Details  
________________________________ 
14. Fitting, Fainting, Blackouts, Loss of 
Consciousness, Muscle Weakness, Loss 
of Sensation 
  Yes 
  No 
Details  
________________________________ 
15. Headaches 
  Yes 
  No 
Details  
________________________________ 
16. Sight or Hearing Problems   
  Yes 
  No 
Details  
________________________________ 
17. Nervous Conditions 
  Yes 
  No 
Details  
________________________________ 
18. Bone or Joint Injury 
(Back/Knee/Ankle/Hip/Shoulders) 
  Yes 
  No 
Details  
________________________________ 
 
19. Other Joint Problems  
  Yes 
  No 
Details  
________________________________ 
 
20. Work Related Injuries  
  Yes 
  No 
Details  
________________________________ 
21. Are you exposed to a noisy/or dusty 
environment? 
  Yes 
  No 
Details  
________________________________ 
22. How often do you take over the counter 
medications such as aspirin, etc.? 
  Daily 
 Weekly 
 Occasionally 
 Never 
23 Medication.  Are you taking any 
medication prescribed by your Doctor or 
other Health Care provider?  If so, list 
details, i.e., type of drugs, dosage. 
 
________________________________ 
________________________________ 
24 Sleeping patterns. How many hours do 
you sleep on average per night? 
_____ hours. 
25. Do you ever have trouble falling asleep? 
  Yes 
 No 
 Occasionally 
26. Smoking Status 
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  Never smoked 
 Quit smoking more than 10 years 
 Quit smoking less than 10 years 
 Currently smoke (number of years 
________) 
27. If currently smoking, how many 
cigarettes do you currently smoke per 
day? 
____________________________________ 
28. Physical Activity.  How many times per 
week do you exercise for at least 20-30 
minutes continuously? 
  Do not have a regular program 
  Once per week 
  2 - 3 times per week 
  4 - 5 times per week 
 More than 5 times per week 
 
29 Alcohol Consumption.  In the past two 
weeks list how many days you consumed 
an alcoholic beverage. 
 Did not drink in the past 6 months 
 Did not drink in the past two weeks 
 1 - 2 days 
 3 - 4 days 
 5 - 7 days 
 8 - 10 days 
 11 - 14 days 
 
30 In the past two weeks list how many drinks 
on average you had per day. 
Did not drink in the past 6 months 
 Did not drink in the past two weeks 
 1 drink 
 2 – 3 drinks 
 4 – 6 drinks 
 7 or more drinks 
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Appendix B. Physical Activity Readiness Form 
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BOND UNIVERSITY 
Faculty of Health Sciences and Medicine 
PHYSICAL ACTIVITY 
READINESS QUESTIONNAIRE (PAR-Q) 
Please read the following questions carefully.  
If the answer to the question is YES, place YES inside the box.  
If the answer to the question is NO, place NO inside the box. 
1. Do you suffer from any form of diabetes?  
1. Do you suffer from asthma or breathing difficulties?  
2. Has your doctor ever said you have heart trouble? 
3. Do you frequently suffer from pains in your chest? 
4. Do you often feel faint or have spells of severe dizziness? 
5. Has a doctor ever said your blood pressure was too high? 
6. Has a doctor ever told you that you have a bone or joint problem, such as  
arthritis, that has been aggravated by exercise, or might be made worse with  
exercise? 
7. Is there any good physical reason, not mentioned here, why you should not  
participate in physical activity, even if you wanted to? 
8. Are you between the age of 18 and 35 years?  
 
Signature of participant:    …………………………………………     Date      /   / 
Witness:  ………………………………………………………...        Date     /   /  
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Faculty of Health Sciences and Medicine 
 
INFORMED CONSENT FORM 
 
Chief Investigator(s): Name(s):    Rhiannon Fisher 
   Faculty:       Health Sciences and Medicine 
   Contact number(s):  0400836073 
   Supervisor: Assistant Professor Chris McLellan 
 
Project Title:  
The effect of oral contraception on athletic performance and several parameters of human 
physiology in response to exercise in varying temperatures. 
(I) I have read the subject information sheet for the research project “The effect of oral 
contraception on athletic performance and several parameters of human physiology in 
response to exercise in varying temperatures” and clearly understand the content, and what 
is being asked of me as a volunteer in the experiment / project.  
 
(II) The risks associated with my participation in the experiment have been clearly explained 
to me and I clearly understand the risks involved in my participation in the experiment / 
project “The effect of oral contraception on athletic performance and several parameters of 
human physiology in response to exercise in varying temperatures”.  
 
(III) I have been told and accept the possible benefits of my participation in the experiment / 
project “The effect of oral contraception on athletic performance and several parameters of 
human physiology in response to exercise in varying temperatures”. 
 
(IV) I have had the opportunity to ask questions about the experiment / project “The effect of 
oral contraception on athletic performance and several parameters of human physiology in 
response to exercise in varying temperatures” and the questions I have asked have been 
answered to my satisfaction. I also understand that I can ask questions about the experiment 
/ project and my participation in the experiment at any time. 
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(V) I understand that my records will be handled in a confidential manner and that any reporting 
of my personal results will be anonymous or included together with the results of other 
participants, as an average result for the group of volunteers. 
 
(VI) I clearly understand what is being asked of me to participate in the experiment / project and 
I understand the risks and benefits of my participation in the experiment / project “The 
effect of oral contraception on athletic performance and several parameters of human 
physiology in response to exercise in varying temperatures” and I agree to participate as a 
volunteer. 
 
(VII) I understand that I can withdraw from the experiment / project “The effect of oral 
contraception on athletic performance and several parameters of human physiology in 
response to exercise in varying temperatures” at any time without penalty or guilt or 
aggravation from the investigators. 
 
(VIII) I understand that at the appropriate time I will receive feedback on my performance in the 
experiment / project “The effect of oral contraception on athletic performance and several 
parameters of human physiology in response to exercise in varying temperatures”. 
 
(IX) I understand that the experiment / project will be carried out as described in the information 
statement, a copy of which I have retained.  I understand that whether or not I decide to 
participate is my decision and will not affect my relationships with Bond University.   
 
(X) I give my consent to participate in the experiment “The effect of oral contraception on 
athletic performance and several parameters of human physiology in response to exercise 
in varying temperatures”.  
 
Please tick the appropriate box 
 
 The information I provide can be used by other researchers as long as my name and 
contact information is removed before it is given to them. 
 
 The information I provide cannot be used by other researchers without asking me first. 
 
 The information I provide cannot be used except for this project. 
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Signatures:        …………………………………….      …………………… 
   Investigator(s)            Date 
      
                                          ……….…………………………….      …………………… 
   Participant                       Date 
 
         ……………………………………..     ……………………. 
   Witness           Date 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 202 
 
 
 
 
 
 
 
 
 
 
 
 
Appendix D. Exercise Pre-screening and Menstrual Cycle / Oral Contraceptive History 
Form 
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Exercise Pre-Screening Form 
Name: ________________________________    Date:____________ 
Baseline Measurements 
Height:______(cm) 
Weight:______(kg) 
 BMI: __________(kg/m2) 
Waist Girth: _______(cm) 
Resting BP:_____________ (mmHg) 
 
1. Have you ever been told you have high blood sugar?    Yes / 
No 
2. Have you spent time in hospital (including day admission) for any medical 
condition/illness/injury during the last 12 months?    Yes / 
No 
______________________________________________________________________
______________________________________________________________________
______________________________________________________________________ 
3. Are you currently taking prescribed medications for any medical condition?  Yes / 
No 
______________________________________________________________________
______________________________________________________________________
______________________________________________________________________ 
4. Are you pregnant or have you given birth within the last 12 months?  
 Yes / No 
______________________________________________________________________
______________________________________________________________________
______________________________________________________________________ 
5. Do you have any muscle, bone or joint pain or soreness that is made worse by 
particular types of activity?       
 Yes / No 
______________________________________________________________________
______________________________________________________________________
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______________________________________________________________________
______________________________________________________________________ 
 
Menstrual Cycle and Oral Contraceptive History 
 
Age of Menarche (First period): _________________ (years) 
Age of initial oral contraceptive use: ________________(years) 
What type of oral contraceptive pill did you use? (Please circle) 
Monophasic  Biphasic Triphasic Progesterone only i.e. mini pill 
If known, please state the brand of pill used: 
________________________________ 
How physically active have you been since menarche? (Please circle) 
Sedentary Low (1-2 times/wk) Medium (3-4 times/wk)  High (5+ 
times/wk) 
Comments:_____________________________________________________________
______________________________________________________________________ 
Have you experienced any menstrual disturbances since menarche?   Yes / No 
If yes what disturbances have you experienced? How long did you experience them? What 
treatment was used?  
_____________________________________________________________________________
_____________________________________________________________________________
_____________________________________________________________________________
_____________________________________________________________________________
_____________________________________________________________________________ 
 
Are you currently using oral contraception?     Yes / No 
If yes, what type, brand and duration of use?  
_____________________________________________________________________________
_____________________________________________________________________________
_____________________________________________________________________________
_____________________________________________________________________________
_____________________________________________________________________________ 
 
Have you used oral contraception in the past?      
 Yes / No 
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If yes, what type, brand, duration of use and age of use?  
_____________________________________________________________________________
_____________________________________________________________________________
_____________________________________________________________________________
_____________________________________________________________________________
_____________________________________________________________________________ 
 
If you are taking oral contraception please complete Section A. If you are not taking oral 
contraception please complete Section B. 
 
Section A 
(Please complete if you are currently taking oral contraception) 
 
Please rank in order from most important (1) to least important the reason(s) that you 
take oral contraception. You do not have to rank all 7, only rank those relevant to you. 
 
______ Birth Control  
______ Cycle Control (regular period or timing of menstruation). 
______ To reduce menstrual symptoms (please tick):  
 Heavy Period 
 Painful Period 
 Bloating 
 Breast Tenderness 
 Mood Disturbance 
 Other. Please Specify. _______________________________________________ 
______ Relief from polycystic ovary syndrome or other syndrome/disease 
______ To reduce acne 
______ Decrease risk of anaemia, or reduced bone mineral density 
______ Other. Please Specify. __________________________________________________ 
 
Do you have any concerns about taking the oral contraceptive pill? Please Specify.  
_____________________________________________________________________________
_____________________________________________________________________________
_____________________________________________________________________________ 
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If you are taking oral contraception please complete Section A. If you are not taking oral 
contraception please complete Section B. 
 
Section B 
(Please complete if you are not currently taking oral contraception) 
 
Please rank in order from most important (1) to least important the reason(s) that you do 
not take oral contraception. You do not have to rank all 9, only rank those relevant to you. 
 
_____ Currently using other form of birth control or hormone therapy. Please Specify. 
 ______________________________________________________________________ 
_____ Side effects (please tick): 
 Weight Gain 
 Increase Appetite 
 Acne 
 Nausea 
 Headache 
 Mood Change 
 Reduced Libido 
 Other. Please Specify. __________________________________________________ 
_____ Medical Concerns (please tick): 
 Deep vein thrombosis / blood clotting 
 Increased blood pressure 
 Other. Please Specify. __________________________________________________ 
_____ Medical Condition (please tick):  
 Cardiovascular Disease 
 Other. Please Specify. __________________________________________________ 
_____ Wish to become pregnant 
_____ Commitment to take each day 
_____ Contains hormones / not natural 
_____ Reduced exercise performance 
_____ Other. Please Specify. _____________________________________________________ 
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Appendix E. Athlete Pre-Test Questionnaire 
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ATHLETE PRE-TEST QUESTIONNAIRE 
 
Sports Scientists     Contact Details 
Dr Clare Minahan     Telephone: 61 (7) 5552 7842 
Griffith University Sports Science   E-mail: c.minahan@griffith.edu.au 
School of Allied Health Science 
GRIFFITH UNIVERISTY QLD 4222 
 
 
Tester:________________________________________ Date:______________________ 
Sport:________________________________________ Squad:_____________________ 
Testing Location:_______________________________ Testing Surface:______________ 
Temperature:____________ Humidity:_____________ Testing Time:________________ 
 
Name of athlete:________________________________ Date of birth:________________ 
Age:______________    Gender:  Male  Female    Height (cm):_______ Mass 
(kg):_______ 
Home address:_________________________________ Home phone:________________ 
Email address:_________________________________ Mobile phone:_______________ 
 
Diet 
How would you rate your diet over the last 2 days?  Poor  OK  Good  Excellent 
How many hours ago did you eat your last meal? ________________ 
Recent foods eaten over the last 24 h: 
_____________________________________________________________________________
_____________________________________________________________________________
_____________________________________________________________________________
_____________________________________________________________________________ 
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Meal Foods (including drinks) Portion size (cups, grams) 
Breakfast 
  
Snacks 
  
Lunch 
  
Snacks 
  
Dinner 
  
 
Environment 
Have you been training in hot conditions in the last 2 weeks?    Yes  No 
If yes, provide details: _______________________________________ 
Have you been training or sleeping at altitude in the last 2 weeks?   Yes  No 
If yes, provide details: _______________________________________ 
 
Illness 
Are you currently suffering from any type of illness?     Yes  No 
If yes, provide details: ______________________________________ 
Have you had any type of illness or health problem in the last 2 weeks?   Yes  No 
If yes, provide details: ______________________________________ 
 
Injury 
Do you currently have any injuries?       Yes  No 
If yes, provide details: ______________________________________ 
Have you had any injuries in the last 2 weeks?      Yes  No 
If yes, provide details: ______________________________________ 
 
 
 211 
 
Medications and Supplements 
Are you currently taking any medication?      Yes  No 
If yes, provide details: ______________________________________ 
Have you taken any medication in the last 2 weeks?     Yes  No 
If yes, provide details: ______________________________________ 
Have you taken any supplements in the last 2 weeks?     Yes  No 
If yes, provide details: ______________________________________ 
 
Motivation 
Evaluate your motivation for training today.  Poor  OK  Good  Excellent 
Evaluate your motivation for testing today.  Poor  OK  Good  Excellent 
 
Training 
Evaluate your last week of physical training.  Easy  Moderate  Hard  Very Hard 
How fatigues are you today? (0= not at all; 5 = extremely) _________ 
How many hours ago did you last exercise? _________ 
 
Describe your last three training sessions: 
Time Training Session 
Difficulty (easy, moderate, 
hard) 
Today 
  
Yesterday 
  
2 days ago 
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Travel 
Have you had to travel over the last 7 days?      Yes  No 
If yes, provide details: 
_____________________________________________________________________________
_____________________________________________________________________________
_____________________________________________________________________________
_____________________________________________________________________________
_____________________________________________________________________________
_____________________________________________________________________________
_____________________________________________________________________________
______________ 
Miscellaneous 
Please provide any additional information that you believe may influence your testing results. 
_____________________________________________________________________________
_____________________________________________________________________________
_____________________________________________________________________________
_____________________________________________________________________________
_____________________________________________________________________________
_____________________________________________________________________________
_____________________________________________________________________________
_____________________________________________________________________________
_____________________________________________________________________________
__________________ 
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Appendix F. Fisher, R. N., McLellan, C. P., & Sinclair, W. H. (2015). The Validity and 
Reliability for a Salivary Cortisol point of Care Test. Journal of Athletic Enhancement, 
4:4. (In print form). 
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Appendix G. Fisher, R. N., Sinclair, W. H., Lovell, D. I., & McLellan, C. P. (2015). The 
Immunological Response to Surf Life Saving Competition. Journal of Australian Strength 
and Conditioning. 23(2), 15-20 (In print form). 
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